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The landscape of digital technology innovations which can assist healthcare provision has 
expanded rapidly over the past decade.  With the adoption of consumer and healthcare-based 
technologies including mobile device and network access, the use of tele-monitoring in the 
management of chronic medical conditions will be incorporated into routine clinical care within 
this generation. Remote patient monitoring has an established role in the management of 
patients with obstructive sleep apnoea syndrome who require positive airway pressure support. 
However, the use of two-way remote monitoring via a cloud-based platform to initiate and 
optimise home non-invasive ventilation (NIV) is novel. Rising obesity rates and new evidence 
supporting the use of home NIV in patients with severe chronic obstructive pulmonary disease 
(COPD) and chronic hypercapnic respiratory failure has resulted in increased referrals for 
breathing support assessment and treatment. Chronic hypercapnic respiratory failure develops as 
a consequence of imbalance in the respiratory load capacity drive relationship and is associated 
with high morbidity and mortality. Advanced physiological measurements such as parasternal 
electromyography (EMG) to quantify neural respiratory drive and forced oscillometry technique 
to quantify airway resistance and reactance are well established in research but evidence for their 
clinical application in disease monitoring in patients with sleep disordered breathing and chronic 
hypercapnic respiratory failure is lacking.  
The anticipation is that big data from remote monitoring of home breathing support therapies 
and serial advanced physiological measurements will provide mechanistic insights of chronic 
respiratory failure, facilitate early optimisation of treatment, prompt early recognition of 
treatment failure and prioritise at risk patients to provide a personalised approach to the 
management of chronic respiratory disease. The aim of this thesis was to evaluate the adoption of 
two-way remote monitoring in patients with sleep disordered breathing and hypercapnic severe 
COPD and determine the feasibility of serial advanced physiological measurements in chronic 
respiratory disease.  
Methods 
A summary of the evolution of clinical pathways for two-way remote monitored breathing 
support and home ventilation in NHS Greater Glasgow and Clyde are detailed. A retrospective 
review of the clinical outcomes in observational cohorts of patients who were managed with two-
way remote monitored home NIV for hypercapnic severe COPD and obesity related respiratory 
failure were evaluated. Clinical outcomes were compared to those of patients who survived a life-
threatening exacerbation of COPD with persistent hypercapnic failure who were not referred for 
breathing support assessment (controls). Four physiological studies were performed. Firstly, the 
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optimisation of parasternal EMG signals using different skin preparation and electrodes was 
explored. Secondly, inter-observer variability of parasternal EMG analysis between two UK based 
respiratory physiology research centres was assessed. Thirdly, the simplification of neural 
respiratory drive index analysis by using EMG signals to estimate respiratory rate to determine 
the feasibility of future omission of additional sensors improving accessibility. The fourth study 
explored the feasibility of serial advanced physiological measurements alongside standard care in 
a wide range of respiratory diseases.  
Results 
Clinical pathways for remote management of breathing support patients are now routine clinical 
care within NHS Greater Glasgow and Clyde. It is feasible and safe to use remote monitored home 
ventilation in patients with hypercapnic severe COPD. Continued use of two-way remote 
monitored home NIV prolonged time to re-admission or death in patients with hypercapnic 
severe COPD when compared to the control cohort. Continued use of remote monitored home 
NIV in hypercapnic severe COPD resulted in a median reduction of 14 occupied bed days per 
annum. Continued use of remote NIV prolonged time to re-admission or death in patients with 
obesity related respiratory failure compared to those non-adherent or discontinued NIV. Two-way 
remote home NIV can facilitate safe day case initiation of home NIV in patients with stable 
hypercapnic respiratory failure. It is feasible to use long term cardiac electrodes for parasternal 
electromyography measurements. Acceptable reproducibility of parasternal EMG analysis 
between two UK research centres has been demonstrated. The derivation of respiratory rate from 
parasternal EMG signals is feasible. Serial advanced physiological measurements can be 
incorporated into standard care in a wide range of respiratory diseases. Serial oscillometry 
measurements in patients with obstructive sleep apnoea syndrome has provided novel insight 
into the role a small airways disease.  
Conclusion 
The work undertaken in this thesis enabled significant service improvement within NHS Greater 
Glasgow and Clyde. The utilisation of remote monitoring in disease management provides realistic 
service provision with tangible service and cost efficiencies, addressing increased service demands 
and justifying future cost-effective analysis. This work has been a catalyst for ongoing digital 
innovation projects incorporating EHRs, ambulatory physiological monitoring and home device 
data into a multi-media multi-disciplinary platform for high-risk COPD patients. Serial advanced 
physiology data has advocated ongoing studies in acute respiratory failure secondary to COVID-19 
infection. Adoption of these new technologies into routine clinical care will address increasing 
service demands, improve patient outcomes, and provide physiological insights into chronic 
respiratory failure and COVID-19 related respiratory failure.
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List of abbreviations 
A   Cross section of the airway 
AE-COPD  Acute exacerbation of chronic obstructive pulmonary disease 
Ach   Acetylcholine 
AHI   Apnoea hypopnoea index 
∆AHI   Change in AHI 
AHP   Allied health professionals 
AHRF   Acute hypercapnic respiratory failure 
APAP   Auto-titrating positive airway pressure 
AU   Arbitrary units 
Audit-QIP  Audit- quality improvement project 
AutoEPAP  Auto-titrating expiratory positive airway pressure 
AVAPS   Average volume assured pressure support 
AVAPS-AE Average volume assured pressure support with auto-titrating 
expiratory positive airway pressure support 
AWR   Airways resistance 
Ax   Area of reactance 
BMI   Body mass index  
BP   Blood pressure 
CBG   Capillary blood gas 
CF   Cystic fibrosis 
cmsH2O   centimetres of water, measurement of pressure 
CO   Carbon monoxide 
CO2   Carbon dioxide 
COPD   Chronic obstructive pulmonary disease 
COPD-OSA Chronic obstructive pulmonary disease- obstructive sleep apnoea 
overlap syndrome 
CPAP   Continuous positive airway pressure therapy 
CSF   Cerebral spinal fluid 
CV   Coefficient variation 
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DA   Dopamine 
DH   Dynamic hyperinflation 
ECG   Electrocardiogram 
EEG   Electroencephalogram 
EELV   End expiratory lung volume 
EFL   Expiratory flow limitation 
EHR   Electronic health records 
EMG    Electromyogram 
EMGdi   Diaphragmatic electromyogram 
EMGpara  Parasternal electromyogram 
EMGpara%max  Normalised parasternal electromyogram 
EMGpara-RR  Respiratory rate derived from RMS parasternal electromyography 
signal 
∆EMGpara  Change in parasternal electromyography 
∆EMGpara%max Change in normalised parasternal electromyography 
∆meanEMGpara Change in mean parasternal electromyography 
EOG   Electro-oculogram 
EPAP   Expiratory positive airway pressure 
mEPAP   Median expiratory positive airway pressure 
95%EPAP  95th centile expiratory positive airway pressure 
ERV   Expiratory reserve Volume  
ESS   Epworth sleepiness scale 
FEF25-75  Forced expiratory flow at 25% to 75% of vital capacity 
FEV1   Forced expiratory volume in one second 
FEV1/FEV6 Ratio of forced expiratory volume in 1 second to forced expiratory 
volume in 6 seconds 
FEV1/FVC  Ratio of forced expiratory volume in 1 second to forced vital 
capacity 
FFM   Full face mask 
FOT   Forced oscillometry technique  
FL    Flow limited 
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FRC   Functional residual capacity 
Fres   Resonant frequency 
GABA   Gamma amino-butyric acid 
GA   Galanin 
GGC   Greater Glasgow and Clyde 
GGH   Gartnavel general hospital 
GSBSRC   Glasgow sleep and breathing support research centre  
HA   Histamine 
HCO3   Bicarbonate 
HOT   Home oxygen therapy 
HMV   Home mechanical ventilation 
Hrs   Hours 
HRQOL   Health related quality of life 
iBR   Intelligent back up rate  
IC   Intercostal  
ICS   Intercostal space 
ILD   Interstitial lung disease 
IPAP   Inspiratory positive airway pressure 
mIPAP   Mean inspiratory positive airway pressure 
95%IPAP  95th centile inspiratory positive airway pressure 
IQR   Interquartile range 
IRV   Inspiratory reserve volume 
iVAPS   Intelligent volume assured pressure support 
KCO   Transfer co-efficient 
kPa   Kilo pascals 
L   Litres 
L/min   Litres/minute 
LDT   Laterodorsal tegmentum 
LSS   Limited polysomnography 
mCAT   Modified COPD assessment tool 
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meanEMGpara  Mean parasternal electromyography measurement  
meanEMGpara%max Mean normalised parasternal electromyography measurement 
meanNRDI  Mean neural respiratory drive index 
ml    Millilitres 
MIP   Mouth inspiratory pressure 
MEP   Maximum expiratory pressure 
MRC   Medical research council dyspnoea scale 
MSc   Master of science degree 
mV   Millivolts 
NFL   Not flow limited 
NHS   National health service 
NIV   Non-invasive ventilation  
NM   Nasal mask 
NRD    Neural respiratory drive 
NRDI   Neural respiratory drive index 
∆NRDI   Change in neural respiratory drive index 
NREM   Non-rapid eye movement sleep stages 
OBDs   Occupied bed days 
ODI   Oxygen desaturation index 
OHS   Obesity hypoventilation syndrome 
ORRF    Obesity repeated respiratory failure 
OSAS   Obstructive sleep apnoea syndrome 
P0.1   Pressure generate during the first 100ms of inspiration 
PAP   Positive airway pressure 
PCO2   Partial pressure of carbon dioxide 
PO2   Partial pressure of oxygen  
PEF   Peak expiratory flow 
PEEP   Positive end expiratory pressure 
Pflex   Inflexion point, pressure at which airway resistance is overcome 
PLM   Periodic limb movement 
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Ppl   Pleural pressure 
Pcrit   Critical pleural pressure 
Paw   Airway pressure 
Palv   Alveolar pressure  
Pao   Airway opening pressure 
Pel    Elastic recoil pressure 
PS   ECOG performance status 
PS   Pressure support 
PSG   Polysomnography 
PVA   Patient ventilator asynchrony 
Q   Volumetric flow rate 
QEUH   Queens Elizabeth University Hospital  
R   Radius 
RCT   Randomised control trial 
REM   Rapid eye movement sleep stage 
RIP   Respiratory impedance plethysmography 
RMS   Root mean squared 
Rrs   Resistance 
RR   Respiratory rate 
RV   Residual volume 
R5   Total airways resistance 
R20    Large airways resistance 
R5-R20   Small airways resistance 
SD   Standard deviation 
SDB   Sleep disordered breathing 
SHOOF   Scottish home oxygen order form 
SpO2   Peripheral oxygen saturations 
SNIP   Sniff nasal inspiratory pressure 
ST   Spontaneous timed mode 
TLC   Total lung capacity 
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TLCO   Transfer factor for the lung for carbon monoxide 
TM   Telemedicine 
TMN   Tuberomammillary nucleus 
TOSCA Transcutaneous peripheral oxygen saturations and carbon dioxide 
assessment 
TpCO2 Transcutaneous partial pressure of carbon dioxide  
TpO2 Transcutaneous partial pressures of oxygen 
TST90 Total sleep time when oxygen saturations are less than 90% during 
polysomnography 
VA    Lung volume in which carbon monoxide diffuses 
Va   Alveolar ventilation 
VAPS   Volume assured pressure support 
VC   Vital capacity 
Vc   Videoconference 
VLPO   ventrolateral pre-optic area 
vPAG   Ventral periaqueductal grey matter 
V/Q mis-match  Ventilation/perfusion mismatch 
Vt   Tidal volume 
Xrs   Reactance 
X5insp   Reactance at 5Hertz during inspiration 
X5exp   Reactance at 5Hertz during expiration  
Zrs   Respiratory impedence 
5-HT   5-hydroxytryptamine 
∆XRS   In-breath difference in reactance at 5hertz  
∆p   Pressure difference in the airways 






















The primary function of the respiratory system is to maintain oxygen and carbon dioxide 
homeostasis through inhalation, gas exchange at the alveoli and exhalation. Ventilation is 
dependent on respiratory muscle capacity and neural respiratory drive (NRD) to 
overcome airways resistance, respiratory system compliance and the elastic load, 
otherwise known collectively as the respiratory load (Figure 1.1). An imbalance in these 
opposing forces can lead to alveolar hypoventilation and respiratory failure which often 
manifests in advanced pulmonary disease. Non-invasive ventilation (NIV) is used in acute 
and chronic hypercapnic respiratory failure to augment ventilation. Advances in 
telemedicine has enhanced the management of chronic health conditions. Two-way 
remote monitored home breathing support could facilitate early optimisation of home 
ventilation out with the hospital setting alleviating the increasing burden of obesity and 
chronic respiratory conditions present on health care.   
This thesis will review the physiology of ventilation, physiology investigations, advanced 
physiology markers and the evolution of telemedicine. Evaluation of the implementation 
experience and outcomes of two-way remote monitored home NIV and Continuous 
positive airway pressure (CPAP) therapy as a novel treatment option for home ventilation 
and breathing support within Greater Glasgow and Clyde (GGC) will be reported. 
Subsequent clinical outcomes in patient cohorts provided with two-way remote 
monitored home NIV for persistent hypercapnic failure in severe chronic obstructive 
airways disease (COPD) and obesity related respiratory failure (ORRF) are examined. The 
feasibility of advanced physiological measurements will be reported as part of an 
observational cohort study of patients managed with two-way remote breathing support, 
“Exploratory Endpoints”.  
 
1.1 Physiology of ventilation 
The respiratory cycle consists of the inspiratory and expiratory phases to maintain 
adequate ventilation. The diaphragm, a thin, dome shaped muscle which fills the inferior 
thoracic aperture creating the floor of the thoracic cage and roof of the abdominal cavity, 
is integral to ventilation and is anchored along the costal cartilages, L1-L3 intervertebral 
discs and Xiphoid process. Motor innervation of the diaphragm originates from the 
cervical plexus, spinal roots C3-C5, which form the phrenic nerves. These run through the 
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posterior mediastinum to supply the right and left hemi-diaphragms. The diaphragm is 
activated during inspiration, flattening to cause a downwards movement. This increases 
intra-thoracic volume creating a sub-atmospheric intra-thoracic pressure gradient 
(transpulmonary pressure), effecting airflow into the lungs. (Figure 1.2) Simultaneously, 
activation of the external intercostal muscles (which pull the ribs in the anterior caudal 
direction) during inspiration increases intra-thoracic volume contributing to 
transpulmonary pressure. Damage to the phrenic nerve can manifest as hemi-diaphragm 
paralysis with paradoxical movement of the diaphragm during inspiration, impaired 
ventilation and subsequent dyspnoea.[1] As transpulmonary pressures equalise, 
inspiration ceases and the expiratory cycle begins where the elastic recoil of the lung and 
chest wall allow the thoracic cage and diaphragm to return to original positions. 
Activation of accessory muscles of expiration, in the abdominal wall and intercostal 
muscles are integral to maintain adequate ventilation during periods of increased 
respiratory load seen during exercise. Within the alveoli, surfactant produced by Type II 
epithelial cells within the alveolar wall reduces surface tension that opposes alveolar 
expansion. Depleted surfactant production results in alveolar collapse and impaired 
ventilation often seen in paediatric respiratory distress syndrome.  
 
The non-linear relationship of pressure and volume during ventilation is demonstrated in 
figure 1.3 with the respiratory system compliance represented by the gradient of the 
slope at any given time. As maximal volumes are reached during inspiration, pressure 
changes slow down resulting in reduced compliance. (Figure 1.3) Obesity can result in 
reduced compliance due to the mass loading effect of increased adipose tissue within the 
chest wall and abdomen.[2][3]  
 
Ventilation exchanges air to and from the alveoli, the thin-walled terminal sacs at the end 
of the airways surrounded by capillaries, to facilitate exchange of oxygen into the blood 
and carbon dioxide (CO2) elimination into the alveoli during exhalation. Oxygenated blood 
travels from the lungs to the rest of the body where oxygen is taken up in the tissues 
during aerobic metabolism. Optimal gas exchange is governed by adequate ventilation, 
diffusion of gases and perfusion of the lungs. This physiological balance can be disrupted 
in disease, resulting in respiratory failure. For example, in COPD patients with emphysema 
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and hyperinflation, the ventilation perfusion relationship is impaired by limited diffusion 
capacity and inadequate ventilation. Heterogeneity of COPD can present with a variation 
of ventilation/perfusion (V/Q) mis-match patterns. An understanding of normal 
physiology and recognition of disease patterns can help personalise management of 
chronic disease. Tools to facilitate measurement and interrogation of physiological 
changes are vital to aid physiological phenotyping and optimisation of treatment in 







Illustration of the relationship of respiratory load with Neural Respiratory Drive and respiratory 





Figure 1-2 Respiratory mechanics 
Illustration of thoracic wall and diaphragmatic movement during inspiration (-----), creating a 
transpulmonary pressure initiating the inspiratory cycle.  
 
 




Figure 1-3 Pressure volume curve of a patient on volume control mode of ventilation 
Illustration of the non-linear relationship between airways pressure (cms H2O) and volume (Litres 
(L)) in a subject with no cardiorespiratory disease.  Optimal compliance is demonstrated when 
pressure and volume have a linear relationship.  Lower inflection point (Pflex) is the pressure at 
which airway resistance is overcome.  Upper inflection point represents the elastic recoil of the 





1.2 Established methods for measuring lung function 
Spirometry 
Formal assessment of lung function can be quantified by spirometry or whole-body 
plethysmography. Spirometry quantifies lung function using forced expiratory 
manoeuvres. Forced Vital Capacity (FVC), the total volume exhaled following a maximal 
inspiration and forced exhalation, is measured in Litres (L).[4] Forced Expiratory Volume 
at one second (FEV1) is also measured during this manoeuvre and estimates airways 
resistance (AWR) in lung disease. The forced expiration to vital capacity ratio (FEV1/FVC) 
distinguishes normal, and obstructive airway disease as seen in Table 1.1. FEV1 is a bio-
marker of disease progression and predictive of survival in neuro-muscular diseases but a 
less reliable predictor in disease progression in COPD patients.[5][6] In addition to 
measurement which can be compared with age-sex-ethnicity reference data, spirometry 
data can be presented graphically as flow-volume loops (Figure 1.4). Different disease 
states have typical effects on flow-volume loops, demonstrating the differential 
diagnostic value of spirometry in respiratory disease (Figure 1.4).[4]  
During periods of increased load (exercise) the end expiratory lung volumes (EELV) 
decrease in normal subjects (Figure 1.5). In patients with COPD and obesity, resting tidal 
volumes shift to the left in comparison to normal subjects. In obesity and COPD, the EELV 
increases during periods of increased respiratory load, resulting in high volumes of 
ventilation, shifting to left, predisposing these subjects to dynamic hyperinflation and 
increase sensation of dyspnoea (Figure 1.5, leftward arrow).  
 
Lung Volumes 
Static lung volumes, including Total Lung Capacity (TLC), Residual Volume (RV) and 
Functional Residual Capacity (FRC), can be measured by whole body plethysmography or 
inert gas dilution techniques (figure 1.6). FRC marks the end of passive expiration and is 
reduced in morbid obesity as a consequence of decreased Expiratory Reserve Volume 
(ERV) whilst RV remains relatively preserved.[7], [8] Hyperinflation due to loss of lung 
elastic recoil secondary to emphysematous disease is measurable by increased RV, FRC or 






Diffusion capacity of the lung, measured by a single breath hold of dilute carbon 
monoxide (CO) estimates gas exchange and is represented by transfer factor for the lung 
for CO (TLCO), Lung volume in which CO diffuses (VA) and the transfer coefficient (KCO).  
Compliance 
Compliance is variable throughout the respiratory cycle and can be quantified as the 
gradient at any point in the pressure volume curve as seen in figure 1.3, with a reduction 
at maximal volumes. Dynamic compliance can be quantified using an oesophageal balloon 
catheter to measure pressure changes during the respiratory cycle. Due to invasive 
techniques and respiratory muscle load in disease, quantifying compliance is impractical 
out with research settings. 
 
Airway Resistance and Reactance 
AWR is inversely proportional to the radius of the airways, increasing in smaller airways 
due to reduced radial traction in airway calibre. Turbulent airflow during high pressure 
gradients, such as a forced expiratory manoeuvre, also increases AWR. Airway muscle 
tone is regulated by the sympathetic and parasympathetic nerves. Cholinergic 
parasympathetic activation causes bronchoconstriction and smooth muscle contraction. 
Muscarinic antagonist’s reverse airway obstruction by blocking acetylcholine on 
muscarinic receptors in airways smooth muscle. Beta2-adrenergic agonists bind to Beta2 
receptors on airway smooth muscles to open calcium-activated potassium channels 
hyperpolarising smooth muscle cells leading to smooth muscle relaxation, increased 
airway calibre and reducing AWR. Inhaled muscarinic antagonists and beta agonist 
therapy are used in obstructive airways disease. 
 
Forced oscillometry technique (FOT) is a simple, non-invasive and effort independent test 
to quantify lung function including in-phase airways resistance and the out-of-phase 
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reactance. Forced oscillations of sound waves detect airway changes and together with 
pressure, flow transducers to determine respiratory impedance; the sum of resistance 
and reactance.[10] Reactance reflects capacitance (the elasticity of lung) and inertia 
properties of the lung. Resistance in both large and small airways can be derived from 
FOT and used as a bio-marker in small airways disease and obesity[10], [11] [12], [13] 
Further details of this technique and its application in disease monitoring are discussed in 
Chapters 2 & 5.  
 Obstructive airways disease Restrictive airways disease Obesity 
FEV1 (L) Reduced Normal/ Reduced Normal/ Reduced 
FVC (L) Reduced Reduced Normal/ Reduced 
FEV1/FVC  Reduced Normal/ Increased Normal/ Reduced 
RV Increased Reduced Normal/ Reduced 
TLC Increased Reduced Normal/ Reduced 
RV/TLC Increased Normal/ Reduced Normal/ Reduced 
DLCO Reduced Reduced Normal/ Reduced 
KCO Normal/ Reduced Reduced Normal/ Increased 
 
Table 1-1 Spirometry patterns 






Figure 1-4 Flow Volume Loops 
Illustration of flow volume loops from “Standardisation of spirometry” by Miller et al.[4] Flow-
volume loop of normal physiology (Figure 1.4.1), moderate airflow limitation in asthma (Figure 
1.4.2), severe airflow limitation in COPD (Figure 1.4.3), variable intra-thoracic upper airway 
obstruction (Figure 1.4.4), variable extra-thoracic upper airway obstruction (Figure 1.4.5) and 
fixed upper airway obstruction (Figure 1.4.6).   
Figure 1.4.1 Figure 1.4.3 Figure 1.4.2 




Figure 1-5 Flow volume loop in patients with obesity and COPD 
Maximal and tidal flow volume loops in age-matched females with normal lung function, obesity, 
COPD, and obese COPD. Tidal volumes shift to the left in obesity and COPD. End expiratory lung 
volume decreases during exercise in the healthy female, the obese, COPD and obese COPD 
females demonstrate dynamic hyperinflation (leftward arrows). COPD demonstrates both flow 






Figure 1-6 Lung volumes and capacities during the respiratory cycle 
Illustration demonstrates total lung capacity measured in millilitres (mL) and volumes during tidal 
breathing (tidal volume). The forced vital capacity (vital capacity) is the sum of maximum 
inspiratory capacity (inspiratory capacity) and maximal voluntary expiration (Expiratory reserve 
volume). The inspiratory reserve volume represents the difference between the inspiratory 
capacity and tidal volumes. The functional residual capacity is the sum of expiratory reserve 




1.3  Physiology in Sleep Medicine 
Complex neurochemical pathways are integral to maintain the balance between states of 
wakefulness and sleep. Wakefulness is governed by the “ascending arousal system” 
containing neural pathways with serotonin, histamine, dopamine, acetylcholine, and 
noradrenaline neurotransmitters. Extracellular adenosine activates the ventrolateral pre-
optic area (VLPO) suppressing the “ascending arousal system” and accumulates 
throughout wakefulness to induce sleep. (Figure 1.7) The central circadian clock in the 
suprachiasmatic nucleus further regulates the VLPO producing a complex balance 
between arousal neurochemicals, VLPO and the circadian cycle to maintain the 
sleep/wake cycle.[14], [15] Adenosine receptor antagonists, such as caffeine and 
theophylline inhibit the onset of sleep.[15] The orexin system, originating in the lateral 
hypothalamus, is another layer of control, promoting wakefulness and normal sleep 
architecture including influencing pathways responsible for rapid eye movement (REM) 
atonia. Damage to this system can result in excessive daytime somnolence, fragmented 
sleep and cataplexy seen in narcolepsy.[14]  
Sleep is categorized as Rapid Eye Movement (REM) controlled by cholinergic neurons and 
Non-rapid Eye Movement (NREM) regulated by noradrenaline and serotonin pathways. 
Cholinergic activity increases in a cyclical manner during NREM stages to trigger REM 
sleep where almost complete muscle atonia with only the diaphragm maintaining 
ventilation pre-disposes patients with underlying respiratory disease to REM-related 
hypoventilation. 
 
1.3.1  Investigations of Sleep Disordered Breathing (SDB) 
Transcutaneous Pulse Oximetry and Carbon Dioxide Assessment (TOSCA) 
Transcutaneous monitoring of capillary oxygen saturations and carbon dioxide levels can 
be measured using a sensor containing Oxygen (tpO2) platinum cathode, a glass carbon 
dioxide (tpCO2) sensor, heating element and reference electrode.[16]  Summary of data 
acquired includes mean tpCO2, maximum tpCO2, mean tpO2, minimum tpO2 and oxygen 
desaturation index (ODI). This is used to screen for nocturnal hypoventilation and in the 
optimisation of NIV therapy. A TCM5 FLEX monitor (Radiometer Ltd, Copenhagen, 




Limited channel polysomnography (LSS) measures 5 physiological variables overnight 
(nasal flow, pulse oxygen saturations, thoracic and abdominal respiratory impedance 
plethysmography (RIP) bands, body position and heart rate can be worn by the patient at 
home to identify and quantify the severity of sleep disordered breathing using 
apnoea/hypopnea index (AHI) and ODI. AHI >15events/hr is diagnostic of obstructive 
sleep apnoea (OSA) and correlated with daytime somnolence is diagnostic of obstructive 
sleep apnoea syndrome (OSAS). SOMNOmedics SOMNOscreen Plus (Randersacker, 
Germany) was used for limited polysomnography in this study.  
 
Polysomnography 
Polysomnography (PSG), the inpatient sleep laboratory investigation for sleep disordered 
breathing (SDB) incorporates 5 channel limited polysomnography with 
electroencephalogram (EEG), mandibular electromyogram (EMG), electro-oculogram 
(EOG), electrocardiogram (ECG), leg EMGs and a video recording (Figure 1.8). PSG 
facilitates sleep stage analysis via EEG analysis which is presented as a hypnogram. (Figure 
1.9) Sleep staging combined with video and other analysis of the associated channels is 
used for the diagnosis of parasomnias, sleep movement disorders and contributes to the 
diagnosis of narcolepsy and other hypersomnia’s. Polysomnography can be required for 
evaluation of selected patients with sleep disordered breathing, usually reserved for 
difficult cases, where there are medico-legal issues etc.  SOMNOmedics SOMNOscreen 






Figure 1-7 Neurochemical pathways of the sleep/ wake cycle 
Illustration of neurochemical pathways in the brain that regulate sleep and wakefulness. A- The 
ascending arousal system with excitatory projections to the brain cortex. B- Hypothalamic 
pathways controlling the deactivation of the ascending arousal system. Both pathways include 
acetylcholine (Ach), dopamine (DA), histamine (HA), laterodorsal tegmentum (LDT), 
norepinephrine (NE), orexin (ORX), perifornical region (PeF), pedunculopontine tegmentum (PPT), 
tuberomammillary nucleus (TMN), ventral periaqueductal gray matter (vPAG), 5-
hydroxytryptamine (5-HT). With the ventrolateral pre-optic area (VLPO) regulated by gamma 







Figure 1-8 Polysomnography 
Illustration of channels in a polysomnographic recording- including periodic limb movement (PLM, 
PLM1, PLM2), Snore monitoring (snore), flow analysis (flow), oxygen desaturation events (SpO2 
events), oxygen saturations trace (SpO2), heart rate (Pulse), cardiac arousals (cardiac events), 
electrocardiogram (ECG), oro-nasal flow analysis (pressure flow), respiratory impedance 
plethysmography of thorax (Thorax) and abdomen (Abdomen).   
Data presented illustrates obstructive sleep apnoea with regular obstructive breathing pauses 
(cessation of flow signal, variation in thoraco-abdominal movement) with associated 






Figure 1-9 Hypnogram 
Illustration of sleep stage analysis during polysomnography derived from electroencephalogram 
representing arousals, wakefulness (W), rapid eye movement sleep (R), non-rapid eye movement 




1.4 Respiratory muscle function 
Impaired respiratory muscle capacity results in respiratory load-capacity imbalance and 
consequential alveolar hypoventilation. (Figure 1.1) Increased Neural Respiratory Drive 
(NRD), the neuronal activation to motor units from the respiratory centre, can maintain 
ventilation homeostasis and is associated with increased dyspnoea[17][18]. 
Diaphragmatic function is integral in the assessment of impaired respiratory muscle 
function and whilst chest radiography is a convenient screening tool to identify those at 
risk of diaphragmatic paralysis, it is not diagnostic.[19] Oesophageal balloon catheters, 
pressure transducers and phrenic nerve stimulation is well-established but an invasive 
uncomfortable method to quantify respiratory muscle capacity.[13], [20] Phrenic nerve 
activation by either electrical or the better tolerated magnetic stimulation can quantify 
hemi-diaphragmatic function.[21], [22] Positional Vital Capacity (VC) measurements 
provide a simple dynamic non-invasive assessment of the diaphragm. [1][23] Whilst sniff 
nasal inspiratory pressure (SNIP) and mouth inspiratory pressure (MIP) non-invasively 
quantifies global inspiratory muscle strength corresponding with airway and oesophageal 
pressures and although feasible in clinical practice, do not identify hemi-diaphragmatic 
weakness.[24][25] Maximum expiratory pressure (MEP) and peak expiratory flow (PEF) 
quantifies expiratory muscle strength and airway obstruction with cough PEF often used 
in neuromuscular disease monitoring to identify deteriorating respiratory function and 
airway clearance. [26] 
Respiratory muscle weakness predisposes patients to nocturnal hypoventilation resulting 
in transient nocturnal hypercapnia and in severe cases persisting daytime hypercapnia. 









1.5 Chemoreceptors in respiration 
Ventilatory control incorporates a complex feedback loop integrating a sensory limb, 
central control, and effector limb (Figure 1.10). The sensory limbs consist of peripheral 
and central chemoreceptors which are located peripherally in the carotid/aortic bodies 
and centrally in the medulla oblongata of the brainstem.  
Peripheral chemoreceptors detect changes in arterial pH, pCO2  and pO2 levels. In states 
of low pO2 these receptors feedback to the medulla oblongata, pons, and cortical 
respiratory motor centres to increase respiratory rate, tidal volume, increase cardiac 
output and prioritise blood flow to the brain and kidneys. Central chemoreceptors detect 
changes in the pH of cerebral spinal fluid (CSF) , as a result of pCO2 freely diffusing across 
the blood-brain barrier, where it dissociates to H+ and HCO3-, lowering CSF pH, triggering 
the central chemoreceptors to stimulate the cortical respiratory motor centres and 
subsequent efferent limb of the feedback loop. In addition, mechanoreceptors in the 
chest wall feedback to the medulla where the central chemoreceptors respond to these 
signals and alter the ventilatory drive in the cortical respiratory motor centres stimulating 
the efferent limb/respiratory muscles to alter ventilatory patterns to normalise acid-base 
balance, pO2 and pCO2 levels.[28] 
In states of persistent hypercapnia, the choroid plexus cells in the blood brain barrier 
facilitate bicarbonate ions to diffuse into the cerebral spinal fluid, altering the pH and 
resetting baseline pCO2 levels. This is commonly seen in chronic hypercapnic failure 
secondary to severe COPD and obesity hypoventilation syndromes where normal 
compensatory mechanisms of increased ventilatory drive to increase alveolar ventilation 
are limited due to increased airway resistance, reduced compliance, increased respiratory 
load, respiratory muscle fatigue resulting in a blunted ventilatory response and higher 




Figure 1-10 Ventilatory drive as a negative feedback loop 
Control of ventilatory drive as a negative feedback loop. Peripheral chemoreceptors detect the 
change in pO2 whilst both peripheral and central chemoreceptors detect changes in pH, pCO2 and 
work of breathing via the mechano-receptors in the chest wall. Afferent feedback to the medulla 
and respiratory centres in the cortex result in efferent output to the effector muscles in the 
respiratory system to alter the ventilatory response to maintain acid-base balance, optimal pO2 
and pCO2 levels.[28] 
 
1.6 Neural Respiratory Drive  
 
1.6.1 Neural respiratory drive: The evolution from invasive to non-invasive techniques 
NRD represents the neuronal activation to motor units from the respiratory centre to 
overcome respiratory load to initiate the respiratory cycle. NRD is an established 
physiological marker in research to quantify the work of breathing.[29][17] An imbalance 
in the respiratory load capacity relationship results in alveolar hypoventilation and 
respiratory failure. (figure 1.1) Pressure generated during the first 100ms (P0.1) of 
inspiration against an occluded airway, measured by a balloon catheter sited in the 
oesophagus, quantifies NRD but is dependent on flow generation, muscle integrity, 
muscle function and lung volume.[30], [31] In conditions such as Chronic Obstructive 
Pulmonary Disease (COPD) where dynamic hyperinflation (DH) and intrinsic positive end-
expiratory pressure (PEEP) alters the length-tension properties of the diaphragm and 
increases inspiratory load required to overcome to initiate flow, P0.1  is an unreliable 
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marker of NRD. Electromyogram (EMG) of the respiratory muscles, the diaphragm and 
intercostal muscles, is a feasible alternative to indirectly quantify NRD and demonstrates 
increased NRD in hyperinflation and COPD.[13], [32][29], [33] 
 
Needle and surface EMGs first identified the role of the diaphragm in ventilation during 
tidal breathing and increased respiratory load.[20][34]–[39] Whilst preliminary animal 
studies demonstrated variable parasternal EMG activity in the rostro-caudal and 
mediolateral distribution during inspiration with similar distribution observed in human 
studies, identifying increasing inspiratory effort/EMG activity in the more caudal 
intercostal muscles with the greatest generated by the second intercostal muscle.[37], 
[38], [40][41]–[43] Normalising EMG by expressing NRD as a percentage of EMG signals 
during maximal manoeuvre such as maximum voluntary ventilation or maximal 
inspiration to total lung capacity, allows wider application as a biomarker in monitoring 
chronic disease, such as COPD and Cystic Fibrosis.[17]  
 
Quantifying NRD using needle EMG limits contamination of adjacent muscle activity 
(cross-talk) and eradicates the need to normalise resting breath EMG to maximal 
manoeuvres to allow a wider application of NRD results.[41], [42] However, needle EMG 
represents single motor unit function, failing to quantify the total number of units 
recruited and therefore the global effect of the muscle on inspiration.[42] Multi-pair 
oesophageal electrode catheters inserted via the nasal passage with balloons in the 
oesophagus and the stomach, directly measures pressure changes during the respiratory 
cycle to quantify global activation of the diaphragm (EMGdi), independent of the muscle 
length and is an establish research tool to measure NRD in normal and chronic disease 
states but is invasive limiting its use in clinical practice.[18], [29], [44]–[46]  Surface 
electrodes can represent global activation of the diaphragm during inspiration in both 
humans and dogs but cannot exclude cross-talk from adjacent intercostal or abdominal 
muscles activated during the respiratory cycle and during periods of increased respiratory 
load. [47]–[51] However, crosstalk during periods of quiet breathing or deep anaesthesia 
is negligible.[39], [48] Although not interchangeable with diaphragmatic EMG, parasternal 
EMG recordings via surface electrodes in the second intercostal space (EMGpara) is a 
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feasible non-invasive method of measuring respiratory load and NRD in research and 
clinical practice. [17][52], [53]  
 
1.6.2  Neural respiratory drive in pulmonary disease 
The altered length tension properties of the diaphragm in COPD patients reduces 
efficiency during inspiration, increases accessory muscle activation and increases NRD 
compared to healthy subjects correlating with disease severity.[54]–[58] NRD in COPD is 
increased compared to matched healthy subjects, and corresponds to disease severity 
and breathlessness.[29], [44], [57], [59], [60] In chronic respiratory disease, NRD rises 
during periods of increased respiratory load and can be negatively correlated with 
ventilation, otherwise referred to as neuro-ventilatory uncoupling and is evident when 
progressive dynamic hyperinflation (DH) during graded exercise impairs the pressure-
generating capacity of the diaphragm.[57][29] During exercise progressive DH correlates 
with reduced pressure-generating capacity of the diaphragm and dyspnoea in COPD 
patients.[61] Long acting bronchodilators demonstrated improvement in lung function, 
reduction in dyspnoea and NRD in this cohort of patients.[61], [62] However, dyspnoea 
does not correlate with neuro-ventilatory uncoupling but represents the awareness of 
increased NRD secondary to altered respiratory load, providing insight into 
pathophysiology of dyspnoea in chronic disease.[63]  
 
During states of increased respiratory load, parasternal intercostal muscle activation 
augments inspiratory effort in a rostro-caudal distribution. [37], [38], [41][64] Surface 
EMG of the second intercostal muscle demonstrates the greatest role in inspiration, is 
similar to diaphragmatic EMG and is a reliable reproducible method of quantifying NRD in 
COPD.[42], [43][53][65] NRD derived from parasternal EMG and NRD index (NRDI), the 
product of normalised EMG (EMGpara%max) and respiratory rate, can be used as a bio-
marker of disease monitoring following exacerbations or periods of increased respiratory 
load in both COPD and asthmatic patients. [65], [66] Utilising EMGpara during acute 




NRD correlates with lung function and acute exacerbations in Cystic Fibrosis(CF) and 
Interstitial Lung Disease (ILD).[17][68], [69][70] Higher NRD levels were observed in CF 
patients compared to healthy controls during exercise before they experienced increased 
dyspnoea, suggesting habituation of the sensation of breathlessness as a result of 
persistent high NRD levels in CF.[71] NRD is elevated in uncontrolled asthma compared to 
well controlled disease and matched healthy controls.[72] 
 
1.6.3  Neural respiratory drive in obesity, obstructive sleep apnoea and breathing 
support 
Increasing prevalence of obesity has led to an increase in morbidity and mortality.[73] As 
a result the prevalence of sleep disordered breathing (SDB) and chronic hypercapnic 
respiratory failure secondary to obesity has risen.[73] [74] NRD is elevated in patients 
with SDB and correlates with Body mass index (BMI). NRD further increases in the supine 
position representing increased PEEP in obese subjects.[75]  Continuous Positive Airway 
Pressure (CPAP) therapy can offset PEEP with a subsequent reduction in NRD up to 
30%.[75]–[77] Likewise, patients with chronic hypercapnic failure secondary to obesity 
demonstrate a decrease in NRD with adequate Non-invasive ventilation(NIV).[78] 
Quantification of this off-loading effect of NIV with NRD analysis predicts adherence in 
COPD-OSA overlap syndrome and potentially facilitate early optimisation of home 
ventilation and could predict treatment adherence.[79][80] However, challenges in 
domiciliary ventilation are increasing and evidence demonstrates patient ventilator 
asynchrony (PVA) in NIV for chronic hypercapnic failure can lead to decreased ventilator 
tolerance and de-ventilation dyspnoea.[81] Although parasternal EMG can detect PVAs 
during nocturnal NIV, the presence of PVAs does not impact nocturnal ventilation. 
[82][83]  
 
NRD can be reliably measured by surface electrodes at the second intercostal space and 
provides an assessable technique to quantify NRD in chronic respiratory disease.  NRD can 
stratify severity of disease, track fluctuations and predict clinical outcomes (successful 
discharge, optimised breathing support), facilitating a personalised approach to the 
management of chronic respiratory disease. Further evaluation of optimal techniques, 





Telemedicine(TM) is the delivery of health care and health information by incorporating 
information communication technologies in the exchange for health information to guide 
diagnosis, management and disease prevention when the patient and physician are in 
remote locations.[84][85] TM provides large datasets for evaluation, research and 
education for patients and healthcare professionals. Following the introduction of the 
internet, TM has developed from telephone-based consultations to the use of multimedia 
communications and wearable devices. [86] Modern digital infrastructure facilitates large 
data retrieval from wearable devices for research and analysis to deliver enhanced 
disease management and prevention of chronic disease.  
 
1.7.1 Telemedicine in Obstructive Sleep Apnoea Syndrome (OSAS) 
Obesity is a global health issue.[87], [88] With rising prevalence of both overweight and 
obesity comes further health implications, including diabetes[89], hypertension[90], 
cardiovascular disease[91], cerebrovascular disease[92], sleep disordered breathing[74] 
and all-cause mortality rates[93]. Obesity is a risk factor in obstructive sleep apnoea and 
the global obesity epidemic has resulted in increased prevalence of obstructive sleep 
apnoea syndrome (OSAS).[94], [95][74] 
 
OSAS is characterised by repeated upper airway occlusion, arousals during periods of 
sleep with intermittent hypoxia and hypercapnia which produces increased sympathetic 
activity leading to oxidative stress and systemic inflammation.[96] Untreated OSAS has 
significant health implications including excessive daytime sleepiness[97], impaired 
concentration[98], road traffic accidents[99], hypertension[100], [101], diabetes[102], 
cerebrovascular events[103], cardiovascular events[104] and all-cause mortality[105]. 
Sleep disordered breathing(SDB), which includes OSAS and Obesity Hypoventilation 
Syndrome (OHS), is associated with increased health related contact, medication use and 
socioeconomic costs.[106] Continuous positive airway pressure (CPAP) is the standard 
treatment for OSAS, improving adverse health outcomes[107] and is cost-effective[108]. 
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Adherence to treatment is integral in realising the long term benefits of CPAP in OSAS but 
studies have shown CPAP adherence to be low after the initial treatment phase[109], 
[110]. Telemedicine in SDB has potential to improve outcomes by providing patient 
support, early detection of treatment issues, reducing health professional’s workload (if 
service re-orientation managed appropriately). Published work so far has shown the use 
of tele-monitoring, tele-communications and patient education can reduce the burden on 
health professionals whilst facilitating early detection of treatment issues[111]–[113]. 
However, uncertainty regarding the most important intervention which facilitates a 
greater treatment effect and implementation of an individualised approach within 
existing service remains a challenge[111], [114]. 
 
CPAP is an effective treatment for OSAS and can reduce adverse health outcomes if usage 
exceeds 4 hours of PAP a night[115]. Whilst patient perception of excessive sleepiness 
improves with the use of CPAP therapy exceeding 6 hours a night[116], compliance to 
CPAP therapy is poor with adherence levels as low as 46%[109]. Adherence (70% days 
with CPAP usage 4hours; the level set for reimbursement in US health system) to CPAP 
therapy is seen as the major challenge in OSAS management and has been the focus of 
many telemedicine studies. However, adherence is population based and an imperfect 
surrogate endpoint for individual outcomes, as 3hours of continuous usage may reduce 
symptom burden in some patients whilst others may need more PAP usage. Factors 
influencing CPAP adherence, such as interface/device issues, intolerance of pressures, 
drying of the airways, claustrophobia and other psychological barriers, make this a 
difficult challenge to address[117]. Therefore, it is important to incorporate symptom 
burden, improvements in respiratory failure and other validated biomarkers when 
analysing PAP adherence. Telemedicine facilitates big data retrieval and individual data 
analysis to allow better understanding and provision of a personalised approach in the 
management of SDB.  
 
Tele-monitoring (TM) of CPAP therapy has been shown to have a positive effect on 
patient outcomes with a positive trend in adherence and accuracy in the transmitted data 
in an early pilot study in 2007[118]. Tele-monitoring with identification of individuals with 
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therapy issues combined with telephone trouble-shooting has been shown to improve 
CPAP adherence.[119] Whilst patient access to web based telemonitoring improves CPAP 
adherence and encourages patients engagement, automated messaging (triggered by 
pre-set intervention points) with access to CPAP usage can also improve adherence and 
reduce time spent on patient education compared to standard therapy.[120][121][122] 
Although automated messaging with TM may improve patient outcomes, it is important 
to consider how this advice is delivered to ensure maximum patient benefit. Pengo et al 
evaluated the effect of positive framed messages compared to negative framed messages 
and usual care during the initiation of CPAP therapy and found an improvement in 
compliance with the positive message arm and 50% reduction in dropouts compared to 
other arms.[123]  
 
Internet based resources for patient education have been shown to have a positive effect 
in adherence to CPAP[124]. Web based OSA education, telemonitoring with automated 
messaging demonstrated an improvement in treatment adherence in the combination of 
web-based education and TM with automated messaging arms compared to a single 
intervention or standard care. Whilst TM with automated messaging alone improved 
compliance, web-based education did not but demonstrated improved clinic 
attendance.[111]  
 
Videoconference (VC) calls enable health professionals to educate and assess therapy 
issues such as mask fit and application which otherwise may have required a hospital 
visit. The use of VC in patient education during the initiation of CPAP therapy has been 
proven to be as effective as face-to-face training and may provide future service 
efficiencies[125]. Reassuringly, treatment adherence is equivalent in patients who are 
managed through videoconference calls in comparison to usual face-to-face 
consultations, supporting a scrutinised adoption of videoconferencing to determine its 
benefits on patient experience, travel and service efficiencies. [126] 
 
Evidence of the cost-effectiveness of TM needed as many studies lack robust data and 
well-defined cost outcomes within their analysis. A systematic review of cost-
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effectiveness of TM by De La Torre-Diez et al in 2015 highlighted the lack of robust 
randomised control trials in this area with many studies underpowered or low quality 
data[127]. However, more recent studies have demonstrated cost savings with TM 
justifying further exploration to optimise both patient and financial outcomes in future 
research[128]–[131].  
 
Several studies have reviewed the impact of who delivers these interventions, comparing 
sleep physicians, primary care physicians and health care professionals[128], [129], [132], 
[133]. Although better outcomes were associated with sleep specialist involvement in 
CPAP management[132]–[134], more recent studies suggest that both primary care 
management of OSAS and health care professionals can deliver this service achieving 
similar patient outcomes[128], [129]. Task shifting the management of OSAS to primary 
care and health care professionals demonstrates not only service efficiencies but 
potential cost effectiveness and should not be ignored considering the burden on our 
specialist services. 
[128] 
1.7.2 Telemedicine in home NIV and its use in Chronic Obstructive Pulmonary Disease  
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory condition 
characterised by persistent and often progressive airflow obstruction that is not fully 
reversible and/or the destruction of the lung parenchyma[135]. Diagnosis is based on 
patient symptoms and spirometry. COPD is a smoking related disease but occupational 
exposures (harmful chemicals and dusts) contribute to this disease[136]. The prevalence 
of COPD increases with age and it is thought that approximately 3 million people in the 
UK have COPD with 2 million undiagnosed[136]. Exacerbations of COPD lead to impaired 
ventilatory function and gas exchange resulting in respiratory failure[137]. During 
exacerbations, a reduction in muscle function results in increased symptoms, increased 
healthcare usage and in severe cases results in hospital admissions. COPD exacerbations 
are the leading cause of hospitalisation in the UK, with 15.9% of all admissions[138] and 
have demonstrated a rise in health care cost of the general population[139]. COPD is the 
third most common cause of death in the USA[140] and is projected to be the fourth 
leading cause of death in the world by 2030[141]. COPD is characterised by progressive 
and irreversible airways disease. Airways obstruction and emphysema progress with 
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advancing age, resulting in a deterioration in obstruction of the large and small airways, 
small airways collapse, gas trapping, dynamic hyperinflation, and increased PEEP.  The 
respiratory load in COPD rises and therefore NRD increases to maintain adequate 
ventilation compared to normal subjects, corresponding to disease severity and 
breathlessness.[29], [44], [59][57], [60]In severe disease, an increase in dead space, 
ventilation/perfusion mismatch and impaired transpulmonary pressures secondary to 
muscle shortening in dynamic hyperinflation contributes to hypercapnic failure. NIV can 
overcome intrinsic PEEP and augment ventilation.   
Several studies reviewed the use of telemedicine in the management of COPD to optimise 
clinical and service outcomes with tele-monitoring of peripheral oxygen saturations (SpO2 
) in COPD demonstrating no improvement in clinical outcomes compared to standard 
therapy[142]–[144]. In one study, telemonitoring of SpO2 combined with heart rate 
monitoring, questionnaires, weekly weight and blood pressure measurements, did not 
improve patient outcomes but increased hospitalisation. [143] Although the 
incorporation of physiological parameters, symptom burden, telephone communication 
with patient education within tele-monitoring can improve clinical outcomes and 
healthcare usage, careful consideration of acceptable targets and interpretation must be 
established to ensure there is an overall benefit.[145][146] A multi-factorial approach to 
telemedicine in management of chronic disease, encouragement of patient engagement, 
patient education, appropriate service model and evidence based targets are required to 
deliver an individualised service beneficial to both the patients and health care resources.  
The use of acute NIV in acute hypercapnic failure in an exacerbation of COPD has been 
well established with developing evidence of the use of domiciliary NIV in severe COPD. 
Recent studies have assessed the clinical benefits of home NIV in both stable COPD and 
following an acute exacerbation with a reduction in one year all-cause mortality seen in 
patients treated with high-intensity home NIV in severe stable COPD who had low 
emergency admission rates.[147] However, the RESCUE trial found no improvement in 
admission free survival in those treated with home NIV in severe COPD in patients with 
persistent hypercapnia 48 hours following acute NIV.[148] The failure to demonstrate a 
significant improvement in the time to re-admission or death and carbon dioxide 
reduction could be a result of the moderate pressure support delivered in this study 
compared to the Kohnlein et al. Nevertheless, this study highlighted the importance of 
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timing in the assessment for home NIV. Early initiation of home NIV following acute 
hypercapnic failure may not benefit all patients considering a cohort will return to a 
eucapnic state following an acute hypercapnic exacerbation of COPD.[148] 
The UK HOT HMV study addressed the caveats recognised from previous studies to 
identify those who would gain maximal benefit from home NIV in severe COPD.[149] This 
study evaluated the impact of domiciliary NIV in addition to long term oxygen therapy in 
severe COPD with persisting chronic hypercapnic respiratory failure 2-4 weeks following 
an exacerbation requiring acute NIV. Time to hospital re-admission or death was 
prolonged in the home NIV and home oxygen arm in comparison to oxygen therapy 
alone. In addition, this study demonstrated a reduction in exacerbation frequency and 
control of ventilatory failure in the home NIV arm. Screening for persistent hypercapnic 
failure 2-4 weeks following an exacerbation minimises selection of patients who would 
otherwise have returned to an eucapnic state following a life-threatening exacerbation of 
COPD. However, only 6% of those screened were included in this study leading to patients 
who may otherwise have been considered for home NIV including the growing COPD-
OSAS overlap cohort being excluded from analysis and therefore not fully representative 
of clinical practice. Likewise, patients unable to be stabilised for 2-4 weeks post 
hypercapnic exacerbation, who would likely be re-admitted would not have met the study 
requirements and should be considered a research priority to avoid repeated hospital 
admissions impacting on patient morbidity/mortality and has significant healthcare 
implications.[149]  
As a result, tertiary referrals for home NIV has increased in light of the growing evidence 
supporting home NIV in hypercapnic severe COPD. [149][147][148], [150] Clinical 
assessment by a physician identifies those suitable for NIV therapy, assess patient 
engagement and cognitive ability to independently manage home NIV. Cognition can be 
significantly impaired in both stable COPD and to a greater degree following an acute 
exacerbation compared to controls[151]. Whilst low cognitive performance and 
independence was demonstrated in a range of respiratory diseases during inpatient NIV 
set-up and at 6-week review[152]. Early recognition of patients at risk of poor adherence 
to domiciliary NIV may facilitate a personalised approach to initiation and patient 
education to maximise benefits of home NIV[153].  
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Data analysis from tele-monitored NIV devices has been showed to be reliable and 
combined with SpO2monitoring facilitates optimisation of NIV therapy and reduces 
nocturnal respiratory events. [154] Tele-monitoring data provides remote access of daily 
usage, indicating patients tolerance to NIV with low usage and signifying disease severity 
in those with increased use of home NIV.[155], [156] Early detection of excessive air 
leakage with tele-monitored NIV data can aid early optimisation of ventilation, improve 
sleep quality and adherence.[157], [158] Remote data from tele-monitored NIV devices 
provides accurate ventilation data to enable therapy optimisation with the potential to 
improve clinical and service outcomes in home NIV.[159]  
Tele-monitoring of home ventilation provides a rich data set for future studies to create 
preventative models in chronic disease with predictors of exacerbations of chronic 
respiratory disease. Rising apnoea hypopnoea index (AHI) on NIV data analysis from tele-
monitored devices correlates with exacerbated heart failure and fluid accumulation.[160] 
Whilst, a persistent rise in respiratory rate (RR) and percentage of respiratory cycles 
triggered by the patient was associated with increased risk of exacerbations in COPD, with 
higher RR shown up to 10 days preceding exacerbations. [161] [162] However, further 
studies are required to identify the best predictors in disease exacerbations from NIV data 
analysis. 
Remote monitoring of PAP therapy provides the opportunity to explore the potential of 
day-case initiation of NIV in stable chronic hypercapnic patients. Patout et al 
demonstrated no difference in 3-month PCO2 and adherence rates in PSG home NIV set-
up versus nurse-led oximetry-capnography monitoring set-up, suggesting a rationalised 
approach to NIV initiation is safe and effective[79].  Home NIV initiation with tele-
monitoring in patients with stable chronic respiratory failure has been shown to be as 
effective as inpatient NIV initiation in terms of control of ventilation, quality of life and 
cost-effective[163]. 
The growing burden on the health service requires us to address the disease management 
both in acute exacerbations and chronic disease, utilise new technologies to identify 
physiological parameters which may be used as predictors of disease trajectory and 
potentially develop a personalised preventative disease management model. Specialist 
review is required to identify patients at a suitable timepoint following an exacerbation, 
assess physical and cognitive abilities to manage home NIV to ensure the appropriate 
55 
 
application of this new treatment in hypercapnic COPD patients. Telemedicine can enable 
the fusion of remote NIV/CPAP data, symptom burden, physiological parameters with 
improved communication technology to build a rich data set for analysis of predictors of 
disease and improve patient outcomes. Current studies are assessing the use of web-
based platforms in remote monitoring of home NIV and other physiological parameters. 
At present, there are no multicentre studies utilising these methods to measure 





1.8 Volume Assured Pressure Support modes of non-
invasive ventilation 
Volume assured pressure support (VAPS) titrates pressure support required to maintain a 
pre-set target tidal volume or target alveolar ventilation over several breaths during NIV. 
Average VAPS(AVAPS, Philips Respironics) mode targets tidal volume whilst intelligent 
VAPS (iVAPS, ResMed) adjusts both pressure support and respiratory rate to deliver 
target alveolar ventilation[164]. Target tidal volume and alveolar ventilation is calculated 
using height, arm span or ulnar length to estimated ideal body weight. Typical initial 
target tidal volume for non-invasive ventilation would range from 6mls/kg to 10mls/kg of 
ideal body weight (Figure 1.11). Auto-titration of expiratory pressures (AutoEPAP) is an 
additional function to offset variable expiratory flow limitation seen throughout sleep 
cycles and positions (Figure 1.12). AutoEPAP is estimated using oscillometry to assess 
changes in airways resistance and reactance (AVAPS AE) or by flow-time curve analysis 
(iVAPS autoEPAP).  
 
AVAPS has been shown to be equivocal to fixed spontaneous-timed (ST) NIV in several 
studies of several disease cohorts[165][166][167]. Murphy et al, demonstrated control in 
nocturnal hypoventilation in COPD-OSA overlap  with similar settings achieved overnight 
with auto-titrating NIV compared to standard fixed pressure support with 
polysomnography[168]. This study suggested improved treatment adherence and 
subjective sleep comfort with auto-titrating NIV[168]. Likewise, Storre et al demonstrated 
AVAPS and fixed NIV therapy was equivocal with improved perceived sleep efficiency with 
AVAPS therapy[169]. The use of AVAPS in acutely decompensated hypercapnic failure 
secondary to COPD exacerbations showed a greater improvement of ventilatory failure 
and conscious levels compared to ST mode NIV.[170]  Similarly, the use of auto-titrating 
mode in patients with obesity hypoventilation has shown improved control of ventilatory 
failure compared to ST mode with similar improved subjective sleep quality.[171] Auto-
titrating NIV can improve ventilation in chronic hypercapnic failure secondary to 




Utilising VAPS NIV in the initiation of home NIV has been shown to reduce the length of 
stay  during hospital initiation whilst demonstrating equivocal control of ventilatory 
failure in stable hypercapnic severe COPD patients.[173]At our centre our evolved service 
model is based on the use of VAPS modes routinely. AVAPS-AE mode is typically used for 
acute NIV and initial titration during inpatient set up. Experience has shown reduction in 
occupied bed days for NIV initiation with this strategy.[174] Although the study numbers 
remain small, these demonstrated the safety of VAPS NIV in a wide range of diseases and 
its additional benefits compared to fixed ST NIV. Availability with two-way remote 
monitoring with the Lumis ResMed devices and reduced cost of these have made them 
the preferred device in NHS Scotland. iVAPS auto EPAP (Lumis, ResMed) is the default NIV 







Figure 1-11 Average Volume Assured Pressure Support (AVAPS) non-invasive ventilation mode. 
Illustration of AVAPS feature- automatic adjustments of pressure support according to patients 
needs to guarantee an average tidal volume (Target Vt), counterbalancing the changing workloads 
of ventilation due to body position, sleep stages and overall respiratory mechanics. Representing 
inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) 
requirements with maximum inspiratory positive airway pressure (IPAP max) and minimum 
inspiratory positive airway pressure (IPAP min) settings.  
 
 
Figure 1-12 Average Volume Assured Pressure Support therapy with auto-titrating expiratory 
positive airway pressure (AVAPS-AE) non-invasive ventilation mode. 
Algorithm responds to variations in inferred tidal volume and resistance (measured by 
oscillometry wave), adjusting therapy to maintain target tidal volume (Target Vt), airway patency, 
offset airway resistance (resistance) and expiratory flow limitation. Representing inspiratory 
positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) requirements with 
minimum pressure support target (PS min) and maximum pressure support target (PS max).  
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1.9  Conclusion 
 
The utilisation of advanced physiological measurements in combination with standard 
diagnostics provides valuable insights into the pulmonary mechanics of respiratory 
disease, facilitates physiological phenotyping, and have potential role as a biomarker in 
chronic respiratory disease to aid early identification of treatment success. Increased 
prevalence of obesity related respiratory failure and the strong evidence base for home 
non-invasive ventilation in hypercapnic severe COPD has led to increased pressures on 
tertiary breathing support services. Tele-monitoring of home NIV and CPAP facilitates 
prompt identification of therapy issues, early treatment optimisation, whilst providing a 
rich data set of ventilatory parameters and physiological response for further analysis, 
exploration into machine learning and development of predictive modelling. Fusion of 
advanced physiological measurements and tele-monitoring has the potential to provide 
physiological insights into chronic respiratory disease, respiratory failure, and its response 
to long term breathing support. Adaption of new technologies such as volume assured 
pressure support non-invasive ventilation, two-way remote tele-monitoring, and 
exploration of the feasibility of advanced physiological measurements of chronic 



















2.1  Two-way remote monitoring of home ventilation in the 
Glasgow Sleep and Breathing Support Research Centre  
In Q2 of 2015, four hospitals within Glasgow, merged into one purpose built multi-million-
pound hospital now known as the Queen Elizabeth University Hospital (QEUH), resulting 
in an exponential rise in in-patient breathing support assessment. The Glasgow Sleep and 
Breathing Support Research Centre (GSBSRC) was established in 2016 and based across 
two sites: the QEUH and Gartnavel General Hospital (GGH).  Rising prevalence of obesity, 
obesity related respiratory failure (ORRF) and recent emerging evidence supporting home 
NIV in severe COPD with persistent hypercapnic failure has resulted in increased 
pressures on local services presenting many clinical and service challenges.  
 
The legacy service model for initiation of home NIV incorporated in-patient multiple night 
NIV titration with transcutaneous monitoring with additional ancillary investigations if 
indicated. This was either during an elective admission or transfer to the tertiary centre 
in-patient beds at the QEUH. This model was unable to meet the heightened demands on 
the service from tertiary referrals, a reduction in bed availability due to the recent merge 
of local hospitals in to one site, unrepresentative sleep patterns and limited access to 
diagnostics.  
 
GSBSRC adopted new technologies to aid in the development of new clinical pathways to 
improve diagnostics and service efficiencies. Utilising average volume assured pressure 
support with auto-EPAP(AVAPS-AE) mode NIV using a Respironics A40 device 
(Respironics, Philips, UK) for inpatient initiation, titration, benchmarking with 
transcutaneous monitoring and establishing on ST mode as destination therapy 
demonstrated significant service efficiencies in comparison to the previous in-patient 
model[174]. Procurement of NIV devices and future TM solutions are determined in NHS 
Scotland by the National Procurement Framework, where the evaluation of cost, device 
quality and vendor support are integrated, providing a ranked or open recommendation 
for device adoption within Scottish health boards, clinicians, and finance teams. Resmed 
™ auto-titrating volume assured pressure support, CPAP and NIV generators are the 
number 1 preferred device supplier from the 2014 contract. Resmed ™ developed a range 
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of ventilators enabled with tele-monitoring via a data card and wireless connectivity for 
all Positive Airways Pressure (PAP) devices (Figure 2.1). This data is uploaded to Airview 
™, a secure cloud-based patient management system, accessible to healthcare 
professionals to review patient data, analyse physiological parameters and adjust 
ventilator settings to facilitate early optimisation of treatment and improve patient 
outcomes (Figure 2.2 & Figure 2.3). NHS Scotland Sleep, Home Ventilation and Oxygen 
Procurement Framework 2018 determined there would be no extra cost for indefinite 
data provision from TM CPAP/NIV.  
 
In addition to new device technology, the progressive introduction of electronic health 
records (EHR) throughout NHS Greater Glasgow and Clyde (NHS GG&C) has facilitated 
vetting of referrals and early investigations in those deemed to have a high probability of 
sleep disordered breathing (Figure 2.4). EHR portal is part of the Scottish Government 
initiative on e-Health, to allow immediate access to clinical notes, integrate patient 
journeys, to provide a safe and effective service whilst collating big data for audit and 
future population studies. 
 
2.1.1  Initiation of Tele-monitored PAP therapy in GSBSRC 
Home NIV was commenced in patients with persistent hypercapnic failure secondary to 
ORRF or severe COPD using Lumis 150 or Lumis 100 ventilators (Resmed, UK) (Figure 2.1). 
Both ventilators facilitate remote monitoring with the Lumis 150 providing adaptive mode 
average volume assured pressure support (iVAPs) in addition to Spontaneous Timed (ST) 
and lesser used NIV modes. Remote reviews of individual ventilatory requirements 
highlight therapy issues, enable remote therapy prescription changes to allow early 
optimisation of home NIV. (Figure 2.2 &2.3) Likewise, Obstructive Sleep Apnoea (OSA) 
patients with daytime somnolence were commenced on a similar device therapy via 
Airsense 10 Autoset (Figure 2.5) with remote monitoring and adaptive positive airways 
pressure support (APAP) or CPAP modes.  
 
Assessment of suitability for inpatient or outpatient investigations was identified at 
breathing support clinic or via electronic vetting (Figure 2.4). Complex patients with 
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multiple medical conditions were investigated and initiated on PAP therapy on an in-
patient basis. Inpatient PAP set up incorporates auto-titrating ventilators on initial night 
of PAP therapy to guide ventilator requirements necessary for domiciliary devices (Figure 
2.6).  Inpatient initiation allows daily clinical review of gas exchange, ventilation 
requirements and patient education to optimise therapy prior to discharge. All patients 
deemed suitable for remote monitoring were provided with written consent (Appendix 1) 
and the device activated prior to discharge with virtual clinic appointment one-week post-
discharge.  
 
Clinical pathways for remote review of patient data and telephone consultations have 
been developed and modified depending on type of PAP therapy and place of initiation 
(inpatient/outpatient). Virtual clinical review allows evaluation of investigations, clinical 
documentation, assessment of symptom burden and detailed TM data review of PAP 
therapy including compliance reports (Figs 2.2 & 2.3) to identify therapy issues to 
facilitate early optimisation. An outline of virtual clinic review structure is detailed in 
Figure 2.7. 
  
2.1.2 Outpatient initiation of Tele-monitored PAP therapy  
Day-case initiation of PAP therapy was considered in patients with stable COPD with 
persistent hypercapnia, obesity related respiratory failure or OSAS. Early remote data 
review (24-48hours) for patients who are frail or have multiple co-morbidities should be 
arranged. Formal virtual clinic review one-week following initiation facilitates detection of 
therapy issues to promote early optimisation. The out-patient pathway is detailed in 
Figure 2.8. Assessment of symptom burden, quality of sleep, device integration, therapy 
issues, remote prescription changes allow individualised follow up and optimisation of 
NIV. Six-week review is advised for patients who are frail, multiple comorbidities and 
severe hypercapnic failure. Whilst patients tolerating therapy with symptom control, 
patients from remote locations (Western Isles) and those with significant physical 





Figure 2-1 Resmed Lumis 150™ bilevel positive airway pressure ventilator with humidification 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2-4 Electronic vetting for NHS Greater Glasgow and Clyde tertiary sleep service 
Illustration of electronic vetting utilising electronic health records via clinical portal. Referral pathways 
include inpatient assessment, breathing support clinic review, referral directly for limited polysomnography 
(LSS) for high risk patients and hypercapnic severe COPD pathway. Patients with evidence of obesity 
hypoventilation on LSS are reviewed in breathing support clinic with capillary blood gas analysis (CBGs) 
prior to initiation of positive airway pressure (PAP) therapy- either continuous positive airway pressure 




Figure 2-5 Auto-titrating positive airway pressure (PAP) device 
The Airsense 10 Autoset device (ResMed, UK) delivers auto-tirating PAP therapy with the option 







Figure 2-6 Inpatient pathway for breathing support assessment at Glasgow sleep and breathing 
support research centre. 
The diagnostic evaluation includes polygraphy, transcutaneous monitoring of carbon dioxide 
(CO2), oxygen saturations (SpO2) and morning capillary blood gas analysis (CBGs). Therapy nights  
include the initiation of positive airway pressure therapy (PAP) or non-invasive ventilation(NIV), 
further monitoring if required. The second therapy night involves PAP or NIV titrations to auto-
titrating PAP therapy (APAP), continuous positive airway pressure (CPAP), spontaneous-timed NIV 





Figure 2-7 Remote data review, teleconsultation pathways and troubleshooting for Glasgow 










































































































Figure 2-8 Day case positive airways pressure initiation pathway 
Illustration of a typical pathway for day case initiation of PAP therapy in Glasgow sleep and 





2.2 Clinical outcomes using remote monitored Non-
invasive ventilation 
Chapter 3 will focus on a retrospective review of an observational cohort of patients who 
were commenced on two-way remote monitored home NIV in severe COPD with 
persistent hypercapnic failure (cohort 1), patients who required acute NIV for 
hypercapnic failure secondary to an exacerbation of COPD but were not referred onward 
for long term breathing support (cohort 2- “control”) within the GSBSRC service from 
March 2017 to January 2018. A further retrospective review of observational data from 
patients with ORRF (cohort 3) within the GSBSRC service was reviewed in NHS Greater 
Glasgow and Clyde between July 2016 and January 2018. GSBSRC COPD home NIV 
protocol is detailed in Figure 2.9. In this study we review the feasibility of two-way 
remote monitored home NIV in hypercapnic failure secondary to severe COPD and ORRF, 
the impact on clinical outcomes and service efficiencies.  
 
2.3 Exploratory Endpoints 
Chapter 5 focuses on exploratory advanced physiological endpoints incorporated within 
“The Exploratory Endpoints” study protocol (Appendix 2) allowing the inclusion of 
patients with any respiratory condition who can consent for exploratory physiological 
measurements to be taken alongside their standard respiratory care. Patients requiring 
two-way remote monitored PAP therapy or home NIV were also considered for 
recruitment and a typical pathway for the exploratory endpoints in this cohort is detailed 
in figure 2.10.  
Patients who met the inclusion criteria seen in appendix 2 and physically able to 
participate in our physiology endpoints study alongside the standard care for respiratory 
conditions were given information detailing the study requirements (Appendix 3) and 
written consent was given (Appendix 4).  
Baseline visit included basic anthropometrics, capillary blood gas in patients with 
evidence of chronic hypercapnic failure, parasternal electromyogram (EMGpara) 
measurements, forced oscillometry, heart rate variability, FEV1/FEV6, Blood pressure (BP) 
and Oxygen Saturations (SpO2). All physiology methods will be discussed in detail below. 
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All patients completed Health Related Quality of Life Questionnaires (HRQOL) including 
the Epworth Sleepiness Scale (ESS), modified COPD Assessment Tool (mCAT), Medical 
research council dyspnoea score (MRC) and ECOG Performance Status (PS) (Appendix 5).  
Study visits included baseline, 3months, 6 months and 12 months. All anthropometric and 
physiological measurements were repeated at each visit in addition to completion of 
symptom burden questionnaires.  Virtual review of therapy for those managed with two-
way remote monitored PAP therapy/NIV followed the patient pathways previously 
discussed in this Chapter.  
 
2.3.1  Parasternal Electromyography 
Neural Respiratory Drive can be quantified using surface electrodes positioned in the 2nd 
intercostal space, as discussed in Chapter 1. The simplification of this method is explored 
in Chapter 4 and appendices 6-8. Parasternal electromyography (EMGpara) is measured 
during tidal breathing at rest and normalised through maximal respiratory manoeuvres 
(EMGpara%max). Normalisation allows wider application within a study population. 
Neural Respiratory Drive Index (NRDI) is a product of normalised parasternal EMG 
(EMGpara%max) and respiratory rate (RR) which can be used as a physiological biomarker 
in disease monitoring and its clinical application is discussed in chapter 5. 
 
Instrument Set up 
Once the patient was in a semi-recumbent position in bed, electrode position was 
identified using bony landmarks to detect the 2nd intercostal space (Figure 2.11). Skin is 
cleaned and prepared, as discussed in detail in chapter 4, before electrodes were applied. 
Signals were sampled at 2kHz with band pass filters at 10Hz to 1000Hz by Dual Bio Amp 
(ADInstruments, Chalgrove, UK). Amplified signals were then passed to a digital converter 
(Powerlab, ADInstruments, Chalgrove, UK). Further analysis and digital filtering of signals 
was then done within Labchart software (ADInstruments, UK) on a personal computer. RR 
can be estimated from oro-nasal flow analysis or respiratory impedance plethysmography 
(RIP) bands. All study patients had respiratory rate estimated by RIP bands. In a small 
number of patients, oro-nasal flow was processed and analysed through a spirometer 
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module, Dual Bio Amp and Powerlab. PowerLab Input channel set up for signals are seen 
in Table 2.1.  
All patients had at least 5 mins of resting tidal breathing prior to at least 10 sniff 
manoeuvres, measured as per ERS guidelines. EMGpara measurements were taken at 
baseline and where feasible at 3months and 6months alongside standard respiratory care 
including following the initiation of continuous positive airway pressure support or non-
invasive ventilation depending on underlying diagnosis.   
All results are presented as absolutes values, mean standard deviation of EMGpara, 
EMGpara%max and NRDI at baseline, 3 months and 6months in each cohort.  
 
2.3.2 Forced Oscillometry 
The theory and application of forced oscillometry (FOT) has been discussed in Chapters 1 
and 5. FOT is an established research tool in both paediatric and adult medicine, 
providing insights into pulmonary mechanics in normal and chronic respiratory disease.  
 
Instrument set up  
FOT was measured using a portable device (Tremoflo, Thorasys, Canada), facilitating 
study recruitment over split sites. Calibration of the device can only be completed when 
correlating software and Calibration Test Load is available and was completed before 
each study visit.  
On the first study visit for each patient, a new folder identified by individual study 
number was created with patient demographics and smoking history. At each study visit a 
new mouthpiece with bacterial/viral filter is opened and placed on the handheld unit of 
the oscillometer. With the patient sitting in an upright position, a nose clip to seal nasal 
passages, face in an upward position of approximately 15 and hands supporting cheeks 
and mouth floor prior to the standard test initiation (Figure 2.12). Once a seal was 
created around the mouthpiece with the tongue underneath, the patient is asked to 
commence tidal breathing. When steady, quiet breathing had been observed for at least 
3 cycles, the patient is informed, oscillometry measurements initiated and sampled for 
20seconds on at least three occasions according to 2003 ERS guidelines[175]. In cases 
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where analysis of results demonstrated a Coefficient Variation (CV) greater than 15 if 
feasible, further measurements were taken.  
 
The results are presented as the mean for each component calculated by FOT. FOT 
parameters calculated included: Total resistance (R5), Small airway resistance (R5-R20), 








Figure 2-9 NHS Greater Glasgow and Clyde initiation of home non-invasive ventilation in 
patients with hypercapnic severe chronic obstructive pulmonary disease 
SHOOF- Scottish home oxygen order form, Va- alveolar ventilation, autoEPAP- auto-titrating Expiratory 
positive airway pressure, iBR- intelligent back up rate, PS- pressure support, EPAP- expiratory positive 
airway pressure, %spont breath- percentage of spontaneous breaths, CBGs- capillary blood gas analysis, 
SPO2- peripheral oxygen saturations (%), ODI- oxygen desaturation index, TcCO2- Transcutaneous carbon 












































































































































































































































































































































































































































































































Figure 2-11 Parasternal electromyogram patient setup. 
The study candidate is positioned at 45 degrees; bony landmarks are identified at the parasternal 
margins of the 2nd intercostal space and right clavicle as seen (Red arrows). Flow cannula is 
attached to the spirometer module and place on the patient for oro-nasal flow analysis (yellow 
arrow) and thoracic efforts are monitored by a respiratory impedance plethysmography band 
across the mid-point of the thorax (black arrow) 
 
Channel Signal 
Channel 1 ECG 
Channel 2 Filtered EMG 
Channel 3  Thoracic RIP 
Channel 4  Spirometry module 
Table 2-1 Channel setup for parasternal electromyography analysis on the digital converter 
Power lab module (ADInstruments, Chalgrove, UK) 





Figure 2-12 Forced oscillometry technique 
Photograph demonstrating the standardised candidate setup for oscillometry measurements. At 
each study visit a new mouthpiece with bacterial/viral filter is opened and placed on the handheld 
unit of the oscillometer (blue arrow). With the patient sitting in an upright position, a nose clip to 
seal nasal passages (yellow arrow), face in an upward position of approximately 15 and hands 














 Clinical outcomes using remote 





COPD is characterised by fixed airflow limitation which can follow a chronic progressive 
course. Severe airflow limitation in COPD predisposes to hypercapnic respiratory failure 
during acute exacerbations and persistent hypercapnic failure in stable severe disease. 
COPD is the second most common cause for emergency admissions in the UK which 
accounts for over 1 million bed days at a cost of over £800 million a year[176].  34% of 
those admitted to hospital with an exacerbation of COPD are re-admitted within 90 
days[177].  Exacerbations and hospital admissions are strongly associated with post-
discharge mortality, the reduction of which are a COPD patient’s priority[178][177][179]. 
Reducing exacerbations and subsequent hospital admissions should be a key priority to 
address the growing health and economic burden of COPD.   
 
The risk of hospital re-admissions and future life-threatening events is high in patients 
who develop acute hypercapnic failure as a result of an exacerbation of COPD[180]. Acute 
NIV reduces hospital length of stay, need for intubation and mortality for patients with 
COPD exacerbation and decompensated hypercapnic respiratory  failure[181]–[183].  
 
Recurrent and persistent hypercapnic failure is associated with a decreased long term 
survival and higher admission frequency compared to severe COPD patients with 
transient hypercapnic failure following a life threatening exacerbation of COPD requiring 
acute NIV[184][185][186]. The application of home NIV in persistent hypercapnic failure 
in COPD has been an area of growing interest with high pressure NIV showing favourable 
outcomes in comparison to low pressure NIV[187][188]. Initial research in long term 
home NIV in hypercapnic COPD patients demonstrated no improvement in 1 year 
morbidity, mortality or hospitalisation in stable severe COPD[189] [190]. However, both 
studies included patients with severe COPD with infrequent exacerbations, low pressure 
support and did not confirm hypercarbia on arterial blood gases in one study prior to 
recruitment. McEvoy et al used low pressure support NIV in less severe COPD (FEV1 
<50%) with mild hypercapnic failure (PCO2 >6kPa) to demonstrate an improved survival 
but found a reduction in HRQOL outcomes and no reduction in hospitalisation[191]. A 
high-pressure support approach to domiciliary NIV focuses on improvement of gas 
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exchange to reduce the burden of hypercapnic severe COPD. However patient selection is 
important to ensure the correct delivery to confirm overall benefit as demonstrated in 
one study where recruitment too soon after a life-threatening exacerbation of COPD 
failed to identify those with less severe disease and transient hypercapnia who would not 
met the criteria for home NIV in usual practice[148]. Further high intensity home NIV 
studies have demonstrated improved HRQOL outcomes, control of hypoventilation and 1 
year survival in severe COPD with more severe persistent hypercapnia (PCO2 
>6.6kPa)[147], [187]. The most recent landmark high intensity home NIV study, the UK 
HOT-HMV study demonstrated a significant improvement in time to re-admission 
following the initiation of home oxygen therapy and home NIV in patients with persistent 
hypercapnia 2-4 weeks following an acute exacerbation. [149] Additionally, the failure of 
formal clinical review by a respiratory physician following discharge after a life 
threatening hypercapnic exacerbation of COPD has been reported as high as 26% in the 
UK [192]. Patient selection with timely post-discharge assessment of persistent 
hypercapnic failure following an exacerbation is integral to delivering a safe and effective 
home NIV service in this heterogenous patient cohort and a future research priority. 
 
Consideration of contributing co-morbidities such as co-existing obstructive sleep apnoea 
are important to determine PAP therapy delivery with a prevalence of COPD-OSA of 1-
2%[193]. Several studies have shown an improvement in outcomes in COPD- OSA overlap 
patients with CPAP therapy but these were not randomised control trials nor included 
patients with hypercapnic failure on NIV[194], [195]. Screening for co-existing sleep 
disordered breathing would highlight the need for a multi-faceted approach in patient 
management, may provide improved PAP titration and outcomes but currently evidence 
for this is unclear therefore further RCTs are required. However utilising auto-titrating 
PAP therapy could address this without the need to screen all patients for COPD-OSA and 
should be a future research priority in a bid to rationalise the approach to initiation of 
home NIV in this patient cohort.  
 
The severity of sleep disordered breathing is strongly associated with increasing obesity. 
Increased respiratory load of severe obesity can result in the imbalance of the respiratory 
load-capacity relationship (Figure 1.1) resulting in alveolar hypoventilation. The presence 
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of sleep disordered breathing and persistent daytime hypercapnia is diagnostic of obesity 
hypoventilation syndrome (OHS) otherwise referred to as obesity related respiratory 
failure (ORRF) in this thesis.  Augmentation of ventilation with NIV in ORRF has been 
shown to improve morbidity and mortality[156], [196], [197]. Whilst, continuous positive 
airways pressure (CPAP) therapy offsets PEEP and has been shown to reduce the work of 
breathing in obesity[75]–[77]. PAP therapy in ORRF can be delivered by CPAP or NIV. 
Disease phenotyping may facilitate the use of appropriate PAP therapy and improve 
outcomes with recent studies demonstrating control of hypoventilation and symptoms 
with CPAP in ORRF with severe SDB (AHI >30 events/hr)[198][199]. In addition, Masa et al 
demonstrated a significant improvement in PCO2 with NIV versus CPAP or lifestyle advice 
in ORRF with severe OSA, demonstrating an additional improvement in HRQOL outcomes, 
spirometry and 6-minute walk test results[199]. NIV can provide superior control of 
hypoventilation compared to CPAP and newer auto-titrating modes may also provide 
additional benefits such as improved sleep quality and control of ventilation [169]. As a 
result, NIV could be considered as first line therapy in ORRF with significant respiratory 
failure, recent acute decompensation or as second line following poor response to CPAP. 
However, there is a lack of larger non-inferiority RCT evidence demonstrating NIV as a 
superior treatment for ORRF and further studies powered to assess both clinical and 
physiological outcomes are required. 
 
Telemedicine delivers health care and health information to patients in remote locations 
to aid diagnosis, optimise patient management, facilitate data retrieval for research 
evaluation and education using modern digital infrastructure and multimedia 
platforms[84]–[86]. Tele-monitoring  of CPAP therapy in OSAS patients has been shown to 
have a positive effect on treatment adherence and patient engagement[118]–[120]. 
Incorporating telemonitoring and automated messaging in CPAP management can 
improve treatment adherence and reduce time spent on patient education with an 
importance on positive framed messaging to optimise patient outcomes[121]–[123]. The 
use of videoconference (Vc) calls can enable health professionals to educate and assess 
therapy issues within the home setting and has been shown to be as effective as face-to-
face training with equivalent CPAP therapy adherence[125], [126]. Whilst the use of 
internet based patient education alone or in combination with telemonitoring and 
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automated messaging can improve treatment adherence to CPAP therapy[111][124]. 
These studies highlight that a multi-faceted approach to telemedicine in chronic disease is 
required to optimise patient outcomes and realise service efficiencies. 
 
Whilst there is an established research base for telemonitoring in OSAS patients, 
telemonitoring in home NIV remains a research priority.  Previous studies have 
demonstrated no improvement in clinical outcomes with telemonitoring of peripheral 
oxygen saturations (SpO2) in COPD patients and can increase hospitalisation[142]–[144]. 
A multi-faceted approach incorporating physiological parameters, symptom burden, 
telephone communication with patient education within telemonitoring improves clinical 
outcomes and healthcare usage in COPD patients[145]. 
 
 Patout et al demonstrated low cognitive performance and independence during inpatient 
NIV set-up and at 6-week review in a range of respiratory diseases[152]. Additionally, 
COPD can negatively impact patient cognition and to a greater degree following an acute 
exacerbation[151]. However early recognition of those at risk of poor adherence to NIV 
can facilitate personalised PAP initiation and education to maximise therapy 
benefits[200]. This cognitive impairment in patients requiring NIV invalidates any direct 
comparisons of clinical outcomes in telemonitored NIV with CPAP therapy in OSAS. 
 
Telemonitoring of home NIV provides reliable ventilation data for clinician review, 
facilitates early optimisation of ventilation, improves treatment adherence and decreases 
healthcare utilisation[154][158][201][202]. Remote data retrieval facilitates the 
identification of poor tolerance, mask leakage resulting in suboptimal ventilation and NIV 
dependence signifying disease severity[155]–[158]. Remote data retrieval and analysis 
has been shown to predict disease exacerbation and could facilitate the development of 
preventative predictive personalised management of chronic disease[160]–[162]. Whilst 
safe remote NIV titration has been shown to be as effective in control of hypoventilation 
and HRQOL outcomes in telemonitored home NIV in hypercapnic severe COPD, negating 
the need for prolonged inpatient polysomnography driven NIV titration. Continued 
prospective analysis of telemonitored NIV data, symptoms burden, health care utilisation 
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and physiological parameters are required to build a rich data set for analysis of 
predictors of disease exacerbations and incorporation of such into multi-media-based 
platforms to develop a personalised predictive model of chronic disease management 
and realise service efficiencies.  
This study reviews the feasibility and clinical outcomes of remote monitored home NIV in 
chronic respiratory failure patients following the adaption of this new technology and 
development of clinical pathways within NHS GG&C.  
 
3.2 Hypothesis 
Two-way remote monitoring of home non-invasive ventilation provides effective therapy 
and allows treatment provision to patients with persistent hypercapnic failure due to 
severe COPD and obesity-related respiratory failure. 
 
3.3 Methods 
3.3.1 Study design 
A retrospective review of an observational cohort of patients with severe COPD with persistent 
hypercapnic failure who were commenced on two-way remote monitored home NIV (cohort 1), 
patients who required acute NIV for hypercapnic failure secondary to an exacerbation of COPD 
but were not referred onward for long term breathing support (cohort 2) within the GSBSRC 
service from February 2017 to January 2018. A further retrospective review of observational data 
from patients with ORRF (cohort 3) within the GSBSRC service was reviewed in NHS Greater 
Glasgow and Clyde between July 2016 and January 2018. All patients were vetted via electronic 
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3.3.3 Severe COPD with persistent hypercapnic failure 
We analysed the data of 69 COPD patients treated with acute NIV for decompensated 
hypercapnic respiratory failure within Queen Elizabeth University Hospital NHS GG+C. 
There are 2 separate cohorts (Figure 3.1). 
Cohort 1: Intervention 
Retrospective review of 42 patients commenced on 2-way remote monitored NIV 
following an admission with a life-threatening exacerbation of COPD and hypercapnic 
failure between 1st February 2017 and 31st January 2018. Indication for home NIV in 
severe COPD was persistent hypercapnic failure with PCO2 levels >7kPa or >6.5kPa with 
re-current admissions with life-threatening exacerbations requiring acute NIV. Patients 
were initiated on home NIV after 2-4 weeks of stable disease following acute NIV. 
Patients were initiated on home NIV during index admissions when recurrent life-
threatening admissions requiring acute NIV resulted in 2-4 weeks disease stability 
preceding home NIV initiation as an unrealistic target. Remote monitored NIV was 
delivered via a Lumis 150 ventilator (Resmed, UK) (Figure 2.1). Settings included fixed 
Spontaneous Timed mode (ST), or volume assured pressure support (iVAPS) with auto-
titrating EPAP. This cohort can be further divided into total cohort of 42 patients and sub-
group analysis including 28 patients who continued long term domiciliary NIV and 14 
patients where NIV was discontinued for various clinical reasons. Data from hospital 
admissions, occupied bed days, respiratory nurse visits and mortality were included.  
Cohort 2: Control Arm 
A retrospective audit of 27 patients who required acute NIV for hypercapnic respiratory 
failure as a result of an exacerbation of COPD between March- November 2017 at the 
QEUH. This cohort has been treated as the control arm in the review as they required 
acute NIV for hypercapnic respiratory failure but were not referred on for breathing 
support assessment and initiation of domiciliary NIV. These patients had acute 






3.3.4 Obesity related respiratory failure 
Cohort 3: Obesity related respiratory failure (ORRF) 
43 patients were initiated on home NIV during an inpatient admission with 
decompensated cardio-respiratory failure, elective inpatient admission or as a day-case 
initiation at GSBSRC. Indications for home NIV in ORRF were BMI> 35kg/m2, persistent 
hypercapnia (PCO2 >6kPa), evidence of sleep disordered breathing- where feasible full or 
limited polysomnography was performed. Inpatient initiation was considered where 
obesity related physical restrictions or place of residence precluded them from day-case 
initiation. All inpatients had continuous Transcutaneous Carbon Dioxide and Oxygen 
Assessment (TOSCA, TCM5, Radiometer, England) during the initiation night and on 
consolidation nights of home-NIV. Elective inpatient assessment is detailed in Figure 2.6 
in Chapter 2. All inpatients were initiated on volume assured pressure support with auto 
titrating EPAP (iVAPS) on Lumis 150 devices (Lumis, Resmed, UK) (Figure 2.1). Day case 
initiation of home NIV was provided for patients with ORRF and stable hypercapnic failure 
as detailed in Chapter 2.  
 
3.3.5 Data retrieval  
All patients consented to their data being accessed and shared on Airview™ platform 
(Airview, RESMED, UK) by health professionals (Appendix 1). All patients were followed 
up via remote tele-consultation to optimise home NIV as detailed in Figure 2.5 in Chapter 
2. Tele-consultation and remote access to ventilatory support data allowed individualised 
follow up including remote prescription change, interface changes, day case trouble 
shooting sessions or clinic reviews. Remote requirements data was collected from the 
Airview™ platform.  
 
3.3.6 Outcome measures 
Baseline data were recorded including gender, age, BMI, polysomnography (full or limited 
5 channel) and lung function if available. Primary outcome in all cohorts was time to 
readmission or death, censored at date of admission, date of death or 28/7/2020. 
Secondary outcomes included time to re-admission, survival, number of hospital 
admissions, occupied bed days (OBDs), serial blood gas analysis, adherence to NIV 
therapy, remote NIV service requirements and allied health professional reviews. Target 
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adherence was ≥70% days with usage ≥4hours; the levels set for reimbursement in the US 
health system. Patients adherence to therapy are referred to as “users” and those failing 
to meet the target usage are known as “non-users” in these results. All data is presented 
as totals for cohort 1 and 2 with sub-group analysis for patients’ adherent and non-
adherent to home NIV therapy in cohort 1. Data availability was limited in all cohorts with 
some historical data used (spirometry) in this retrospective review.  
 
3.3.7 Statistical analysis 
Baseline characteristics are presented as mean (standard deviation), median 
(interquartile range), absolute values or percentages where appropriate.  
Primary outcomes and secondary outcomes are presented as Kaplan-Meier survival 
analysis and the Mantel-Cox log rank test for cohorts where appropriate.  
Subgroup analysis compared those adherent with NIV therapy(“users”) and non-adherent 
patients (“non-users”) using Kaplan-Meier and Mantel-Cox tests. Normal distribution was 
tested using Shapiro-Wilk test. Wilcoxon signed-rank test was used for hospital 
admissions, OBDs, AHP input and control of hypoventilation. COPD data analysis was 
carried in IBM SPSS as part of a collaboration with the University of Glasgow and MSc 
Stratified Medicine project.  Analysis was conducted using IBM SPSS Statistics V.24 (IBM, 








3.4.1 Population demographics  
Hypercapnic severe COPD  
42 patient datasets representing patients commenced on two-way remote monitored 
home NIV and 27 patients were in the control cohort as shown in Table 3.1. Sex, BMI, and 
age are similar across both cohorts except for a higher rate of males and a lower rate of 
comorbidities (suspected or confirmed overlapping OSA, long term opiate therapy) in the 
NIV non-users’ sub-group. The FEV1% predicted value was around 40% across both study 
groups, in line with a “severe” classification of COPD[183] considering spirometry data 
was historical rather than a contemporary result. There was a higher proportion of males 
to females in both cohort 1 and cohort 2. Mean age was 64.5 years with no age 
differences between the cohorts. BMI was higher in users of home NIV therapy compared 
to non-users. Comorbidities which could potentially contribute to hypercapnic respiratory 
failure were present in 14/42 (38%) of the home NIV cohort patients, including 10/14 
patients with suspected or confirmed COPD-OSA overlap syndrome.  
Obesity related respiratory failure 
43 patient datasets representing ORRF initiated on two-way remote home NIV initiation 
with cohort demographics seen in Table 3.2. Mean age and sex was similar in this cohort 
and in sub-group analysis. Severe obesity was demonstrated with mean BMI of 49.9 
kg/m2. Sub-group analysis showed users of home NIV had a higher mean BMI, higher AHI, 
ODI and lower TST90 than non-users. Symptom burden measured by the Epworth 
Sleepiness Scale (ESS) was moderate and similar throughout sub-group analysis. Median 
CO2 was 8.3 kPa and bicarbonate was 37mmol/L on initiation of home NIV in all ORRF 
patients. However, sub-group analysis of CO2 and bicarbonate showed no difference in 







3.4.2 Primary outcome  
Hypercapnic severe COPD  
Time to re-admission or death was significantly prolonged in patients with persisting 
hypercapnic failure who commenced home NIV compared to the control cohort of COPD 
patients who had had an episode of acute hypercapnic respiratory failure but had not 
been referred for breathing support follow up (p<0.01) (Figure 3.2A). The median time to 
admission or death was 160 days (95% CI 69.4-250.6) in the home NIV cohort compared 
to 66 days (95% CI 21.9-84.7) in the control cohort. Subgroup analysis (Table 3.3) showed 
significant differences between the sub-cohort of home NIV users versus non-users (who 
discontinued home NIV) and the control cohort, both p<0.001 (Figure 3.2B). There was no 
significant difference between the control cohort and in non-users sub-group 
analysis(p=0.5). Table 3.3 summarises time to admission or death, survival, and admission 
events in each group.  
Obesity related respiratory failure 
Time to re-admission or death analysis over the available follow-up period demonstrated 
a non-significant trend to poorer outcome in non-users in comparison to users of home 
NIV therapy (Figure 3.3) The median admission free survival could not be calculated as 
low event rates and good survival outcome resulted in data acquisition not passing the 
50% probability of survival level.  
 
3.4.3 Secondary Outcomes 
3.4.3.1 Overall Survival 
Hypercapnic severe COPD  
Overall survival showed a non-significant trend to an improved survival in the home NIV 
cohort compared to the control cohort (p=0.066) (Figure 3.4Ai). Sub-group analysis 
demonstrated improved survival in NIV users versus non-users (p=0.07) (Figure 3.4Aii). 





Obesity related respiratory failure 
Sub-group analysis demonstrated a non-significant trend to improved survival in NIV 
users compared to the total study population and NIV non-users (Figure 3.5). Survival 
data did not pass 50% probability of survival level.  
 
3.4.3.2 Time to hospital re-admission 
Hypercapnic severe COPD  
Time to hospital admission was significantly prolonged in the home NIV cohort compared 
to the control cohort (p<0.05) (Figure 3.4Bi). Sub-group analysis demonstrated a 
prolonged time to hospital admission in home NIV users compared to non-users and the 
control cohort (both p <0.001) (Figure 3.4ii). There was no significant difference between 
the control cohort and home NIV non-users (p=0.38). Median time to hospital admission 
for users was 390 days versus 49 days in non-users and 70 days in the control cohort. 
(Table 3.3)  
Obesity related respiratory failure 
Sub-group analysis demonstrated a non-significant trend to prolonged time to hospital 
admission in NIV users versus NIV non-users (Figure 3.6). Time to hospital admission data 
did not pass 50% probability level to calculate median values.  
 
3.4.3.3 Healthcare usage 
Hypercapnic severe COPD  
Healthcare usage for 12months prior to and 12 months after the initiation of home NIV in 
hypercapnic severe COPD patients and sub-group analysis are presented in Table 3.4. 
Hospital admissions was significantly decreased in the 12 months following the initiation 
of home NIV in the analysis of cohort 1 (total) and in sub-group analysis of NIV users 
(p<0.05 both) (Figure 3.7A). The number of occupied bed days (OBDs) significantly 
decreased in the 12 months following home NIV initiation (p<0.05) (Figure 3.7B). Sub-
group analysis demonstrated a non-significant reduction in OBDs in NIV users and NIV 
non-users, p=0.05 and p=0.059, respectively. Clinical review from a respiratory specialist 
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nurse or allied health professional (AHP) showed no significant change following NIV 
initiation (figure 3.7C).  
Obesity related respiratory failure 
Healthcare usage 12months prior to and 12months after the initiation of home NIV in 
patients with ORRF are presented in Table 3.5. The number of hospital admissions 
significantly decreased in the 12 months following the initiation of home NIV in the 
analysis of cohort 3 and in sub-group analysis of NIV users (p< 0.05 both) (Figure 3.8A). 
The number of occupied bed days significantly decreased following home NIV initiation 
and in sub-group analysis of NIV users (p<0.05 both) (Figure 3.8B).  
 
3.4.3.4 Control of hypercapnic respiratory failure 
Hypercapnic severe COPD  
Follow up capillary blood gas measurements were only available in 13/42 patients.  There 
was a significant reduction in PCO2 and bicarbonate levels in home NIV users (p<0.05 
both), with a modest non-significant reduction in home NIV non-users (Figure 3.9). 
Obesity related respiratory failure 
Follow up capillary bloods gas measurements were available in 31/43 patients. There was 
a significant reduction in PCO2 and bicarbonate levels in home NIV users (p<0.05 both), 
with a non-significant reduction in home NIV non-users. (Figure 3.10) 
 
3.4.3.5 Remote management of home Non-invasive ventilation 
Hypercapnic severe COPD  
All patients were initiated on average volume assured pressure support mode (iVAPS) 
with adaptive back up rate (iBR). 9 patients switched to spontaneous timed (ST) mode 
following data trends either on remote monitoring or during initiation. A low-pressure 
support requirement was demonstrated; median IPAP of 14 cmsH2O (95% CI 11-17.3 
cmsH2O) and median EPAP of 4.9 cmsH2O (95% CI 4-8 cmsH2O) with lowest pressure 
support observed in non-users, as detailed in Table 3.6. Median back up rate was 18 
breaths/min ( 95% CI 17-20 breaths/min). Requirements for remote management of 
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home NIV in this cohort are detailed in Table 3.7 and Figure 3.11. Following initiation of 
remote monitored home NIV a severe COPD patient would typically require 7 data 
reviews, 2 telephone consultations and 1 prescription change. A minority of patients 
required follow up day-case reviews or AHP input.  
Obesity related respiratory failure 
All patients were initiated on average volume assured pressure support mode (iVAPS) 
with adaptive back up rate (iBR). 4 patients switched to ST mode following data trends 
either on remote monitoring or during initiation. A low-pressure support requirement 
was demonstrated; median IPAP of 15.9 cmsH20 (95% CI 12.9- 18.6cmsH2O) and median 
EPAP of 9 cmsH20 (95% CI 6.3-10.4cmsH2O) with lowest pressure support requirements 
observed in non-users, as detailed in Table 3.8. Median back up rate was 18 breaths/min ( 
95% CI 16-21 breaths/min).  Requirements for remote management of home NIV in this 
cohort are detailed in Table 3.8 and Figure 3.12. Following the initiation of remote 
monitored home NIV a patient with ORRF would typically require 4 data reviews, 2 
telephone consultations and 1 prescription change. A minority of patients required follow 
up as day-case reviews or with AHPs.  
 
3.4.3.6 Inpatient versus day-case home NIV initiation 
Hypercapnic severe COPD  
27/42 patients were initiated on remote monitored home NIV during an inpatient 
admission following a life-threatening exacerbation of COPD. 2/42 patients were 
admitted electively for initiation due to travel restrictions preventing day case set-up. 
6/42 patient were started on home NIV at a linked district general hospital utilising 
remote monitoring to avoid inpatient transfer to our tertiary inpatient service. Age and 
other demographics were similar between these sub-groups. (Table 3.9) There were no 
differences observed in adherence to home NIV, remote monitoring service requirements 
or outcomes observed in sub-groups analysis of day-case versus inpatient initiations 
(Table 3.9 & Figure 3.12). Similarly, sub-group analysis did not demonstrate significant 
differences in time to re-admission or death and overall survival (Figure 3.13). Small 
sample size is likely responsible for some non-significant data heterogeneities with the 




Obesity related respiratory failure 
24/43 patients were initiated on home NIV during their index admission, of which 5 
patients were started on home NIV at a linked district general hospital and 4 patients 
during an elective admission. Age and other demographics were similar in sub-group 
analysis of this cohort. (Table 3.10) Adherence to home NIV was highest in those patients 
initiated on home NIV whilst as an inpatient either in the local or regional hospitals with a 
lower adherence to therapy observed in patients who had home NIV started as a day-case 
(56%). Whilst remote monitored service requirements were similar throughout the sub-
groups. (Table 3.10) Sub-group analysis did not demonstrate significant differences in 






Figure 3-1 Service adoption of remote monitored home non-invasive ventilation (NIV) in NHS 
Greater Glasgow and Clyde and study summary of a retrospective review of patients with 
hypercapnic severe chronic obstructive pulmonary disease initiated on NIV 
NIV- non-invasive ventilation, Audit-QIP- audit quality improvement project, COPD-OSA- chronic 
obstructive pulmonary disease- obstructive sleep apnoea overlap syndrome, AE-COPD- acute 
exacerbation of COPD, AHRF- acute hypercapnic respiratory failure, IVAPS-autoEPAP- auto-
titrating volume assured pressure support with auto-titrating expiratory positive airway pressure, 
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Table 3-1 Population demographics for patients admitted with a severe life-threatening 
exacerbation of COPD and hypercapnic failure.  
This table represents those commenced on two-way remote monitored home NIV (home NIV) 
with sub-group analysis demonstrating adherence to treatment and those who were not referred 
for consideration of home NIV following acute NIV (control cohort).  M-male, F-female, SD- 
standard deviation, BMI- body mass index, FEV1%- percentage predicted of forced expiratory 













Total Users Non-users 
 n  n  n 
Gender 22 M 21F 43 16M 17F 33 6M 4F 10 
Mean age (SD) 57 (13) 43 57 (13) 33 53.9(11.1) 10 
Mean BMI (SD) 49.9 (11.5) 41 50 (11.5) 30 42.4(8.4) 9 
Mean FEV1% 
predicted (SD) 
64(21) 12 64(21) 10 80.5(6.4) 2 
Mean FVC % 
predicted (SD) 
68 (20) 12 68 (20) 10 80.5(5) 2 
Mean FEV1/FVC % 
(SD) 
87 (9) 12 87 (9) 10 96.5(14.8) 2 
AHI  40 (31) 23 40 (31) 16 22.9(23.7) 7 
ODI 40 (27) 23 40(27) 16 28.2(26) 7 
Mean oxygen 
saturations % (SD) 
85 (6) 21 85 (6) 15 84(5.6) 6 
Mean TST90 % (SD) 63 (35) 21 63 (20) 13 74.7(34) 6 
Mean ESS (SD) 15 (3) 9 15 (3) 5 14(4) 4 
Median CO2 kPA 
(IQR) 
8.4 (3) 37 7.6 (6.6- 10.3) 30 7.2(6.1-8.1) 8 
Median HCO 
mmol/L (IQR) 
37 (8) 37 36(29-41) 30 35(29-39) 8 
Table 3-2 Population demographics for patients with Obesity related respiratory failure. 
Patients treated with remote-monitored home NIV (home NIV) with sub-group analysis of those 
adherent to NIV (users) and those failing to meet targets as >4hours usage >70% of nights used 
(non-users). M-male, F-female, SD- standard deviation, IQR- interquartile range, BMI- body mass index, 
FEV1%- percentage predicted of forced expiratory volume in 1 second, FEV1/FVC- ratio of forced expiratory 
volume in 1 second to forced vital capacity, AHI- apnoea hypopnea index (events per hour), ODI- 4% oxygen 
desaturation index (events per hour), TST90-= percentage of total sleep time with oxygen saturations <90%, 




Control- patients with hypercapnic severe chronic obstructive pulmonary disease who recently 
required acute NIV for a life-threatening exacerbation but were not referred on for consideration 
of home ventilation assessment.  
 All patients   Home NIV  Control 
  Total users Non-users  
Median study follow-
up days (IQR) 
323(260) 319 (213) 319 (229) 320 (323) 323 (382) 
Median admission 









47 (19.5-74.5) 66 (21.9-110.1) 















50 (72.5) 27 (64.3) 14 (50) 13 (92.9) 23 (85.2) 
Hospital Re-
admission Events (%) 
42(67.7) 22 (59.5) 12 (46.2) 10 (90.0) 20 (80) 
Mortality events (%) 20 (29) 9 (21.4) 4 (14.3) 5 (35.7) 11 (40.7) 
Table 3-3 Primary and secondary outcomes in patients with hypercapnic severe chronic 
obstructive pulmonary disease who were commenced on two-way remote monitored home 




Figure 3-2 Kaplan-Meier analysis of time to re-admission or death in severe COPD patients 
initiated on home non-invasive ventilation (NIV)and vs control cohort 
A- Time to re-admission or death in patients managed with remote monitored home NIV (blue) versus 
control cohort (green).  B-Sub-group analysis of time to re-admission or death demonstrating those 
adherent to home NIV (users(blue)), those non-adherent or discontinued(non-users(red)) on home NIV 
compared to the control cohort (green). Control - hypercapnic severe COPD patients who survived recent 






Figure 3-3 Kaplan-Meier analysis for time to re-admission or death in patients with obesity 
related respiratory failure initiated on home non-invasive ventilation: 
Presented as total (black) and sub-group analysis time to admission or death in those adherent to 
home NIV (>70% nights used >4hours) (“users” (blue)) and patients failing to meet set adherence 






Figure 3-4 Kaplan-Meier analysis of overall survival and time to re-admission of patients with 
hypercapnic severe COPD initiated on remote monitored home non-invasive ventilation vs 
control cohort. 
Ai- Kaplan-Meier analysis for overall survival in hypercapnic severe COPD patients initiated on 
remote monitored home non-invasive ventilation (NIV)(blue) and hypercapnic severe COPD who 
survived recent life-threatening exacerbation but not referred on for home ventilation 
assessment (control cohort) (green). Aii- Sub-group Kaplan-Meier analysis for overall survival in 
hypercapnic severe COPD patients in those adherent to home NIV (>70% nights used >4hours) 
(“users” (blue)), patients failing to meet set adherence targets (‘non-users” (red)) and control 
cohort (green). Bi- Kaplan-Meier analysis of time to re-admission in hypercapnic severe COPD 
patients on remote monitored home NIV (blue) and control cohort(green). Bii- Sub-group Kaplan-
Meier analysis of time to re-admission in those adherents to home NIV (users(blue)), those non-











Figure 3-5 Kaplan-Meier analysis of overall survival in patients with obesity related respiratory 
failure initiated on home NIV 
Presented as total cohort (black) and sub-group analysis of overall survival in those adherent to 
home NIV (>70% nights used >4hours) (“users” (blue)) and patients failing to meet set adherence 
targets (‘non-users” (red)). 
 
 
Figure 3-6 Kaplan-Meier analysis of time to re-admission in patients with obesity related 
respiratory failure initiated on home NIV 
Presented as total cohort (black) and sub-group analysis of time to re-admission in those adherent 
to home NIV (>70% nights used >4hours) (“users” (blue)) and patients failing to meet set 





























































Table 3-4 Healthcare usage prior to and after the initiation of two-way remote monitored home 
non-invasive (NIV) in patients with hypercapnic severe COPD. 
All data expressed as median and interquartile range (IQR). AHP- allied health professional. 
 
 Total Users Non-users 















1 (0-1) 0(0) 1(1) 0(0) 0.5(0-2) 0(0) 
Occupied bed 
days (IQR) 
10(0-36) 0(0) 13(2-32) 0(0) 1.5(0-48) 0(0-0.5) 
Table 3-5 Healthcare usage prior to and after the initiation of two-way remote monitored home 
NIV in patients with obesity related respiratory failure. 






Figure 3-7 Healthcare usage prior to and after the initiation of remote monitored home non-
invasive ventilation in patients with hypercapnic severe COPD. 
Data presented as those adherent to therapy (>4hours use for >70% nights used) (blue) and those 
non-adherent to NIV (red). A-The individual number of hospital admissions per patient. B- 





Figure 3-8 Healthcare usage prior to and after the initiation of remote monitored home non-
invasive ventilation in patients with obesity related respiratory failure. 
Data presented as those adherent to therapy (>4hours use for >70% nights used) (blue) and those 
non-adherent to NIV (red). A-The individual number of hospital admissions per patient. B- 




Figure 3-9 Serial blood gases measurements in patients with hypercapnic severe chronic 
obstructive pulmonary disease prior to and after initiation on remote monitored home non-
invasive ventilation.  
Data presented as those adherent to therapy (>4hours use for >70% nights used) (blue) and those 
non-adherent to NIV (red).  A- Serial Carbon Dioxide (CO2) measured in kilopascals (kPa). B- Serial 





Figure 3-10 Serial blood gases measurements in patients with obesity related respiratory failure 
prior to and after initiation on remote monitored home non-invasive ventilation. 
Data presented as those adherent to therapy (>4hours use for >70% nights used) (blue) and those 
non-adherent to NIV (red).  A- Serial Carbon Dioxide (CO2) measured in kilopascals (kPa). B- Serial 




Figure 3-11 : Service requirements for remote management of home NIV in patients with 
hypercapnic severe COPD 
A- Number of data reviews. B- Number of telephone consultations. C- Number of remote 
prescription changes. D- Number of day-case trouble shooting sessions. E- Number of nurse 





 Total Users Non-users 
Median IPAP 
(IQR) 
14 (11-17.3) 15.4(13.3-17.7) 11.2(7.9-15.3) 
Median EPAP 
(IQR) 
4.9 (4-8) 5.9(4-8.4) 4(4-5.8) 
Median back up 
rate (IQR) 
18 (17-20) 18(17-20) 18(17-20) 
Median usage 
(hours) (IQR) 
5.8 (2.5-7.3) 6.7(6-9.2) 2(0-3.2) 
Table 3-6 Pressure support requirements with adaptive mode (iVAPS) ventilation in severe 
COPD with persistent hypercapnic failure. 
Data presented as total group analysis and sub-group analysis patients in those adherent to home 
NIV (>70% nights used >4hours) (“users”) and patients failing to meet set adherence targets 
(‘non-users”). All pressures measured in centimetres of water (cmsH2O) and back up rate 
measured in breaths/min. All presented as median and interquartile ranges (IQR). IPAP- 




 COPD ORRF 
NIV data review (IQR) 7(3-9) 4 (3-4) 
Telephone consultations (IQR) 2(1-4) 2(1-3) 
Remote prescription changes 
(IQR) 
1(0-2) 1(0-2) 
Day case troubleshooting (IQR) 0(0-1) 0(0-1) 
AHP reviews (IQR) 0(0-2) 0(0-1) 
Table 3-7 Requirements for remote management of home non-invasive ventilation (NIV) in 
patients with hypercapnic severe COPD and obesity related respiratory failure 
AHP- including allied health professionals such as specialist nurse or physiologist reviews. 







Figure 3-12 Service requirements for remote management of home non-invasive ventilation 
(NIV) for patients with obesity related respiratory failure 
A- Number of data reviews. B- Number of telephone consultations. C- Number of remote 
prescription changes. D- Number of day case trouble shooting sessions. E- Number of nurse 






 Total Users Non-users 
Median IPAP (IQR) 15.9(12.9-18.6) 16.7(13.3-19) 13(8.7-16.4) 
Median EPAP (IQR) 9(6.3-10.4) 9.1(6.4-10.2) 8.5(6-11) 
Median back up rate (IQR) 18(16-21) 18(16-22) 18(15-21) 
Median usage (hours) (IQR) 5.7 (4.7-7) 5.9(5-7.2) 2.5(2-5) 
Table 3-8 Pressure support requirements with adaptive mode (iVAPS) ventilation in patients 
with obesity related respiratory failure 
Data presented as total group analysis and sub-group analysis of those adherent to home NIV 
(>70% nights used >4hours) (“users”) and patients failing to meet set adherence targets (‘non-
users”). All pressures measured in centimetres of water (cmsH2O) and back up rate measured in 
breaths/min. All presented as median and interquartile ranges (IQR). IPAP- inspiratory positive 
airway pressure, EPAP- expiratory positive airway pressure.  
 
 
 Day-case IP emergency IP elective Regional 
Number of patients 12 21 2 6 
Mean Age (SD) 62.9 (9.5) 62.4 (9.5) 62.5(3.5) 59.3(9.6) 
Home NIV adherence (no. of 
patients) 
5 9 0 3 
Number of patients discontinued 
NIV 
6 7 1 3 
Median Airview reviews (IQR) 6(3-8) 8(3-9) 7(6-7) 9(6-11) 
Telephone consultations 4(2-5) 1(1-3) 4(1-6) 3(1-4) 
Prescription changes 1(0-1) 1(0-2) 2(0-4) 1(1-1) 
Day case trouble shooting 1(0-1) 0(0-2) 0(0) 0(0) 
AHP review 0(0-1) 1(0-2) 1(0-2) 0(0-2) 
Median Time to re-admission or 
death (IQR) (days) 
131(31-365) 134(30-365) 96(34-158) 72(34-365) 
Median admission free days (IQR) 
(days) 
147(31-365) 85(27-365) 200(34-365) 52(30-74) 
Median survival  
(IQR) (days) 
365(330-365) 365(365) 262(158-365) 273(66-365) 
Table 3-9 Population demographics, remote requirements, and clinical outcomes of patients 
with hypercapnic severe COPD initiated on home non-invasive ventilation- inpatient versus 
outpatient initiation.  
Treatment adherence (>70% of nights used for >4hours). NIV- non-invasive ventilation, IP- 







 Day case IP emergency IP elective Regional 
Number 19 15 4 5 
Mean Age (SD) 58(12) 56(14) 53(11) 54(12) 
Home NIV adherence (no. of patients)  11 14 4 4 
Number of patients discontinued NIV 3 1 0 1 
Median Airview reviews (IQR) 5(3-8) 3(2-5) 4(3-9) 5(3-6) 
Telephone consultations 2(2-4) 2(0-3) 3(1-4) 1(1-2) 
Prescription changes 1(1-2) 1(0-1) 2(1-3) 1(0-2) 
Day case trouble shooting 0(0) 0(0) 0(0) 0(0) 
AHP review 0(0) 0(0) 0(0) 0(0) 
Median Time to re-admission or death 
(IQR) (days) 
915 (166-1167) 965(672-1191) 1200(1130-1191) 1037(529-1140) 
Median admission free days (IQR) 
(days) 
952(166-1167) 965(672-1191) 1200(1130-1319) 1037(529-1140) 
Median survival  
(IQR) (days) 
1000(910-1174) 1138(902-1191) 1200(1130-1319) 1037(529-1140) 
Table 3-10 Population demographics, remote requirements, and clinical outcomes of patients 
with obesity related respiratory failure initiated on home non-invasive ventilation- inpatient 
versus outpatient initiation 
Treatment adherence (>70% of nights used for >4hours). NIV- non-invasive ventilation, IP- 





Figure 3-13 Kaplan-Meier analysis in severe COPD patients initiated on home non-invasive 
ventilation- inpatient versus outpatient initiation 
A- Time to re-admission or death. B- Overall survival. C- Time to hospital admission. IP- inpatient 






Figure 3-14 Kaplan-Meier analysis in patients with obesity related respiratory failure initiated 
on home non-invasive ventilation- inpatient versus outpatient initiation 
A- Time to re-admission or death. B- Overall survival. C- Time to hospital admission. IP- inpatient 







This study demonstrates the feasibility of delivering effective home NIV using two-way 
remote monitoring in patients with persistent hypercapnic failure due to severe COPD 
and obesity related respiratory failure. 
3.5.1  Time to re-admission or death 
This study demonstrates the realistic application and benefit of home NIV in patients with 
severe COPD and persisting hypercapnic failure supporting previous RCTs findings. 
Patients who continued home NIV showed significant improvement in time to re-
admission or death during follow up, in comparison to a control cohort of patients who 
had life-threatening COPD exacerbations requiring acute NIV and had not been referred 
for breathing support assessment. There was no significant impact on outcomes to those 
poorly adherent or discontinued home NIV compared to the control cohort. These results 
are consistent with HOT-HMV trial by Murphy et al demonstrating the delay and 
reduction in hospital admissions in patients with COPD and persistent hypercapnic failure 
randomised to home oxygen therapy or home oxygen and home NIV[149]. Hypercapnic 
COPD patients in our cohort who continued home NIV with remote-monitoring had some 
differences from the patients in the HOT-HMV NIV treatment arm with less severe airflow 
obstruction and higher obesity rate. The similar outcomes however demonstrate ability to 
rapidly implement RCT evidence to real world experience and supports the realistic 
provision of remote monitored home NIV out-with a clinical trial setting.  
 
Sub-group analysis of time to admission or death in the ORRF cohort demonstrated 
poorer outcomes in those patients who were non-adherent or discontinued home NIV, 
which is consistent with previous reports[196], [197], [203]. Data retrieval from remote 
monitoring of home NIV identifies low adherence and discontinuation of therapy 
facilitating early proactive interventions to optimise therapy. It is unclear if this would be 
acceptable to patients, deliverable or would improve overall outcomes. Qualitative 
studies exploring patient activation and patient views on proactive management of 
remote monitored NIV compliance data are logical. These could be followed up by co-
design of deliverable interventions to tackle remote monitoring detected NIV compliance 
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issues, with observational or randomised trial to determine the service impact, patient 
outcomes, and cost-effectiveness of any intervention. 
 
3.5.2  Control of hypercapnic respiratory failure 
The secondary outcomes in this study support the use of remote monitored home NIV in 
hypercapnic severe COPD. Control of hypoventilation was confirmed by improved PCO2 
and serum bicarbonate measurements at follow up in NIV users (Figure 3.9). This 
improvement occurred despite the lower pressure support provision by home NIV in 
iVAPS auto-EPAP mode in comparison to previous high intensity home NIV studies[147], 
[148]. Comparable outcomes in this study provide reassurance about the safety and 
quality of this option, and of basing a service model around the utilisation of two-way 
remote monitored home NIV to provide early optimisation, improve service efficiencies 
and maintain patient outcomes.  
Safety of remote monitored home NIV in ORRF was also confirmed with significant 
decreases in carbon dioxide and serum bicarbonate levels following initiation and remote 
optimisation (Figure 3.10). Similar low pressure support provision was observed in this 
cohort.  
The back-up rate recorded in both cohorts was high in comparison to previous high 
intensity home NIV studies as a result of the auto titrating back up mode (iBR) integrated 
into IVAPS mode Resmed algorithm based on flow-time curve analysis, discussed in 
Chapter 1, section 1.8. Experience with iBR component of iVAPS mode in COPD is that 
higher target rate is required to achieve a proportion of mandatory breaths during the 
respiratory cycles with the treatment aim set a 50% spontaneous breaths and 50% 
triggered breathes. High trigger respiratory rates are not achieved with this mode. 
Utilising iVAPS mode we aimed to provide comfortable respiratory support to control 
hypoventilation rather than pre-set NIV pressure support and back up rate provision seen 





3.5.3 Survival and Time to re-admission 
Overall survival with home NIV in severe COPD and ORRF cohorts improved with 
adherence and continued use (Figures 3.4A & 3.5). Survival data in ORRF cohort was 
consistent with previous studies demonstrating poor outcomes in non-adherence and 
discontinuation of home NIV[196], [197], [203]. A similar trend was demonstrated in time 




Further cost-effectiveness analysis of the HOT-HMV outcomes demonstrated a reduction 
in exacerbation-related costs and patient-reported costs in comparison to the control arm 
with the costs for the NIV device and physician visits having the greatest impact on cost 
per QALY[204]. The significant reduction in hospital admissions and occupied bed days, 
with a median reduction of 14 OBDs per patient per annum in those continued home NIV, 
without an increase in respiratory specialist nurse input in our study demonstrates 
potential cost savings and service efficiencies by utilising remote monitored home NIV in 
this service model. A similar decrease in health care usage was seen in the ORRF cohort 
with minimal requirement for day-case trouble-shooting sessions to optimise therapy. 
Individualised follow-up using remote monitored home NIV allows early optimisation, 
fewer physician reviews and reduces patient travel costs. There is no additional cost for 
NIV remote-monitoring data in NHS Scotland. Expansion of this service model which has 
lower device costs and requires fewer physician visits than the HOT-HMV service model 
would be anticipated to further enhance cost-effective care provision. Future 
assessments of cost effectiveness of remote monitored home NIV and the development 
of a proactive COPD service model are required.  
 
3.5.5 In-patient versus outpatient initiation of home Non-invasive ventilation 
Day-case initiation of home NIV has been shown to be non-inferior to inpatient NIV 
initiation and titration[205], [206]. Cost savings are evident with outpatient NIV 
initiation[205]. The utilisation of tele-monitoring in outpatient home NIV initiation has 
been shown to be safe with tangible cost effectiveness[163]. Whilst a recent randomised 
controlled trial has demonstrated that initiation of home NIV in COPD in an outpatient 
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setting utilising remote monitoring is non-inferior to inpatient NIV titration[207]. Control 
of hypoventilation confirmed its safety and whilst cost of outpatient initiation was 
associated with cost savings of >50% in comparison to inpatient set-up[207]. This study 
demonstrated similar outcomes from “gold standard” multi-night multi-sensor-based 
setup versus intensively monitored outpatient NIV setup. Our data provides similar 
outcomes supporting outpatient home NIV initiation with remotely monitored 
individualised follow up in severe COPD patients, with monitoring limited to capillary 
blood gases unless an inpatient stay was required. Conversely, clinical outcomes in the 
ORRF cohort were poorer in those initiated on home NIV as an outpatient. However, a 
recent multi-centred RCT has demonstrated outpatient home NIV initiation utilising 
volume assured pressure support modes in patients with obesity hypoventilation 
syndrome was non-inferior in control of hypoventilation and no difference in clinical 
effectiveness, cost or safety in comparison to inpatient NIV titration[208]. Full publication 
of this data is awaited and further cost analysis to be reviewed. This study was not 
powered to analyse this sub-group analysis and therefore these results are explorative 
but justify further studies to consolidate these findings in COPD patients, explore clinical 
outcomes in ORRF and allow further patient phenotyping to facilitate individualised 
patient pathways. 
 
3.5.6 Remote monitoring 
Remote monitoring of home NIV in various disease cohorts has been found to be non-
inferior, acceptable for patients, improve therapy adherence and reduce healthcare usage 
with favourable cost efficiencies[201], [202], [209], [210]. Integrating telemonitoring of 
PAP therapy with two-way patient engagement devices to allow early optimisation can 
improve treatment adherence and reduction of mask leakage[211]. Monitoring and 
optimisation of home NIV is integral to continued home NIV usage. Maintaining adequate 
face to face reviews in patients with severe COPD can be challenging with physical 
inability to attend clinics, urgency of therapy changes and variable patient engagement 
with new therapies. Two-way remote monitored home NIV can provide an adjunct to 
routine clinical care, encourage patient engagement, allow early optimisation of home 
NIV, reduce travel costs and facilitate individualised follow up in severe COPD. Our study 
demonstrates the application and development of patient pathways utilising two-way 
remote monitored home NIV in severe COPD with persistent hypercapnic failure is an 
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effective and realistic solution to address the increasing pressures seen on home 
ventilation services. Benchmarking of outcomes with similar findings in recent published 
RCT data provides reassurance about the safety of remote monitored based approach to 
home NIV in this cohort of patients.  
Recent studies have demonstrated significant cost savings with remote monitored PAP 
therapy in sleep disordered breathing[128]–[131]. Incorporating physiological 
parameters, symptoms burden, telephone consultation and patient education in tele-
monitoring of COPD patients improves clinical outcomes and healthcare usage[145]. 
Remote monitoring of NIV data in COPD can allow early optimisation and early 
identification of patients at risk of exacerbations[160], [162], [201]. Large data sets 
available in remote monitored home ventilation justify further exploration into machine 
learned analysis utilising predictive algorithms to enable the development of an 
individualised predictive and proactive management model for patients requiring long 
term home ventilation. 
 
3.5.7 Development of new patient pathways 
Our study suggests that remote monitored home NIV can be safely initiated in patients 
with sustained hypercapnic respiratory failure during an acute episode as well as in stable 
disease. We utilised volume assured pressure support ventilation mode to achieve 
titration of home NIV without transcutaneous carbon dioxide monitoring. Control of 
hypercapnia and improvement in outcomes in-line with previous RCTs supports the safety 
of this approach. Routine transcutaneous monitoring in these cohorts can be challenging 
and often unrealistic considering physical implications of severe obesity and severe COPD 
and arranging hospital admission or providing an outreach home monitoring service. 
Local experience using volume assured pressure support has shown significant service 
efficiencies whilst allowing remote optimisation of NIV[174]. Utilising this mode, we 
targeted treatment for symptom benefit, remote monitored ventilation patterns and 
follow up capillary blood gas results rather than in-hospital titration of NIV setting in ST 
mode with continuous transcutaneous monitoring. Clinical user experience is positive and 
remote management did not require additional staffing nor additional day-case trouble-
shooting sessions in severe COPD or ORRF cohorts. Continuous assessment and 
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development of these new patient pathways utilising remote monitored home NIV is 
required to ensure continued safety and quality of treatment is maintained.  
 
3.6 Critique of methods 
Sub-group analysis demonstrated that patients who discontinued on home NIV in 
hypercapnic severe COPD aligned closely with the control cohort outcomes, suggesting 
these patients were not negatively affected by a trial of home NIV. Further exploration 
and extrapolation of data in those who discontinued on home NIV is indicated to identify 
triggers for poor adherence to develop individualised patient pathways and proactive 
approach to home ventilation. However, we must recognise the possibility that despite 
optimisation efforts there may be a cohort of patients who will not continue this 
treatment modality.  
This study has demonstrated the feasibility of delivering two-way remote monitored 
home NIV in severe COPD with persistent hypercapnic failure and ORRF. Clinical 
outcomes in both cohorts are encouraging but we must acknowledge this is a small 
retrospective study and all analyses are exploratory and control cohort was opportunistic 
rather than directly matched. Allocation of treatment was not randomised therefore 
confounding factors cannot be excluded when we interpret this data. The presence of the 
control cohort in this retrospective review highlights the need for improved educational 
resources for physicians and AHPs to ensure equitable access to home NIV for 
hypercapnic severe COPD. Incomplete demographic, comorbidity and compliance of 
other treatment modalities data means we are unable to confirm the control and COPD 
cohort were equally matched. RCTs of home NIV with survival as primary endpoint would 
be required to definitively resolve this but conduct of these would be unfeasible and 
given available evidence unethical. Efforts should focus on establishing large-scale 
observational data from registries and multi-site and tertiary collaboration.  
 
Safety of remote monitored home NIV utilising iVAPS mode is demonstrated despite the 
lower than expected pressure support requirements and high back up rates determined 
by iBR in both cohorts and matches previous RCT results. The Resmed auto-titrating 
algorithm based on flow-time curve analysis could contribute to a shorter expiratory time 
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and therefore in flow limited patients may predispose to hyperinflation and NIV 
intolerance. Whilst, FOT based algorithm have demonstrated abolishment of EFL in COPD 
patients, resulting in low pressure support preventing hyperinflation and therefore may 
be better tolerated than an auto-titrating mode utilising flow-time curve analysis.[212] 
However, there is a lack of non-inferiority studies of ST versus auto-titrating modes, flow-
time versus FOT based auto titrating modes or how settings should be altered to optimise 
NIV therapy and clinical outcomes in hypercapnic severe COPD patients (high intensity 
versus low intensity aiming for improved adherence rather than efficient correction of 
hypoventilation).  Future clinical trial are required studies are required to determine the 
optimal mode for home NIV in this cohort of patients where continued use of home NIV 




This study confirms the benefits of two-way remote monitored home NIV for patients 
with persistent hypercapnic failure due to severe COPD and in obesity-related respiratory 
failure. Continued use of remote monitored home NIV in hypercapnic severe COPD 
patients was associated with improved time to re-admission or death in comparison to 
control cohort and to patients who discontinued home NIV. That noted time to re-
admission or death improvements are in line with previous RCT data. It is feasible to 
utilise remote monitoring to initiate home NIV as an outpatient or to assist home NIV 
follow up after an acute admission episode. The reduction in health care usage with 
continued home NIV with no increase in service requirements highlights that remote 
monitored home NIV is an effective and realistic solution to address the growing 













 Simplifying the measurement of 





Ventilatory homeostasis is dependent on respiratory load, respiratory muscle capacity 
and neural respiratory drive (Chapter 1, Figure 1.1). Impairment of the respiratory muscle 
function can lead to respiratory capacity-load imbalance predisposing to alveolar 
hypoventilation and consequent respiratory failure. Neural respiratory drive (NRD), the 
neuronal activation to motor units from the respiratory centre, can maintain ventilation 
homeostasis during periods of impaired respiratory muscle function and is associated 
with dyspnoea at increased levels.[17], [18] NRD is a well-established advanced 
physiological marker in research and its evolution from an invasive research technique to 
an accessible non-invasive biomarker in respiratory disease monitoring was discussed in 
Chapter 1.  
Parasternal electromyography (EMGpara) is a novel physiological measurement at the 
Glasgow Sleep and Breathing Support Research Centre (GSBSRC). Following collaborations 
with The Lane Fox Respiratory Physiology Research Centre (Guy’s and St Thomas’ NHS 
Foundation Trust, London) and a review of previously documented methodology of 
measuring NRD, local evaluation of parasternal EMG measurements to simplify the 
approach and optimise signal quality are explored in this chapter. Reliability of this new 
technique is evaluated through inter-observer variability analysis with the Lane Fox 
Respiratory Physiology Research Centre. Further exploration of the simplification of NRD 
measurements includes the utilisation of parasternal EMG signals to estimate the 
respiratory rate and directly compare with oro-nasal flow analysis and respiratory 
impedance plethysmography (RIP) band signals. Acceptable reliability of respiratory rate 
derived from parasternal EMG signal could allow the omission of oro-nasal flow cannula 
and RIP bands to reduce the equipment burden and simplify parasternal EMG setup for 
patients and technicians. Improving accessibility of parasternal EMG through 
simplification of the methodology would enable its uptake in further studies including 
ambulatory and home monitoring to facilitate physiological phenotyping, assess 
treatment response, provide mechanistic insights, and facilitate individualised 
management of chronic respiratory disease. Incorporation of a simplified approach to 
advanced physiological measurements into ambulatory wearable devices could provide 
invaluable data for machine learned analysis of predictors of disease trajectory with the 




Simplification of parasternal electromyography technique can reliably quantify neural 
respiratory drive.  
 
4.3 Methods 
4.3.1 Optimisation of skin preparation 
In all scenarios the study candidate was in a semi-recumbent position in bed. Parasternal 
margins at the 2nd intercostal muscle and lateral right clavicle were palpated as discussed 
in Chapter 2 and appendix 6. In each scenario we evaluated different options for skin 
preparations and electrodes to optimise EMG signal. 
Scenario 1: Skin preparation included skin prep gel (Nuprep, DO Weaver and Co, US). 
Electrocardiogram (ECG) electrodes (Covidien/Kendall MEDITRACE 100) were applied to 
the 2nd intercostal space using neuro-diagnostic electrode paste (Ten20, DO Weaver and 
co, US). EMG signals of tidal breathing were sampled using bio amp and PowerLab 
hardware. Samples were taken with limited polysomnography equipment (SomnotouchTM 
Resp Polygraphy, Germany) running simultaneously to explore if these resulted in any 
interference with EMG signal.  
Scenario 2: Skin preparation included trace preparation tape (3M Red Dot Trace Prep, 
3M, Canada), alcohol wipe and dried with standard gauze. Wet gel ECG electrodes 
(XLBLEU tab ‘n’ snap, Fannin Stroud, Dublin, Ireland) were positioned with the central gel 
pad in the 2nd intercostal space at the sternal margin and right clavicle. Signals were 
sampled during tidal breathing.  
Scenario 3: Skin preparation included trace preparation tape (3M Red Dot Trace, 3M, 
Canada), alcohol wipe and dried with gauze. Cardiac Monitor ECG electrodes (Ambu Blue 
Sensor L Electrodes, Ambu, US) were positioned in the centre of 2nd intercostal space, at 
the sternal margin and at the right clavicle. Signals were sampled during tidal breathing.  
Scenario 4: Skin preparation included trace preparation tape (3M Red Dot Trace, 3M, 
Canada), alcohol wipe and dried with gauze. Elite cardiac electrodes (Elite, Skintact, UK) 
were placed in 2nd intercostal space and right clavicle. Signals were sampled during tidal 
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breathing in a normal/control subject and in a patient with chronic obstructive pulmonary 
disease (COPD). 
 
4.3.2 Reproducibility of parasternal electromyogram analysis between two UK based 
respiratory physiology research centres  
Datasets were sampled from the Exploratory Endpoints study described in chapter 2 and 
further discussed in chapter 5. Ten patients were randomly selected from the Exploratory 
Endpoints study population using Excel software (Microsoft) “=Rand ()” function. The 10 
randomly selected datasets represented a range of respiratory conditions (4 OSAS, 1 
ORRF, 2 Severe COPD with hypercapnic failure, 1 Bronchiectasis with hypercapnic failure, 
1 normal control and 1 patient with post-transplant hypoventilation).  
These data were independently analysed in Labchart software (ADInstruments, 
Chalgrove, UK) by an investigator at each centre. Inter-observer reproducibility of 
EMGpara analysis was performed comparing results obtained by Glasgow Sleep and 
Breathing Support Research Centre (GSBSRC) and the Lane Fox Clinical Respiratory 
Physiology Research Centre (Guy’s and St Thomas’, London) investigators for 
EMGpara%max and its product Neural Respiratory Drive Index (NRDI). 
 
4.3.3 Simplifying the measurement of neural respiratory drive index: can parasternal 
electromyogram signal be used to measure respiratory rate? 
Parasternal EMG data was collected as described in Chapter 2 and appendix 6. 15 
datasets from the Exploratory Endpoints study and 10 data sets from the Lane Fox 
Respiratory Research centre were analysed in Labchart software (ADInstruments, 
Chalgrove, UK). 15 patients had severe COPD, 1 COPD-OSA overlap, 5 OSAS, 4 normal 
controls. Low band pass sampling of the root mean squared signal of EMGpara (RMS 
EMGpara) was used to estimate the respiratory rate derived from EMG (EMGpara-RR). 
Reliability of EMGpara-RR was compared with respiratory rate derived from oro-nasal 
flow analysis in 25 datasets and respiratory impedance plethysmography (RIP) band 
signals in 15 datasets as detailed in appendix 8. 
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4.3.4 Data Analysis and statistics 
Reproducibility of EMGpara%max and NRDI was determined using Pearson’s correlation 
coefficient and Bland Altman analysis[213]. Normal distribution of data was confirmed by 
the Shapiro-Wilk test. Data analysis was performed by GraphPad, Prism software 
(GraphPad, San Diego, US). EMG data was presented as absolute values, mean, standard 
deviation and 95% limits of agreement. P value < 0.05 was considered statistically 
significant.  
Bland Altman analysis evaluated agreement between NRDI derived from flow analysis, RIP 
bands and EMGpara-RR. Data analysis was performed by Graphpad, Prism Software 






4.4.1 Optimisation of skin preparation 
Minor interference of the parasternal EMG signal was noted during activation of limited 
polysomnography equipment, as demonstrated in Figure 4.1. The parasternal EMG signal 
quality improved when trace preparation tape (3M Red Dot Trace Prep, 3M, Canada) was 
used in combination with an alcohol swab (Figure 4.2) compared to scenario 1 using 
Nuprep skin preparation gel and Ten20 electrode paste (Figure 4.1). EMG signal quality 
improved using cardiac monitor electrodes (Ambu Blue Sensor L Electrodes, Ambu, US) as 
described in scenario 3 (Figure 4.3). Optimal EMG signal was achieved using cardiac 
monitoring electrodes (Elite, Skintact, UK) to capture signals in a normal/control and a 
patient with COPD, as described in scenario 4 (Figure 4.4). Scenario 4 incorporated the 
same technique used for long duration ECG monitoring to optimise EMG signal and 
reduce interference. 
 
4.4.2 Reproducibility of parasternal electromyogram analysis between two UK based 
respiratory physiology research centres  
 
Observer A was investigator from GSBSRC. Observer B was investigator from Lane Fox 
Respiratory Unit. Considering raw data values, acceptable agreement was noted for 
EMGpara%max (table 4.1) and NRDI (table 4.2). Pearson correlation analyses 
demonstrate strong correlation between observer A and B for both EMGpara%max and 
NRDI (Figure 4.5). Bland Altmann analysis demonstrates acceptable agreement between 
observers A and B for EMGpara%max and NRDI (Figure 4.6). There are some outlying data 
points justified by the small sample size. 
 
4.4.3 Simplifying the measurement of neural respiratory drive index: can parasternal 
electromyogram signal be used to measure respiratory rate? 
Bland Altman analysis demonstrated good agreement for NRDI derived from EMGpara-RR 







Figure 4-1 Parasternal EMGs, evaluating skin preparation and interference scenario 1 
Raw electromyogram signal from the second intercostal parasternal muscles (measured in 
millivolts(mV)) using Nuprep skin preparation gel and MEDITRACE electrodes, demonstrating lack 
of interference from additional polysomnography monitoring equipment. A- Raw signal with 








Figure 4-2 Parasternal EMG data, evaluating skin preparation scenario 2 
Parasternal electromyogram from the second intercostal muscle using trace preparation tape, 
alcohol wipes and XBLEU electrodes. A- Electrocardiogram signal. B- Raw parasternal EMG signal. C- Root 






Figure 4-3 Parasternal EMG data, evaluating skin preparation scenario 3 
Parasternal electromyogram of the second intercostal muscle using trace preparation tape, 
alcohol wipe and AMBU Blue Senor L electrodes. A- Electrocardiogram signal. B- Raw parasternal 




































































































































































































































EMGpara%max Observer A Observer B A-B 
1 14.826 13.209 1.617 
2 24.088 23.592 0.495 
3 15.901 14.147 1.755 
4 15.296 14.896 0.399 
5 12.061 12.756 -0.695 
6 17.801 17.336 0.464 
7 36.159 30.619 5.540 
8 12.118 8.414 3.704 
9 9.289 9.634 -0.335 
10 6.806 5.687 1.118 
Mean (SD) 16.4343 (8.4010) 15.0291(7.3871) 1.4062(1.9088) 
Table 4-1 Normalised parasternal electromyogram results (EMGpara%max) for Glasgow Sleep 
and Breathing Support Research Centre (observer A) and the Lane Fox Respiratory Physiology 
Research Centre (observer B). 
The mean difference in EMGpara%max is 1.406 ± 1.909 µV between Observer A and Observer B 





NRDI Observer A Observer B A-B 
1 122.29 112.887 9.403 
2 370.467 413.410 -42.940 
3 258.438 234.418 24.019 
4 154 150.572 3.428 
5 249.238 388.841 -139.60 
6 371.077 358.711 12.366 
7 650 545.794 104.206 
8 90.625 80.386 10.239 
9 125.6 127.108 -1.508 
10 776.583 68.528 8.055 
Mean (SD) 246.832(178.145) 248.065(166.995) -1.234(60.717) 
Table 4-2 Neural respiratory drive index (NRDI) results for Glasgow Sleep and Breathing Support 
Research Centre (observer A) and the Lane Fox Respiratory Physiology Research Centre 
(observer B). 
The mean difference in NRDI is -1.233 ± 60.717 µV between Observer A and Observer B with 





Figure 4-5 Pearson correlations show inter-observer agreement for the analysis of normalised 
parasternal electromyogram (EMGpara%max) and neural respiratory drive index (NRDI). 
EMGpara%max correlation demonstrates r= 0.9789, 95%CI 0.9104 to 0.9952, p<0.0001. NRDI 
correlation demonstrates r=0.9401, 95%CI 0.7609 to 0.9861, p<0.0001.  Observer A: Glasgow 






Figure 4-6 Bland-Altman plots show good inter-observer agreement for the analysis of 
normalised parasternal electromyogram (EMGpara%max) and neural respiratory drive index 
(NRDI). 
A- Bland Altman analysis of normalised parasternal electromyogram (EMGpara%max). B- Bland 
Altman analysis of neural respiratory drive index (NRDI). Outlying data points for mean NRDI are 





Figure 4-7 Bland-Altman plots show intra-technique agreement for the measurement of neural 
respiratory drive index (NRDI) derived from different respiratory rate (RR) sensors. 
A- Bland-Altman analysis of neural respiratory drive index derived from oro-nasal flow analysis (Flow 
NRDI) and respiratory impedance plethysmography (RIP) band signals (RIP NRDI).  
B- B- Bland Altman analysis of neural respiratory drive index derived from oro-nasal flow analysis (Flow 
NRDI) and respiratory rate derived from low band pass sampling of the parasternal electromyogram 
signal (RMS NRDI).  
C- C- Bland Altman analysis of neural respiratory drive derived from RIP band analysis (RIP NRDI) and 





These data demonstrate the simplification of parasternal electromyography 
measurement is feasible and reliable to quantify NRD. We compared methods of skin 
preparation and different EMG electrodes. Simplified skin preparation method and long 
duration electrodes used for cardiac monitoring (Skintact) returned the highest quality 
EMG signals, with reduced interference from simultaneous device monitoring. These 
refinements resulted in a standardised practice which was simpler for the investigator, 
more acceptable for the subject and sustainable for long periods of continuous 
monitoring which can be required during complex interventions such as non-invasive 
ventilation titrations and potentially for ambulatory wearable EMG. This method was 
used in all study patients recruited for the Exploratory Endpoints study (Chapter 5). 
 
This is the first published evidence of inter-observer variability of parasternal 
electromyogram data between two respiratory physiology research centres in the United 
Kingdom.[214] Our data demonstrated satisfactory inter-observer reproducibility of 
parasternal electromyography and its product neural respiratory drive index (NRDI) in a 
randomised group of patients with chronic respiratory disease. Previous inter-observer 
variability of EMGdi has been demonstrated in 5 COPD patients with an intraclass 
correlation(ICC) of 0.71.[29] Inter-observer variability of surface EMGdi in snoring children 
demonstrated ICC of 0.98[215]. This supports ongoing and future utilisation of 
parasternal EMG as an advanced physiological biomarkers and research endpoint as part 
of large multi-centred studies. 
 
The estimation of respiratory rate derived from the root mean squared of parasternal 
EMG signals further simplifies NRD quantification and is reliable in comparison to the 
established practice of respiratory rate estimations from oro-nasal flow or respiratory 
impedance plethysmography (RIP) band signals.[216]  These data suggest additional 
sensors, oro-flow nasal cannula and RIP bands, could be omitted during the measurement 
of parasternal EMG but further feasibility studies are necessary to consolidate our study 
findings. Rationalisation of NRD analysis would facilitate increased uptake of parasternal 
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EMG as a research endpoint, an advanced physiological biomarker in disease monitoring 
in clinical practice out with research centre and in ambulatory settings.  
 
4.6 Critique of methods 
4.6.1  Patient Selection for inter-observer variability analysis and simplification of neural 
respiratory drive analysis 
Patients were recruited to the Exploratory Endpoints study, a prospective observational 
study. This study was not blinded and therefore underlying respiratory conditions were 
known to the assessor. However, all parasternal EMG analysis for the Exploratory 
Endpoints study was carried out by one assessor limiting variability.  
During recruitment for the Exploratory Endpoints study, initial parasternal EMG hardware 
setup did not include the spirometer module due to lack of equipment and RIP bands 
were used for all study candidates recruited. The introduction of the spirometer module 
in the final months of recruitment allowed a limited number of datasets with a variety of 
respiratory diseases to be analysed (COPD, COPD-OSA overlap, OSAS and normal 
controls). Ongoing parasternal EMG studies at GSBSRC include RIP band and oro-nasal 
flow analysis. The 10 data sets from the Lane Fox Respiratory unit were from patients 
with severe COPD. Further studies with larger disease cohorts are justified to consolidate 
these study findings. 
 
4.6.2  Surface parasternal electromyography measurements 
As the data was used from two research centres, skin preparation and EMG set up may 
differ therefore absolute values for EMGpara from both sites may not be directly 
comparable. However, inter-observer variability demonstrates good reproducibility for 
parasternal EMG analysis and its product NRDI in both respiratory centres. All data 
analysed to derive the respiratory rate from parasternal EMG was carried out by one 
assessor, minimising variability of results. Further feasibility studies in multiple research 
centres could be considered to ensure skin preparation, EMG acquisition and analysis do 
not significantly impact NRD measurements and confirm the reliability of a simplified 
approach to NRD analysis. 
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As previously discussed in Chapter 1, there are some limitations with surface EMG data 
including crosstalk from accessory muscles and the effect of body habitus in signal quality. 
Needle electrode EMG method reduces interference but is invasive and not suitable for 
acutely unwell patients or for monitoring disease response to treatment. Analysis of 
parasternal EMG traces can be difficult in patients who have severe COPD with increased 
accessory muscle use during tidal breathing resulting in increased crosstalk of EMG 
signals. Subsequent use of RMS of parasternal EMG signal to derive the respiratory rate 
could be compromised. Likewise, low voltage signals seen in patients with severe obesity 
could limit respiratory rate derived from RMS of the parasternal EMG signal. These data 
justify future studies to consolidate that utilisation of parasternal EMG derived 
respiratory rate allows the omission of oro-nasal flow cannula and RIP band use to 
improve the accessibility of NRD measurements. Future work should include large sample 
sizes of patients with COPD and obesity to ensure validity of this simplified technique.   
 
4.7 Conclusions 
These data demonstrate the rationalised methodology for parasternal EMG measurement 
provides acceptable signal quality and simplification of NRD analysis using the RMS 
parasternal EMG signal to estimate the respiratory rate is reliable. The simplified skin 
preparation is less cumbersome, and the cardiac electrodes are compatible with longer 
periods of monitoring like those in ambulatory cardiac investigations. This simplified 
methodology will improve accessibility of parasternal EMG as all the equipment is readily 
available in cardiology units and on NHS Scotland procurement. Acceptable inter-observer 
variability between GSBSRC and the Lane Fox Respiratory Physiology Research centre 
endorses future multi-centre studies utilising EMGpara as a research endpoint and 
advanced physiological biomarker in chronic respiratory disease. The rationalisation of 
NRD analysis allowing the omission of oro-nasal flow and RIP band sensors could improve 
the accessibility of continuous parasternal EMG in the home and ambulatory settings. The 
combination of a simplified methodology and rationalised NRD analysis with omission of 
additional sensors could provide a less cumbersome and more accessible approach to the 
quantification of NRD. The development of ambulatory monitoring of NRD using these 
methods would increase the uptake of parasternal EMG as a research endpoint, provide 
physiological insights and facilitate disease monitoring. Improved accessibility of 
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parasternal EMG allows inclusion of patients susceptible to respiratory failure, who 
previously have been unable to participate in advanced physiological measurements due 
to the significant disease burden and physical debilitation of severe chronic respiratory 
disease to provide invaluable insights into pulmonary mechanics of severe respiratory 






















The utilisation of advanced physiological measurements such as oscillometry (FOT) and neural 
respiratory drive (NRD) are well established in research and their clinical application as a bio-
marker of respiratory disease has emerged providing valuable insights into pulmonary mechanics 
in chronic respiratory disease.[65], [217] This chapter will discuss the application and feasibility of 
measuring FOT and NRD in patients with sleep disordered breathing, hypercapnic severe COPD 
and COPD-OSA overlap syndrome. 
During the expiratory phase of the respiratory cycle, maximum expiratory volumes are recorded 
in the first second of expiration. Applying the theory of Poiseuille’s equation (Fig 5.1), where the 
amount of air expired in one second (FEV1) is directly proportional to the radius of the airways, 
diseases of the large airways classically present with a reduction in FEV1 compared to normal 
subjects. A reduction in the ratio of FEV1 to forced vital capacity (FVC) below 0.7 is referred to as 
airflow obstruction and is a common feature in chronic lung diseases. COPD is characterised by 
persistent respiratory symptoms, progressive airflow obstruction which is not fully reversible and 
associated with the inhalation of noxious particles or gas.[183][218] However, in normal ageing 
there can be a greater reduction in FEV1 compared to FVC resulting in ratios of 0.7 in the absence 
of obstructive airways disease therefore age-specific range should be considered in a new 
diagnosis of COPD.[219]  
Negative pleural and alveolar pressures during inspiration correlate with inspiratory flow (Figure 
5.2).[220] Expiration is protracted in obstructive airways disease due to airflow obstruction 
resulting in a reduction in flow below a critical point (Pcrit) required to maintain airway patency 
resulting in flow cessation, airways collapse and positive end-expiratory pressure within the 
airways(PEEP) referred to as the “waterfall concept” (Figure 5.3). This airflow limitation in 
expiration despite increasing pleural pressures is also known as expiratory flow limitation (EFL) 
and is present during maximal manoeuvres or during tidal breathing in severe obstructive airways 
disease.[221][222] Incomplete lung emptying at the end of expiration increases respiratory load 
on the inspiratory muscles to generate a pressure equivalent to PEEP, increasing work of 
breathing compared to normal subjects.[53] Increased End Expiratory Lung Volumes (EELV) 
secondary to incomplete lung emptying results in resting and dynamic lung hyperinflation. 
Hyperinflation reduces inspiratory muscle capacity, increasing the work of breathing, increased 
dyspnoea, reduced exercise capacity and can be predictive of mortality.[223][224][225][226] 
[227][228][229] Dynamic hyperinflation (DH) is seen during exercise in patients with airflow 
obstruction[230][231] and is aggravated during exacerbations of obstructive airways disease as a 
consequence of airway oedema, mucous congestion, increased airways resistance, exacerbated 
EFL and increased EELVs. The increased respiratory load and reduced lung capacity seen in DH 
141 
 
results in heightened NRD and/or increased respiratory rate, which can further exacerbates DH 
and dyspnoea.[137]  
Recognition of EFL during tidal breathing identifies patients who are susceptible to aggravated 
hyperinflation, unstable alveolar ventilation, ventilation/perfusion (VQ) mismatching resulting in 
ventilatory failure and adverse clinical outcomes.[227], [229] However, quantification of EFL can 
be impractical with invasive oesphageal balloons or inconsistent with non-invasive flow-volume 
loop analysis which has high variablilty on an individual basis. Forced oscillometry technique 
(FOT), a non-invasive effort independent assessment of pulmonary mechanics can quantify in-
breath EFL at rest and is equivalent to negative expiratory pressure assessments.[222] Dallaca 
demonstrated that breath by breath analysis using oscillometry can quantify EFL through the 
difference between inspiratory X5(X5insp) and expiratory X5(X5exp) otherwise known as ∆𝑋𝑅𝑆 
(Figure 5.4).[232], [233][234]  
 
5.1.1 Principles of forced oscillometry technique 
FOT transmits pressure oscillations generated by a loud speaker into the lungs, with high to low 
frequency waves travelling to the alveoli to represent the large and small airways respectively. 
FOT quantifies pulmonary mechanics on a breath by breath basis through pressure flow analysis 
and is represented as respiratory impedence(Zrs), the sum of Resistance(Rrs) and Reactance(Xrs), 
which can be used as a generalised marker of airway resistance (Figure 5.5). Airway resistance can 
be further quantified into total airway resistence (R5), large (R20) and small (R5-R20) airways 
resistence with the latter contributing to approximately 20% of Rrs (Figure 5.6).[235] Reactance is 
the product of capacitance (a negative quantitiy representing the elastic properties of the lung) 
and inertance (Figure 5.5). Diseases of the smaller airways such as emphysema have a more 
negative reactance.[236] EFL is quantified by the difference between inspiratory reactance at 5Hz 
(X5insp) and expiratory reactance at 5Hz(X5exp) otherwise known as ∆𝑋𝑅𝑆 (Figure 5.4). Resonant 
frequency(Fres) is the frequency at which capacitance and inertance are equal to zero, with 
normal values at 7-12Hz and are increased in both obstructive and restrictive disease. Area of 
reactance (Ax) is the area under the reactance curve and reflects capacitance, the elastic 






5.1.2 Clinical application of oscillometry in respiratory disease 
FOT can detect EFL present during tidal breathing in patients with COPD giving insight into 
pulmonary mechanics of severe airways disease and identifying those susceptible to dynamic 
hyperinflation.[237] Patients with COPD and tidal EFL demonstrated a greater improvement in 
airways resistence following beta agonist therapy compared to those without tidal EFL.[234] Serial 
FOT measurements in COPD patients with evidence of  bronchodilator reversibility showed a 
larger fall in overall resistence and small airways resistence following beta agonist therapy 
compared to those with no reversibility, demonstrating the heterogeneity of pulmonary 
mechanics in COPD.[234]  FOT has demonstrated a strong correlation between FEV1 and 
reactance in addition to reduced compliance in chronic respiratory disease and progressive 
airflow obstruction.[238] Additionally, the change in reactance in patients recovering from an 
exacerbation of COPD has been shown to correlate with improved symptom burden providing 
insights into the importance of small airways disease in the management of exacerbated 
COPD.[239] FOT facilitates physiological phenotyping of chronic respirtory disease such as COPD, 
leading to targeted treatments and potential disease monitoring.[6] [240] 
FOT has been utilised in paediatric research in chronic respiratory diseases such as asthma and 
cystic fibrosis as it is effort independent  and non-invasive. Small airways resistence has been 
shown to correlate with small airways disease (FEF 25-75) and airways inflammation measure by 
exhaled nitric oxide in asthma.[241]  Small airways resistance and Ax was strongly associated with 
poorly controlled asthma with serial FOT measurements identifying patients requiring treatment 
optimisation to improve patient outcomes in difficult to control asthmatics.[242] In Cystic 
Fibrosis, FOT has shown an increased resistence and reduced reactance in symptomatic children 
and adults compared to normal subjects, with a correlation between FOT and standard pulmonary 
function investigations.[243], [244][245]  
In obesity, compliance of the respiratory system is reduced whilst both expiratory reserve volume 
(ERV) and Functional Residual Capacity(FRC) are negatively correlated with BMI.[2][7] Decreased 
lung volumes and micro-atelectasis contributes to reduced compliance where tidal breathing 
occurs out-with the linear portion of the pressure-flow curve (Figure 5.3).[246] FOT has 
demonstrated increase airway resistance in obesity compared to normal subjects.[247], [248] In 
sleep disorder breathing, large and small airways resistance correlates with disease severity 
measured by AHI as does reactance at 5Hz (X5). [249][250][251] In the supine position, 
respiratory mechanics are altered due to abdominal contents splinting the diaphragm increasing 
airways resistance and EFL. As a result variable expiratory positive airway pressure (EPAP) 
requirements can be seen with postural changes in severe COPD.[252][253] FOT can identify 
dynamic EPAP requirements in severe COPD which would facilitate a personalised approach to 
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NIV titrations.[233] Whilst auto-tirating EPAP using FOT-based algorithm has been shown to 
abolish tidal EFL and reduce neural respiratory drive in hypercapnic severe COPD patients. [212] 
 
FOT provides valuable insights into the pulmonary mechanics of chronic respiratory disease. The 
utilisation of FOT in physiological phenotyping, as a bio-marker of treatment success and in the 
management of respiratory failure could facilitate a personalised approach to the management of 





Figure 5-1 Poiseuille Equation 
Represents the relationship between volume of air expired and radius of the airways, explaining reduction 
in FEV1 in obstructive airways disease. ∆p- the pressure difference in the airways, L- the length of airway, 




Figure 5-2 : Iso-volume flow pressure relationship of the respiratory cycle 
Representation of change in expiratory flow following the critical pleural pressure point (Pcrit) in normal 
physiology, COPD patients without expiratory flow limitation (NFL) and COPD patients with tidal expiratory 








Figure 5-3 The waterfall concept- reduction of airflow below critical pressure point  
Illustration showing the reduction in in air flow below the critical pressure point resutling in airways 
collapse and positive end-expiratory pressure. Palv- Alveolar pressure, Pcrit- critical pressure point, Paw-






Figure 5-4 In breath analysis of reactance measured at 5Hz (∆XRS) 
Illustration of in-breath analysis to quantify expiratory flow limitation (EFL) through the difference 
between inspiratory X5(X5insp) and expiratory X5(X5exp) otherwise known as ∆𝑋𝑅𝑆. Xrs- 
reactance (measured in cmH20sl-1), Rrs- resistance (measured in cmH20sl-1), Ca- alveolar pressure, 




Figure 5-5 Forced oscillometry technique and principles of oscillometry 
Illustration showing pressure (measured in cmsH2O) and flow (measured in litres/second) 
variations during forced oscillometry measurments at tidal breathing. Equation demonstrating the 
sum of resistance (Rrs) + reactance (Xrs) equals respiratory impedence (Zrs). Reactance is the 




Figure 5-6 Airways resistance 
Illustration representing Total airways resistance (R5), Large airways resistance (R20) and small 





Figure 5-7 Forced oscillometry demonstrating area under the curve and resonant frequency in a 
normal subject (A) and in a patient with COPD (B) 
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5.1.3 Parasternal Electromyography 
Surface parasternal electromyography measures the neuronal activation of motor units from the 
respiratory centre, otherwise known as neural respiratory drive (NRD). This advanced 
physiological biomarker quantifies the work of breathing providing insight into pulmonary 
mechanics and the respiratory load capacity relationship (Figure 1.1). The evolution of NRD 
techniques has been discussed in Chapter 1 & 4 with methods in Chapter 2 and appendices 6-8.  
 
5.1.4 Neural respiratory drive in airways disease 
Altered length tension properties of the diaphragm in COPD affect the position and efficiency 
during inspiration resulting in increased use of accessory muscle activation.[54]–[58] Resulting 
NRD in COPD is increased compared to matched healthy subjects, and corresponds to disease 
severity and dyspnoea.[29], [44], [59][57], [60] Progressive DH during graded exercise negatively 
impacts the pressure-generating capacity of the diaphragm which results in increased NRD and 
neuro-ventilatory uncoupling.[57] O’Donnell et al demonstrated a positive correlation between 
DH, increased dyspnoea and a reduction of the pressure-generating capacity of the diaphragm 
during graded exercise in COPD. Once minimal Inspiratory Reserve Volume (IRV) was reached the 
sensation of dyspnoea became intolerable and diaphragm efficiency was significantly 
impaired.[61] Long acting bronchodilators have demonstrated improvement in lung function, 
reduction in dyspnoea and NRD in this cohort of patients.[61], [62]  
During states of increased respiratory load, the parasternal intercostal muscles are integral in 
accessory muscle activation to maintain ventilation and have a rostro-caudal distribution of EMG 
activity. [37], [38], [41][64] The second intercostal(IC) muscles demonstrated a similar activation 
as diaphragmatic EMG and contribute more to accessory inspiration than caudal IC muscles 
whose primary function is to maintain posture during tidal breathing.[42], [43] Quantifying NRD 
with parasternal EMG (EMGpara) of the second IC muscle is reliable and reproducible in COPD 
patients.[53][65] NRD increases in COPD during acute changes in respiratory load, such as 
histamine provocation or exacerbations and reduces following treatment.[65], [66] Neural 
Respiratory Drive Index (NRDI), a product of EMGpara%max and respiratory rate (RR), can be used 
as a biomarker of disease monitoring during exacerbations of COPD, with greater sensitivity and 
specificity than other physiological parameters.[65] Utilising EMGpara during acute exacerbations 
of COPD can predict safe discharge and readmissions rates, with reduced re-admission rates seen 
in those with a greater reduction in NRDI following treatment for an exacerbation.[65], [67] 
NRD can be utilised to monitor a wide range of pulmonary diseases. Correlations between NRD, 
lung function and acute exacerbations have been demonstrated in Cystic Fibrosis(CF) and 
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Interstitial Lung Disease (ILD).[17][68], [69][70] Higher NRD levels were observed in CF patients 
compared to healthy controls during exercise, suggesting habituation of sensation of 
breathlessness with persistent high NRD levels in CF.[71] NRD is elevated in uncontrolled asthma 
compared to well controlled disease and matched healthy controls.[72] 
 
5.1.5 Neural respiratory drive in obesity 
Increasing prevalence of obesity has led to an increase in morbidity and mortality as a result of 
obesity related respiratory failure (ORRF).[73] The prevalence of Sleep Disordered Breathing (SDB) 
has risen as a result of the increased prevalence of obesity.[74]. A study of patients with SDB 
demonstrated a positive relationship between NRD and Body mass index (BMI), whilst 
highlighting an increase in NRD in the supine position, representing increased respiratory load, 
diaphragmatic splinting from abdominal mass effects and increased PEEP.[75]  Continuous 
Positive Airway Pressure (CPAP) therapy can offset PEEP with subsequent reduction in NRD of up 
to 30%.[75]–[77] Patients with chronic hypercapnic respiratory failure secondary to obesity 
hypoventilation syndrome(OHS) demonstrate a decrease in NRD as a result of Non-invasive 
ventilation(NIV).[78] Quantification of this off-loading effect of NIV with NRD analysis can predict 
adherence in COPD-OSA overlap syndrome and potentially facilitate early optimisation in patients 
with chronic hypercapnic respiratory failure to improve patient outcomes.[79] 
Another application of parasternal EMG monitoring is evaluating patient ventilator asynchrony 
(PVA) and potential utilising EMG signal to trigger NIV breaths, rather than relying on flow 
analysis. Previous studies showed no correlation between PVAs measured by parasternal EMG 
signals and control of ventilatory failure with nocturnal NIV.[82], [83]  However, PVAs can lead to 
increased ventilator intolerance and de-ventilation dyspnoea and therefore further work is 
warranted to establish the role of NRD in the optimisation of domiciliary NIV.[81]  
Parasternal EMG is accessible and provides insight into pulmonary mechanics of chronic 
respiratory disease. The evolution of NRD measurement and wider application supports its use as 
an advanced physiological biomarker of disease management. NRD has a potential role in disease 
optimisation and response to therapy during acute exacerbations to predict treatment success.  
Advanced physiological measurements such as FOT and NRD in chronic respiratory disease can 
facilitate physiological phenotyping, targeted disease management, assess treatment response 
whilst providing invaluable insights into disease mechanics. This study will explore the feasibility 
of serial measurements of FOT and NRD alongside standard respiratory care in patients with a 
range of respiratory conditions out with a research centre or controlled research environment. 
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5.2  Hypothesis 
In this study we hypothesise that it is feasible and acceptable to monitor advanced physiological 
parameters such as FOT and neural respiratory drive in a wide range of patients with chronic 
respiratory disease. This study will give us insight into pulmonary mechanics of chronic respiratory 
disease, its response to standard therapy and long term two-way remote monitored PAP therapy 




5.3.1 Study design 
This was a prospective observational study of the feasiblity of serial exploratory advanced 
physiology measurements in patients with a range of respiratory diseases and normal subjects. 
Exploratory Endpoints protocol and patient information sheets are detailed in Appendix 2 and 3. 
All exploratory research was undertaken alongside routine clinical care. (Figure 2.10) 
 
Patients over the age of 16 years, able to provide informed consent, attending for routine clinical 
investigation and management with feasible timescales for repeat measurements were recruited. 
Main exclusion criteria was the inability to provide informed consent. We aimed to recruite 
approximately 75 patients with a range of chronic respiratory diseases as detailed in Appendix 2. 
Patients who met the inclusion criteria were provided with a patient information sheet (Appendix 
3) and written consent was completed (Appendix 4).   
 
105 patients were screened following tertiary referral for breathing support assessment or an 
acute decompensation resulting in hospital admission. 69 patients with a range of respiratory 
conditions were recruited. 12/69 patients were normal/controls where follow up visits were not 
arranged. 43/57 patients (excluding controls) attended study visit 1 and 26/57 patients attended 
at visit 2. 22 patients with hypercapnic severe COPD were screened with 10 patients recruited. In 
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this chapter we focus on the conditions who received similar respiratory management including 
patients managed with remote monitored PAP therapy for OSAS and home NIV for ORRF and 
hypercapnic severe COPD. Patients were separated into phenotypes OSAS, ORRF, hypercapnic 
severe COPD and COPD-OSA overlap. These diagnoses were determined by an experienced clinical 
team based on standard cardiorespiratory evaulation, clinical presentation, and current 
guidelines.   
 
Baseline demographics and anthropometrics data were collected at the baseline visit. Symptom 
burden was assessed with Epworth sleepiness scale, MRC dyspnoea score, modified COPD 
assessment tool (mCAT) and performance status at each visit (Appendix 5). Spirometry was 
performed using a handheld device (Vitalograph copd-6 COPD Screening Device, Vitalograph, 
England) according to standardised ERS guidelines[4]. All patients suspected of sleep disordered 
breathing underwent laboratory-based polysomnography or home limited polysomnography to 
confirm sleep disordered breathing. Diagnosis of hypercapnic severe COPD was based on  
spirometry, clinical presentation and arterial blood gas analysis.  
 
Forced oscillometry (FOT) was measured using a portable device (Tremflo, Thorasys, Canada) in 
the upright position as detailed in Chapter 2 (Figure 2.14). Measurements were taken during 3 
cycles of steady tidal breathing. At least three measurements were taken according to ERS 
guidelines or more if the CV was greater than 15. Results are expressed in figures as the mean ± 
standard deviation.  
 
Parasternal electromyography was measured as detailed in Chapter 2 and in Appendices 6&7. All 
data was collected with patient resting at 45degrees for at least 5 mins of tidal breathing followed 
by 10 sniff manoeuvres. Results are presented as absoluted values, mean ± standard deviation. 
 
Anthropometric measurements, FOT, NRD, PAP/NIV usage, symptom burden and where feasible 
capillary or arterial blood gas data were collected at baseline, 3months, 6 months and 12 months 





This study was sponsored by NHS Greater Glasgow & Clyde with research ethics approval proved 
by London Queen Square Research Ethics Committee (REC reference 16/LO/2090) 
 
5.3.3 Statistical analysis 
Results are shown in Tables 5.1-5.17 with absolute values, mean ± Standard deviation(SD), 
percent predicted spirometry, PAP therapy represented as 95% and median pressures. Normal 
distribution of results was confirmed by Shapiro-Wilk test. Pearson correlation coefficients were 
calculated to evaluate lung function and other demographic data. Spearman’s correlations were 
used in data found to be not normally distributed. Non-parametric Wilcoxon tests analysed 
changes in FOT and EMG data from baseline measurements. Relationships between mean 
EMGpara, EMGpara%max and NRDI and disease severity or symptoms were analysed using linear 
regression analysis. T tests were used were appropriate. P values <0.05 were considered 







5.4.1 Obstructive Sleep Apnoea Syndrome 
20 patients with OSAS were recruited between September 2017 and October 2018. Population 
demographics are shown in Table 5.1. The study populations mean age was 51.2 years (SD 13.3) 
and there was an equal proportion of male: female representation (10 males, 10 females). Mean 
BMI was 41 kg/m2(SD 8.3 kg/m2 ). Mean apnoea hypopnoea index (AHI) was 54 events/hour (SD 
25 events/hour) and a mean oxygen desaturation index (ODI) of 47.9 events/hour (SD 18.2 
events/hour). Mean oxygen saturations was 90.4% (SD 2.9%) and mean Total Sleep Time with 
oxygen saturations <90% (TST90) was 42.6% (SD 30.5%). Mean FEV1 was 82.4% (SD 23.7%) and 
FEV1/FVC was 83.9% (SD 6.7%)(Table 5.1). Daytime somnolence was quantified by the Epworth 
Sleepiness Score (ESS) with a mean of 14.5 (SD 3.9) for this population. Mean values of mCAT, 
MRC dyspnoea score and Performance status (PS) were 22.3 (SD 6.3), 2.4 (SD 1.1) and 1.8 (SD 
0.6), respectively (Table 5.1). 
All 20 patients used Auto-titrating positive airways pressure (APAP) and 50% reached target 
treatment adherence (≥70% days of CPAP usage ≥4hours; the level set for reimbursement in US 
health system). Mean 95th  centile pressure requirements was 12.7 cmsH2O (SD 1.8) and  median 
pressure requirements was 9.7 cmsH2O (SD 1.8). (Table 5.2) All patients were under remote PAP 
therapy review with average remote requirements  of 4(SD 3)data reviews, 2(SD2) telephone 
consultations and no prescription changes or day case troubleshooting sessions. Mean follow up 
was 5.8 months. (Table 5.2) 
 
Exploratory Endpoints 
20 patients had FOT and EMGpara measurements taken at baseline. One patient failed to attend 
for further exploratory endpoints measurements. 19 patients had further measurements taken, 
13 patients had FOT at 3 months and 11 patients at 6months. 14 patients had EMG para 
measured at 3 months and 11 patients at 6months. Baseline FOT and EMGpara are shown in 









A significant decrease in R5-R20 was observed in patient’s adherent to PAP therapy at 3months 
(p<0.05)(Fig 5.8). Reactance measured by Ax and ∆𝑋𝑅𝑆 decreased with PAP adherence (p<0.05 
for both) (Fig 5.9). A further decrease in ∆𝑋𝑅𝑆was demonstrated in those adherent to PAP 
therapy at 6months, p< 0.05 (Figure 5.9B).  50% of patietns demonstrated EFL on baseline COT 
(Table 5.3). Analysis of patients with expiratory flow limitation (∆𝑋𝑅𝑆> 0.28) demonstrated no 
significant correlation in between ∆𝑋𝑅𝑆 and BMI, FEV1, R5-R20, APAP pressures or symptom 
burden (measured by AHI, ODI, ESS, PS, mCAT or MRC). Total airways resistance (R5) decreased in 
patient’s adherent to PAP therapy but did not reach statistical significance and increased in non-
adherence (Appendix 9, Figure 9-1). Disease severity measured by AHI and ODI, demonstrated no 
correlation with BMI. There was no significant correlation with oscillometry results and disease 




A decreasing trend was shown in all three EMG parameters in those adherent to PAP therapy 
(Figure 5.10 &appendix 9). MeanEMGpara%max showed a decreasing trend at 3months 
(p=0.05)and 6 months (p= 0.09) in those adherent to PAP therapy (Figure 5.10B). NRDI and 
meanEMGpara showed a decreasing trend in those adherent to PAP therapy but did not reach 
statistical significance (Figure 5.10A&C). Disease severity measured by AHI and ODI demonstrates 
no statistical significant correlation with meanEMGpara, EMGpara%max or NRDI. Mean oxygen 
saturations and TST90  demonstrated no relationship with parasternal EMG data. There was no 
significant correlation with disease burden, measured by ESS, and meanEMGpara, EMGpara%max 
or NRDI.  
 
Symptom burden 
There was a significant decrease in ESS was observed at 3months and 6 months in all 
patients(p<0.05 for both). There was an overall decreasing trend from baseline values in PS, 
modified CAT score and MRC scores in both adherence and non-adherence of PAP therapy at 3 


















ESS mCAT MRC PS 
1 M 52 33.6 42.6 43 86 97 95 83 15 18 1 2 
2 F 45 34.4 24 62 89 59 35 73 21 28 2 2 
3 M 59 41.2 54 55 
  
83 84 9 14 1 2 
4 M 54 35.5 30 30 94 2.3 96 90 10 24 1 1 
5 M 66 34.3 29 28 93 72 82 80 15 19 2 2 
6 F 54 31.4 50 52 89 49 101 81 13 11 1 1 
7 F 48 37 60 59 92 31 89 90 13 18 1 1 
8 F 37 55.8 82 80 92 27 102 84 18 29 2 2 
9 F 45 45.3 29.2 21.8 94 8 99 100 15 21 3 2 
10 M 81 35.8 71 60 88 94 60 75 11 15 3 2 
11 M 39 60 79 50 87 31 60 93 18 31 4 2 
12 M 70 54.7 46 70 90 52 71 79 8 33 4 2 
13 F 53 48.7 118 31 83 87 89 86 21 28 3 2 
14 M 52 33.9 29 28 93 6 92 80 14 17 2 1 
15 M 37 45.7 66 73 91 36 97 78 12 20 3 2 
16 F 48 38.8 24 29 92 8 78 90  30 3 2 
17 M 39 41.2 74 73 92 57 112 85 20 18 2 2 
18 F 25 42.2 
    
100 
 
17 22  1 
19 M 50 33.4 66 36 91 35 89 86 11 22 3 1 



























Table 5-1 Population demographics for patients with obstructive sleep apnoea syndrome 
initiated on remote monitored positive airway pressure therapy 
AHI- apnoea hypopnoea index (events/hour), ODI- oxygen desaturation index (events/hour), Mean sats%-
mean peripheral oxygen saturations (%), TST90- percentage Total Sleep Time with oxygen saturations <90% 
during either limited or fully polysomnography, ESS- Epworth Sleepiness scale, mCAT -modified COPD 


























1 12.2 9.3 Y 10 7 0 0 12 
2 15.2 12.5 Y 3 2 0 0 6 
3 12.9 9.1 Y 5 2 1 0 6 
4 16 13.6 Y 3 1 1 0 3 
5 12.4 9.1 Y 4 2 0 1 3 
6 11.5 8.9 Y 3 1 1 0 3 
7 12.8 9.9 Y 3 1 0 0 6 
8 11.8 9.5 Y 2 1 0 0 3 
9 
  
Y 6 3 0 0 3 
10 12 9.4 Y 5 3 1 0 12 
11 13.7 9.9 N 13 9 0 2 6 
12 
  
N 1 0 1 0 Lost to FU 
13 15 10.4 N 1 0 0 0 Lost to FU 
14 11 8 N 3 1 0 0 6 
15 11 9.2 N 2 1 0 0 3 
16 14.5 11.8 N 3 1 0 0 6 
17 12.3 9.2 N 4 2 0 0 3 
18 12.1 9.1 N 4 2 0 0 6 
19 
  
N     Lost to FU 

















Table 5-2 Breathing support requirements and requirements for remote management of auto-
titrating positive airway pressures therapy (APAP mode) in patients with obstructive sleep 
apnoea syndrome 
95% PAP- 95% centile PAP requirements. Adherence set as >4hours use for >70% nights used, the level set 






























R5- Large airways resistence, R20- Large airways resistence, R5-R20- small airways resistence, ∆𝑋𝑅𝑆- in-
breath change in reactance measured at 5Hz, Ax- reactance, Vt- tidl volume (litres), Fres- resonant 
frequency (Hertz). Highlighted ∆𝑋𝑅𝑆 identifies those with tidal expiratory flow limitation. All oscillometry 






R5 R5-R20 R20 Ax ∆𝑿𝑹𝑺 Vt (L) Fres 
(hz) 
1 5.18 1.03 4.15 25.88 0.19 1.31 29.9 
2 6.46 0.14 6.32 1.69 0.65 0.32 8.8 
3 5.05 1.15 3.9 21 0.32 1.2 23.15 
4 8.26 2.17 6.09 17.64 1.22 0.92 21.48 
5 7.25 2.93 4.32 48.71 0.99 0.77 31.83 
6 5.22 0.34 4.88 6.67 -0.97 1.77 13.89 
7 3.75 0.05 3.7 8.82 -0.35 0.8 15.5 
8 5.04 0.93 4.11 15.94 -1.78 2.13 
 
9 6.19 1.26 4.93 17.5 -0.24 0.85 24.2 
10 4.55 1.19 3.36 15.24 0.97 1.08 
 
11 6.15 2.33 3.82 32.06 2.59 0.92 24.22 
12 4.24 1.59 2.65 24.38 0.79 1.11 22.81 
13 6.44 1.13 5.31 26.94 0.67 0.99 23.51 
14 4.22 1.01 3.21 18.8 0.36 1.32 25.93 
15 3.17 0.57 2.6 2.69 -0.01 1.03 12.47 
16 4.5 0.28 4.22 9.04 -0.38 0.97 16.73 
17 6.39 2.73 3.66 24.68 0.21 1.11 22.7 
18 4.8 0.89 3.91 11.93 -0.23 0.75 20.71 
19 3.33 -0.73 4.06 6.76 1.33 0.89 12.41 



















Table 5-3 Baseline oscillometry readings in patients with obstructive sleep apnoea syndrome 




Figure 5-8 Change in small airways resistance in patients with obstructive sleep apnoea 
syndrome who were adherent to positive airway pressure therapy- baseline versus 3months 
Adherence- >4hours use for >70% of the nights used. R5-R20 measured in cmsH2OsL-1 
 
 
Figure 5-9 Change in reactance measurements in patients with obstructive sleep apnoea 
syndrome who were adherent to positive airway pressure therapy- baseline versus 3 months 
A- Demonstration of reactance measured by area of reactance(Ax).  
B- Demonstration of in-breath difference of reactance at 5Hz (𝛥XR5)  





Figure 5-10 Mean changes in parasternal electromyography in patients with obstructive sleep 
apnoea syndrome treated with positive airway pressure (PAP) therapy 
A- Average mean parasternal electrmyography (meanEMGpara) in those adherence (blue) and non-
ahderence (red) to PAP therapy. B- Average normalised parasternal electrmyography (EMGpara%max) in 
those adherence (blue) and non-ahderence (red) to PAP therapy. C- Average neural respiratory drive index 
(NRDI) (measured in arbitary units (AU))  in those adherence (blue) and non-ahderence (red) to PAP 
therapy. (Adherence is considered >4hours use in >70% of nights used) Data plotted as mean and standard 




5.4.2 Obesity Related Respiratory Failure 
4 patients with confirmed obesity related respiratory failure were recruited between September 
2017 and August 2018. Population demographics are shown in Table 5.5. Two were males and 
two females with a mean age of 55.8 years (SD 10.7years). Mean BMI was 49.5 kg/m2(SD 11.1 
kg/m2). Mean AHI was 61.3 events/hour (SD 17.1 events/hour) and ODI was 64.1 events/hours 
(SD 17.7 events/hour). Mean oxygen saturations were 81.8% (SD 8.9%) and mean TST90 was 
61.3% (SD 31.3%). Mean FEV1 and FEV1/FVC was 42.8% (SD 12.8%) and 79.3% (SD 15.9%), 
respectively(Table 5.5). Daytime somnolence quantified by ESS showed a mean of 17.8 (SD 3.5). 
Mean mCAT, MRC dyspnoea score and performance status(PS) was 23(SD 2.8), 4(SD 0.8) and 
2.5(SD 0.6) respectively(Table 5.4).  
All subjects were treated with auto-titrating NIV (iVAPS) and auto-titrating expiratory positive 
airways pressure (AutoEPAP). 50% achieved target treatment adherence (≥70% days of PAP usage 
≥4hours; the level set for reimbursement in US health system) (Table 5.6). Mean 95% IPAP values 
were 21.6cmH20 (SD 5.6cmH20) with a mean median IPAP of 14.8cmH20 (SD 2.6cmH20). 95% 
EPAP and median EPAP values were 10.9 cmsH2O (SD 4.1 cmsH2O) and 9.6 cmsH2O (SD 3.8 
cmsH2O) respectively(Table 5.6). Control of hypoventilation is demonstrated with decreasing 
serial carbon dioxide and bicarbonate levels (Appendix 9, Figure 9-4). All patients were under 
remote PAP therapy review with average remote requirements of 6 data reviews (SD 2.8), 
3(SD0.6) telephone consultations, 1 (SD1.3) prescriptions changes and no day-case 
troubleshooting sessions. Mean follow up was 8.3 months. (Table 5.5) 
 
Exploratory Endpoints 
All patients had FOT and EMGpara measurements taken at baseline visits. 3 had further 
measurements at 3months, 3 at 6months and 2 at 12 months. Baseline FOT and EMGpara are 
shown in Appendix 9 (Tables 9.2 & 9.3).  
 
Oscillometry 
FEV1 and FOT had a positive correlations with 95%EPAP and median EPAP values shown in Figure 
5.11 and Table 5.6.  ∆𝑋𝑅𝑆and Ax demonstrated a strong correlation with median IPAP, r= 0.955 
p<0.05 and r= 0.94 p=0.05, respectively (Figure 5.11 A & B). Median EPAP requirements showed a 
strong correlation with R5 and AX, r=0.99 p<0.05 and r= 0.99 p<0.05, respectively (Figure 
5.11C&D). FEV1 demonstrated a strong correlation with  median EPAP requirements, r= 0.93 p= 
163 
 
0.23 (Figure 5.11E). Symptom burden measured by ESS and MRC did not demonstrate a 
relationship with baseline FOT data. 
There was a non-significant decreasing trend in Total airways resistance(R5) in all subjects at 
3months(p=0.25) and 6months (p=0.25). In most subjects large (R20) and small airways 
resistance(R5-R20) decreased with NIV but did not reach statistical significance. Reactance 
measured by ∆𝑋𝑅𝑆 and Ax demonstrated a non-significant decreasing trend in all subjects 
(Appendix 9)  
AHI showed a non-significant positive correlation with BMI, r=0.89 p=0.31 (Figure 5.16B). There 
was a strong correlation with AHI and R5-R20, r=0.88 p=0.32.(Figure 5.16C). ODI demonstrated a 
negative correlation with ∆𝑋𝑅𝑆, r=-0.62 p0.38(Figure 5.16D). BMI demonstrates a strong 
correlation with R5-R20, r=0.87 p=0.13(Figure 5.16E). A strong positive correlation was seen in 
BMI versus R5(r=0.8 p=0.33), R20(r=0.8 p=0.33) and Ax(r=0.8 p=0.33) seen in Figures 5.16 F-H). 
BMI and FEV1 showed a positive correlation, r=0.76 p=0.24 (Figure 5.16I). FEV1 demonstrated a 




There were no significant trends in meanEMGpara, EMGpara%max or NRDI observed at 3months, 
6months and 12 months. There was no significant correlation between change in AHI (∆𝐴𝐻𝐼 ) and 
change in NRDI ( ∆𝑁𝑅𝐷𝐼), change in meanEMGpara ( ∆𝑚𝑒𝑎𝑛𝐸𝑀𝐺𝑝𝑎𝑟𝑎) or change in 
EMGpara%max (∆𝐸𝑀𝐺𝑝𝑎𝑟𝑎%𝑚𝑎𝑥). Diesease severity measured by AHI and ODI demonstrated 
no significant correlations with meanEMGpara, EMGpara%max of NRDI. There was no relationship 
demonstrated between mean oxygen saturations or TST90 with parasternal EMG data.  Symptom 
burden measured by ESS did not show a relationsip with meanEMGpara, EMGpara%max or NRDI.  
 
Symptom burden 
There no significant change in symptom burden, measured by ESS, mCAT, MRC dyspnoea score or 






AHI- apnoea hypopnoea index (events/hr), ODI- oxygen desaturation index (events/hour), mean sats- mean 
peripheral oxygen saturations (%), TST90- percentage Total Sleep Time with oxygen saturations <90 during 
limited or fully polysomnography, ESS- Epworth Sleepiness Scale (ESS), mCAT- modified COPD assessment 
tool score, MRC- Medical Research Council dyspnoea scale, PS- ECOG Performance Scale   
 





















1  28.7  18.5  14.9  13.9  Y  10  3  3  0  12  
2  15.9  13.3      Y  4  3  1  0  12  
3  18.8  14.8  11.1  8.3  N  4  2  0  0  6  

















0  8.25  
(4.5)  
Table 5-5 Breathing support requirements and remote monitoring requirements in patients 
with obesity related respiratory failure requiring home non-invasive ventilation 
All patients were managed on auto-titrating volumes assured pressure support. 95%IPAP- 95th centile 
inspiratory positive airways pressures, mIPAP- median inspiratory positive airways pressures, 95EPAP- 95th 
centile expiratory positive airways pressures,  mEPAP- median expiratory positive airways pressures. 

























1 F 62 61.7 66.6 60 90 28 22 45 84 22  4 3 
2 F 42 56 74.8 84.2 78 90 19 60 85 19 25 4 2 
3 M 66 38.6 42 42 88 66 16 32 56 16 21 3 2 


































Table 5-4 Population demographics in patients with obesity related respiratory failure managed 






































Table 5-6 Correlations between baseline oscillometry and positive airway pressure 
requirements in patients with obesity related respiratory failure requiring home non-invasive 
ventilation 
Statistical signifcant findings are highlighted in red (p<0.05).  R5- Large airways resistence, R20- Large 
airways resistence, R5-R20- small airways resistence, ∆𝑋𝑅𝑆- in-breath change in reactance measured at 
5Hz, Ax- reactance, mIPAP- median inspiraotry positive airway pressure requirements, 95%EPAP- 95th 
centile expiratory positive ariway pressure requirements, mEPAP- median expiratory positive airway 









Figure 5-11 Correlations between baseline oscillometry and positive airway pressure 
requirements in patients with obesity related respiratory failure requiring non-invasive 
ventilation 
A- Correlation in the change in in-breath reactance at 5Hz (∆𝑋𝑅𝑆) and median inspirtory positive airways 
pressure requirements (mIPAP). B- Correlation in baseline reactacnce (Ax) and and median inspirtory 
positive airways pressure requirements (mIPAP). C- Correlation of large airways resistence (R5) and median 
expirtory positive airways pressure requirements (mEPAP). D- Correlation in reactance (Ax) and median 
expirtory positive airways pressure requirements (mEPAP). E- Correlation between forced expiratory 
volume in 1 second (FEV1) and and median expirtory positive airways pressure requirements (mEPAP). All 
oscillometry measured in cmsH2Os/L. All PAP requirements measured in cmsH2O. 
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5.4.3 Severe COPD with persistent hypercapnic failure 
10 patients with confirmed COPD with persistent hypercapnic respiratory failure were recruited 
between September 2017 and August 2018. Population demongraphics are shown in Table 5.10. 
There were 7 females and 3 males with a mean age of 59.6 years (SD 7.3years). Mean FEV1 was 
26.3% (SD 5.1%) and FEV1/FVC of 52.9% (SD 11.49%). Mean arterial carbon dioxide (PCO2) was 7.9 
kPa (SD 1.1kPa) and mean bicarbonate of 34.1 mmol/L (SD 3.2mmol/L). Baseline symptom burden 
showed no intrusive daytime somnolence with a mean ESS of 6.6 (SD 4) but severe respiratory 
symptoms with a mean mCAT score of 29.8 (SD 5.2) with functional limitations represented by 
mean MRC score of 4.7 (SD 0.5) and mean performance status of 3. (Table 5.7)  
All patients were managed with auto-titrating NIV(iVAPS) and auto-titrating expiratory positive 
airways pressure (AutoEPAP). 2 patients achieved target treatment adherence (≥70% days of 
CPAP usage ≥4hours; the level set for reimbursement in US health system)(Table 5.8). Mean 95% 
IPAP values were 19 cmsH2O (SD 6.3 cmsH2O) with a mean median IPAP of 14 cmsH2O (SD 4.6 
cmsH2O). 95% EPAP and median EPAP values were 9.4 cmsH2O (SD 3.3 cmsH2O) and 7.4 cmsH2O 
(SD 2.3 cmsH2O) respectively. All patients were managed with 2-way remote monitored NIV, 
mean remote review of data was 6 and 3 telephone consultations with 1 prescription change 
(Table 5.8). No patients required day case NIV trouble shooting session and the majority of 
patients were followed up for 6 months (mean 6.3 months). Serial measurements of ventilation 
represented by carbon dioxide and bicarbonate demonstrated a non-significant decrease in 
bicarbonate in the majority of users and a decrease in CO2 in users of NIV (Appendix 9). 
 
Exploratory Endpoints 
All patients had FOT and EMGpara measurements taken at baseline visits. 3 had further 
measurements at 3months and 6 at 6months. Baseline FOT and EMGpara are shown in Table 5.9 
and appendix 9.  
Oscillometry 
Change in ∆𝑋𝑅𝑆 showed a strong relationship with change in MRC dyspnoea scale at 3months (r= 
88, p= 0.32). Symptom burden measured by mCAT and MRC did not demonstrate a relationship 
with ∆𝑋𝑅𝑆 in those who had EFL at baseline.  In majority of patients total airway resistance(R5) 
and large (R20) decreased with NIV but did not reach statistical significance. Reactance measured 
by ∆𝑋𝑅𝑆 and Ax demonstrated a no significant trend in all subjects. (Appendix 9). There were no 
correlations demonstrated between BMI with FOT or PAP therapy requirements. No correlation 





There were no significant trends in meanEMGpara, EMGpara%max or NRDI observed at 3months 
and 6months (Appendix 9). There was no significant correlation between change in AHI (∆𝐴𝐻𝐼 ) 
and change in NRDI ( ∆𝑁𝑅𝐷𝐼), change in meanEMGpara ( ∆𝑚𝑒𝑎𝑛𝐸𝑀𝐺𝑝𝑎𝑟𝑎) or change in 
EMGpara%max (∆𝐸𝑀𝐺𝑝𝑎𝑟𝑎%𝑚𝑎𝑥). Disease severity measured by FEV1 demonstrated no 
significant correlations with meanEMGpara, EMGpara%max of NRDI. There was no correlation 
with symptom burden measured by ESS, mCAT or MRC with parasternal EMG data. Severity of 
respiratory failure measured by CO2 and bicarbonate did not demonstrate a significant 
relationship with parasternal EMG data.  
 
Symptom Burden 
There was no significant change in symptom burden, measured by ESS, mCAT, MRC dyspnoea 




















ESS mCAT MRC PS 
1 F 60 30.4 30 69 6.59 34 11.5 6 26 5 3 
2 F 67 31.6 20 54 8.8 36 7.2 8 20 4 3 
3 F 57 16 23 52 8.2 35 
 
6 37 5 3 
4 M 59 25.7 18 35 6.5 34 10 3 31 4 3 
5 M 59 26.2 28 39 6.7 32 7.1 5 34 5 3 
6 F 69 28.4 27 60 9.8 36 6.7 11 28 5 3 
7 F 60 22.7 29 69 8.4 39 7.8 1 34 5 3 
8 F 54 32.8 26 44 7.2 32 8.4 9 29 5 3 
9 F 67 26.4 26 57 8.8 36 7.2 3 25 5 3 



























Table 5-7 Population demographics in patients with hypercapnic severe chronic obstructive 
pulmonary disease who require home non-invasive ventilation 
M- male, F- female, BMI- body mass index (kg/m2), FEV1- forced expiratory volume in 1 second (percentage 
predicted), FEV1/FVS- ratio of forced expiratory volume in one second to forved vital capacity (%), PO2- 
arterial oxygen (kilo pascals (kPa), ESS- Epworth Sleepiness Scale, mCAT- modified COPD assessment tool, 
MRC- Medical research council dyspnoea scale, PS- ECOG performance status. Degree of hypercapnic failure 
is represented by baseline carbon dioxide (PCO2, measured in kilo pascals (kPa)) and bicarbonate levels 






















1 22.9 13.2 4.9 4.9 4 2 0 0 8 
2 29.1 23.9 14.3 11.4 6 3 0 0 6 
3 12.1 10.6 7.1 6.7 8 6 2 0 6 
4 8 7.2 5.3 5.1 3 3 0 0 d/c 
5 18.9 11.8 10.6 6.8 2 0 0 0 6 
6 23.9 16.5 11.7 9.3 10 4 1 0 6 
7 17.3 13.8 8.9 5.4 7 2 1 0 6 
8 19.3 13.3 12.7 10 6 2 1 0 6 
9 19.7 15.9 9 6.7 4 4 1 0 6 
10 
    



















Table 5-8 Breathing support requirements in patients with hypercapnic severe chronic 
obstructive pulmonary disease managed with remote monitored home non-invasive ventilation 
All were managed with auto-titrating volumes assured pressure support (iVAPS). 95%IPAP- 95th centile 
inspiratory positive airways pressure requirements, mIPAP- median inspiratory positive airway pressure 
requirements, 95%EPAP- 95th centile expiratory positive airways pressure requirements, mEPAP-median 
expiratory positive airways pressure requirements. D/C- discontinued. All pressures measured in cms H2O. 
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R5 R5-R20 R20 Ax ∆𝑿𝑹𝑺 Vt (L) 
1 4.96 1.47 3.49 26.37 -0.45 0.65 
2 5.8 2.72 3.6 83.27 3.36 0.52 
3 6.54 2.66 3.88 63.2 -0.21 0.61 
4 4.87 2.18 2.69 88.12 4.58 1.05 
5 4.83 1.82 3.01 58.44 2.63 0.8 
6 11.4 4.96 6.44 141.62 5.51 0.47 
7 4.91 1.99 2.92 64.42 3.99 0.82 
8 8.87 3.36 5.51 130.8 11.29 0.7 
9 8.6 -1.19 9.79 67.29 3.3 0.42 















Table 5-9 Baseline oscillometry measurements in patients with hypercapnic severe chronic 
obstructive pulmonary disease requiring home non-invasive ventilation 
R5- Large airways resistence, R20- Large airways resistence, R5-R20- small airways resistence, ∆𝑋𝑅𝑆- in-
breath change in reactance measured at 5Hz, Ax- reactance, Vt- tidal volumes (litres). Highlighted  ∆𝑋𝑅𝑆 








5.4.4 Chronic obstructive pulmonary disease- obstructive sleep apnoea overlap 
syndrome 
8 patients with COPD-OSA overlap were recruited between September 2017 and August 2018. 
Population demographics are shown in Table 5.10. There were 4 females and 4 males with a mean 
age of 60.6years (SD 8.7years) and mean BMI of 40.4 kg/m2(SD 8.3 kg/m2 ). Mean FEV1 was 48.4% 
(SD 22.5%) and FEV1/FVC of 65% (SD 14%). Mean arterial carbon dioxide (CO2) was 7.6 kPa (SD 
1.3kPa) and mean bicarbonate of 33.6 mmol/L (SD 4.5mmol/L). Mean AHI and ODI were 34.8 
events/hr (SD 17.2 events/hr) and 38.9 events/hours(SD 27.7 events/hr), respectively. Mean 
oxygen saturations was 87.7% (SD 6.3%) and mean TST90 was 66.5% (SD 44.9%). Baseline 
symptom burden showed a mild intrusive daytime somnolence with a mean ESS of 12.3 but 
severe respiratory symptoms with a mean mCAT score of 27 and functional limitations 
represented by mean MRC score of 3.4 and mean performance status of 2.4. (Table 5.10)  
8 patients were managed with auto-titrating NIV(iVAPS) and auto-titrating expiratory positive 
airways pressure (AutoEPAP) and one with APAP. 2 patients achieved target treatment adherence 
(≥70% days of CPAP usage ≥4hours; the level set for reimbursement in US health system)(Table 
5.11). Mean 95% IPAP values were 14.1 cmsH2O (SD 4.3 cmsH2O  with a mean median IPAP of 
10.7 cmsH2O (SD 4.3 cmsH2O). 95% EPAP and median EPAP values were 7.7 cmsH2O (SD 1.8 
cmsH2O ) and 6.3 cmsH2O (SD 1.3 cmsH2O ) respectively. (Table 5.11) All patients were managed 
with 2-way remote monitored NIV, mean remote review of data was 5 and 4 telephone 
consultations with 1 prescription change (Table 5.11). 2 patients required day case NIV trouble 
shooting sessions.  
 
Exploratory Endpoints 
All patients had FOT and EMGpara measurements taken at baseline visits. 2 had further 
measurements at 3months and 6months. Baseline FOT and EMGpara are shown in Table 5.12 and 
Appendix 9.  
Oscillometry 
Disease severity measured by ODI demonstrated a significant relationship with 95%IPAP 
requirements, r= 0.91, p<0.05.  AHI demonstrated a strong but non-significant relationship with 
95%IPAP requirements, r= 0.84 p=0.08. Disease severity demonstrated a strong relationship with 
all PAP requirements but did not correlate with baseline FOT data. BMI or FEV1 did not correlate 
with baseline FOT or PAP requirements.(Appendix 9) Airway resistance decreased in 1 patient 
who was adherent to PAP therapy. Reactance measured by ∆𝑋𝑅𝑆 and Ax demonstrated a non 
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significant decreasing trend in 2/3 patients.  Symptom burden measured by ESS, MRC and mCAT 
scores did not show a relationship in patients with tidal EFL at baseline.  
 
Parasternal Electromyography 
Symptom burden measured by ESS demonstrated a strong relationship with baseline NRDI, R2= 
0.85 p<0.05 (Figure 5.12). There were no significant trends in meanEMGpara, EMGpara%max or 
NRDI observed at 3months and 6months. Disease severity measured by AHI and ODI 
demonstrated no significant correlations with baseline EMG data. There was no correlation with 
ESS and meanEMGpara or EMGpara%max. Hypoxic burden measured by mean saturations and 
TST90 did not demonstrate a relationship with parasternal EMG data.  FEV1 did not showed 
signifcant relationship with baseline EMG parameters. Severity of respiratory failure measured by 
PCO2 and HCO3 did not demonstrate a significant relationship with parasternal EMG data. No 
significant relationships between symptom burden measure by mCAT score or MRC dyspnoea 
scale and baseline parasternal EMG data were demonstrated.  
 
Symptom Burden 
There no significant change in symptom burden, measured by ESS, mCAT, MRC dyspnoea score or 




AHI- apnoea hypopnoea index (events/hr), ODI- oxygen desaturation index (events/hr), mean sats- mean 
peripheral oxygen saturations (%), TST90- percentage Total Sleep Time with oxygen saturations <90 during 
limited or fully polysomnography, ESS- Epworth Sleepiness Scale, mCAT-modified COPD assessment tool 
score, MRC- Medical Research Council dyspnoea scale, PS- ECOG Perfomrance Scale. Degree of hypercapnic 
failure is represented by baseline carbon dioxide (PCO2) measured in kilo pascals (kPa) and bicarbonate 
levels (HCO3) measured in millimoles/Litre (mmol/L). 
 
 




















1 iVAPS 14.2 12.3 7.7 6.1 3 2 1 0 6 
2 iVAPS 13.1 7.6 7.2 6.6 3 0 0 0  
3 iVAPS 20.9 17.8 9.3 7.2 3 2 1 1 3 
4 iVAPS 9 6.1 4.9 4.1 4 4 0 0 2 
5 iVAPS 
    
     
6 APAP 10.7 8.3 
  
10 8 2 1 6 
7 iVAPS 
    
     
8 iVAPS 16.8 11.9 9.3 7.3 7 5 2 0 12 
Mean 
(SD) 


















Table 5-51 Breathing support requirements in patients with chronic obstructive pulmonary 
disease- obstructive sleep apnoea overlap syndrome requiring remote monitored home non-
invasive ventilation 
8 patients were managed with auto-titrating volumes assured pressure support (iVAPS) and 1 with auto-
titrating positive airways pressure support (APAP).  95%IPAP- 95th centile inspiratory positive airways 
pressure requirements, mIPAP- median inspiratory positive airways pressure requirements IPAP, 95%EPAP- 
95th centile expiratory positive airways pressure requirements, mEPAP- median expiratory positive airways 

































1 F 64 44.8 78 78 7.8 33 20.7 19.8 82 92 5 23 5 3 
2 M 60 36 37 51 8.2 31 31 45 86 92 11 24 2 2 
3 M 77 30 
  
6.7 33 47.4 75.7 86 98 10  5 3 
4 M 49 37.6 19 45 6.7 29 17 5 98 2 5 28 2 2 
5 F 54 42.6 45 76 10.2 42.9 62.5 64.7 82 99 19 30 4 2 
6 F 57 32 80 78 
  
29.9 23 92 16 17 19 1 1 
7 F 57 56 41 56 7 31.5 
    
  4 3 
8 M 67 43.8 39 71 6.9 35 
    




































Table 5-104 Population demographics of patients with chronic obstructive pulmonary disease- 
obstructive sleep apnoea overlap syndrome requiring home non-invasive ventilation 
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R5 R5-R20 R20 Ax ∆𝑿𝑹𝑺 Vt(L) 
1 6.75 1.19 5.56 94.12 7.76 0.56 
2 5.08 2.52 2.56 32.37 1.01 0.91 
3 
      
4 6.19 2.76 3.43 101.81 10.67 1 
5 5.4 1.33 4.07 49.38 4.86 0.9 
6 6.7 2.59 4.11 27.76 4.86 0.9 
7 
      















Table 5-12 Baseline oscillometry measurements in patients with chronic obstructive pulmonary 
disease- obstructive sleep apnoea (COPD-OSA) overlap syndrome requiring remote monitored 
home non-invasive ventilation 
R5- Large airways resistence, R20- Large airways resistence, R5-R20- small airways resistence, ∆𝑋𝑅𝑆- in-
breath change in reactance measured at 5Hz, Ax- reactance, Vt- tidal volumes (litres(L)). Highlighted  ∆𝑋𝑅𝑆 
identifies tidal expiratory flow limitation. All oscillometry measured in cmsH2Os/L. 
  
 
Figure 5-12 Linear regression analysis of baseline Epworth sleepiness scale and neural 
respiratory drive index in patients with chronic obstructive pulmonary disease-obstructive sleep 





This study demonstrates the feasibility of serial advanced physiological measurements in patients 
managed with remote monitored PAP/NIV therapy for sleep disordered breathing, COPD-OSA 
overlap and severe COPD with persistent hypercapnic failure.  
 
5.5.1 Obstructive Sleep Apnoea Syndrome 
This small population represents a typical cohort of patients with severe sleep disordered 
breathing with mean AHI of 60 events/hr and mean ODI of 44.8 events/hr with a moderate 
symptom burden, mean ESS of 14/24. There was expected attrition of patient follow up with 55% 
attending the 6month study visit. This is not unexpected, as symptom resolution with PAP therapy 
results in poor attendance for clinical follow up. There were no significant correlations with 
disease severity (measured by AHI or ODI) and FOT results in our OSAS cohort, contradicting 
previous studies demonstrating correlation between airways resistance and reactance with 
disease severity suggesting both upper airway resistance and elastic recoil may contribute to the 
mechanics of OSAS.[250][251] However, 50% of patients demonstrated EFL on baseline FOT 
measurements demonstrating the effect of extra-thoracic restriction secondary to severe obesity 
resulting in low tidal volumes and predisposign the small airways to collapse and EFL. 
In this cohort we demonstrated novel physiological insights into pulmonary mechanics in OSAS 
with significant reductions at 3months in small airways resistance(R5-R20), in-breath X5 (∆𝑋𝑅𝑆) 
and reactance(Ax) in patients adeherent to PAP therapy. Total airways resistance demonstrated a 
reducing trend with adherence to PAP therapy and an increase in non-adherence at 3 months. 
The decreasing trend in all parasternal EMG parameters in those adherent to PAP therapy is 
consistent with previous studies showing increased NRD, respiratory muscle unloading with PAP 
therapy and subsequent reductions in NRD parameters.[254][77], [255] These data suggest long 
term PAP therapy may alter pulmonary mechanics of the large and small airways in patients with 
OSAS, justifying further prospective studies to define the potential role for serial oscillometry 
alongside symptom burden in this cohort to provide further insights into disease mechanics and 
personalised approach to disease management.  
 
5.5.2 Obesity related respiratory failure  
This small cohort of patients demonstrated severe ORRF with a mean BMI of 49.5 kg/m2, AHI of 
61 events/hour and ODI of 64 events/hour and moderate to high symptom burden (mean ESS 
17.7/24). There was expected attrition of patient follow up with 50% attending the 12month 
study visit and is not unexpected in this cohort of sleep disorder breathing as previously 
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discussed. Median IPAP requirements significantly correlate with XRS and Ax which is consistent 
with increased extra-thoracic restriction secondary to severe obesity, low tidal volumes, 
predisposing the small ariways to collapse and EFL. In combination with reduced compliance IPAP 
requirements would demonstrate a positive correlation. Severe obesity increased both the large 
airway resistence and higher EPAP pressures are not unexpected in this cohort as demonstrated 
in Table 5.6. 
Strong correlations between BMI and small airways resistance is consistent with previous 
evidence demonstrating increased airway resistance and small airways resistance correlates with 
decreasing FRC and ERV in obesity.[256] Patients with obesity are susceptible to restrictive 
pulmonary defects, reduced airways calibre, reduced elastic recoil, decreasing pulmonary 
compliance and lung volumes, resulting in micro-atelectasis and heterogenicity of ventilation.[7], 
[257][258][256] 
Control of hypoventilation was achieved with moderate pressure support requirements. 
Parasternal EMG data did not exhibit any significant trends following NIV initiation which 
contradicts previous studies demonstrating significant reductions in NRD with CPAP and NIV in 
ORRF patients.[76], [77], [259][78] 
We have demonstrated it is feasible to measure FOT and parasternal EMG in this cohort, although 
our small number of patients has limited the identification of significant changes in serial 
measurements. Untreated ORRF has a higher risk of developing pulmonary hypertension and 
increased mortality.[73], [260], [261] Idenification and treatment of ORRF with PAP therapy 
reduces morbidity and mortality.[196], [262][263] Serial advance physiology measurements could 
provide further insights into the mechanics of ORRF and its response to home NIV justifying 
further studies with a focus on treatment response, symptom burden and early optimisation of 
NIV. 
 
5.5.3 Chronic obstructive airways disease 
This small cohort of patients with severe COPD and persistent hypercapnia represents similar 
cohort studied in the UK HOT HMV trial with a mean FEV1 of 26% and mean PCO2 of 
7.91kPa.[264][148] Low daytime somnolence scoring suggests no evidence of underlying sleep 
disordered breathing, despite the lack of baseline polysomnography on this cohort. However, the 
high symptom burden (mean mCAT score of 29.8, MRC score of 4.7 and performance status of 3) 
demonstrates a cohort of patients with significant physical limitation due to severe COPD. More 
than 50% of hypercapnic severe COPD patients screened did not participate in the study which 
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may reflect the burden of disease resulting in physical limitations and corresponds to symptoms 
burden recorded in this cohort. 
All patients received NIV in auto-titrating mode delivering an unexpected low pressure support 
requirement to improve hypercapnia.  This contrasts with previous studies demonstrating 
improvement in time to re-admission or death in those treated with NIV for severe COPD with 
hypercapnic failure using high-intensity spontaneous-timed (ST) modes.[148], [264] Minimal 
remote prescription management was required during the 6 month period of follow up (3 
telephone consultation & 1 prescription change). Adherence to NIV was potentially suboptimal in 
this cohort, and future studies to address any issues elicited by remote monitoring to improve 
treatment adherence are justified. 
This is the first observational study to demonstrate serial FOT measurements following the 
initiation of home NIV in hypercapnic severe COPD patients. Although 8 out of 10 patients had 
tidal EFL, this did not correlate with their baseline symptom burden. However, change in ∆𝑋𝑅𝑆 at 
3months demonstrated a strong relationship with change in symptom burden measured by MRC 
dyspnoea scale, which is consistent with previous evidence showing a changes in FOT predicted 
symptoms measured by the St George Respiratory Questionnaire (SGRQ) score.[239] . Large and 
small airways resistance decreased following the initiation of home NIV in this cohort. There were 
no correlations between baseline FOT measurements and NIV requirements in this cohort, 
contradicting previous findings by Dellaca et al demonstrated a correlation between change in EFL 
in the upright and supine positions in COPD patients with changes in PEEP requirements.[253] 
However, we did not review serial FOT measurements following postural changes.  
Serial NRD measurements did not demonstrate significant change following the initiation of home 
NIV therapy which could be explained by the small sample size and poor treatment adherence. 
However, normalised baseline parasternal EMG (EMGpara%max) measurements in this cohort 
were similar to those shown in previous diaphragmatic EMGs in COPD.[29]  There was no 
correlation with NRD parameters and symptom burden or disease severity, contradicting previous 
studies demonstrating increased NRD in COPD, corresponding to disease severity and dyspnoea. 
[29], [44], [57], [59]  
These data support the feasibility of serial FOT and NRD measurement in hypercapnic severe 
COPD patients managed with home NIV. NRD has been used as a physiological biomarker in 
disease monitoring in exacerbations of COPD and in quantification of NRD offloading in COPD-OSA 
overlap patients treated with NIV.[65], [67], [79] Small sample numbers and low adherence rates 
may have impacted the significance of these exploratory outcomes but justifies future studies 
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utilising advanced physiology as bio-markers in disease management and potential role in 
optimisation of home NIV in this cohort of patients. 
 
5.5.4 Chronic obstructive pulmonary disease- Obstructive Sleep Apnoea overlap 
syndrome  
This small cohort represents patients with moderate COPD (mean FEV1 48%) and moderate sleep 
disordered breathing (mean AHI 35 events/hr and ODI 39events/hr) and established hypercapnic 
failure (mean PCO2 7.64kPa). There was a high symptom burden with mean mCAT score of 27 but 
mild daytime somnolence (mean ESS 12.3). All patients were established on auto-titrating volume 
assured pressure support with auto-titrating EPAP mode which like the COPD cohort delivered 
unanticipated low pressure support in comparison to previous studies.[79][194] We were unable 
to demonstrate whether hypoventilation in this cohort was controlled with low pressure support 
due to lack of data and high attrition rates. Baseline anthropometrics and disease severity did not 
correlate with FOT or NRD data. 
NRDI demonstrated a strong negative relationship with symptoms of daytime somnolence 
measured by ESS, suggesting that obstructive airways disease is more influential on the 
respiratory load capacity relationship than the co-existing sleep disordered breathing. NRD 
reductions did not correlate with treatment adherence as previously demonstrated in patients 
with COPD-OSA.[80] However, there was a strong correlation with disease severity of co-existing 
sleep disordered breathing (AHI and ODI) and PAP requirements, justifying further larger studies 
incorporating advanced physiological measurements to expand our knowledge of pulmonary 
mechanics in COPD-OSA overlap syndrome, facilitate physiological phenotyping of COPD-OSA and 




5.6 Critique of the methods 
Patient selection 
Patient recruitment for exploratory endpoints study has been discussed in detail in Chapter 2. As 
this was a prospective observational study, patients were not randomised and therefore subject 
to selection bias. The aim of this study was to demonstrate feasibility of serial advanced 
physiological measurements throughout the patient’s treatment journey with remote monitored 
PAP therapy, as a result patient selection may have skewed these results somewhat and larger 
studies are required to consolidate feasibility. 
 
Population phenotyping 
Patients groups were determined by an experienced clinical team, standard cardiorespiratory 
evaluations and clinical guidelines. Baseline physiology demonstrated obstructive spirometry in 1 
patient with ORRF (Table 5.4) and a higher than expected BMI (BMI>30) in 3/10 hypercapnic 
severe COPD patients (Table 5.7). Likewise 50% of COPD-OSA cohort had normal spirometry 
suggesting a possiblity of incorrect phenotyping. However, all baseline spirometry readings were 
taken with a handheld device after inhaled therapy rather than formal pulmonary function 
laboratory spirometry and therefore may not be fully representatiave of co-exisiting airways 
disease. Additionally, polysomnography was not available for all patients, therefore only patients 
with high clinical suspicion of SDB had sleep studies. Formal baseline lung function and 
polysomnography in all patients would facilitate correct phenotyping and potentially allow further 
analysis of subsequent exploartory physiology measurements to provide further insights into 
respiratory mechanics and physiology respnose to PAP and home NIV therapy.  
 
Study population size and statistical analysis 
As our aim was to assess feasibility of serial FOT and EMG measurements, the study was not 
powered to evaluate changes in these physiological parameters. Small study population size and 
disease heterogeneity may have limited the statistical significance of both oscillometry and 
parasternal EMG measurements. Therefore, interpretations of descriptive data and correlations 
with disease severity, anthropometrics and exploratory physiology is limited but supports future 






The primary aim of our study was to assess the feasibility of advanced physiological 
measurements in patients with chronic respiratory disease requiring remote monitored PAP 
therapy and therefore full lung function including body plethysmography was not recorded in all 
patients. These detailed tests are valuable to assess full lung function and identify those with co-
morbid airflow obstruction and SDB. However, simple handheld spirometry was measured at 
every study visit to identify those with obstructive airways disease. Future insights into pulmonary 
mechanics and the advanced physiological markers should incorporate full lung function.  
 
Physiological measurements 
All advanced physiological measurements were carried out by one investigator and therefore 
limiting any variation in techniques discussed in Chapter 2 and Appendices 6 and 7.  
 
5.7 Conclusions 
These data support the feasibility of serial advanced physiology measurements can be 
incorporated alongside standard respiratory care in a range of respiratory conditions out with a 
research centre setting. It is feasible for serial advanced physiology measurements to be recorded 
in patients managed with remote monitored PAP/NIV therapy. Symptom burden and physical 
limitation of disease seen in the hypercapnic severe COPD patients may limit recruitment in 
future studies requiring study centre visits but this feasiblity data justifies future emphasis on 
ambulatory advanced physiology measurements in those restricted by disease burden. However, 
we have demonstrated novel insights into the role of small airways disease in OSAS patients using 
serial FOT measurements. Small sample size limited exploratory advanced physiology analysis and 
justifies further studies incorporating FOT and NRD to facilitate physiological phenotyping, 
targeted disease management, early assessment of treatment response and optimisation, provide 
insights into pulmonary mechanics, assess the potential use as an advance physiological 
biomarker with a further focus on ambulatory methods to allow inclusion of those patients 


















The aim of this thesis was to explore the use of advanced physiological measurements in 
chronic respiratory disease, evaluate the adoption of new technologies in home 
ventilation and determine the feasibility of serial advanced physiological measurements 
alongside standard care in chronic respiratory disease out with the research centre 
setting. Data from advanced physiology will support current knowledge and provide novel 
mechanistic insights into respiratory disease and chronic respiratory failure. 
The data presented in this thesis demonstrates: 
- Significant service development required to integrate two-way remote monitored 
breathing support and home ventilation within a tertiary service  
- The realistic provision of two-way remote monitored home NIV in patients with 
hypercapnic severe chronic obstructive pulmonary disease and obesity related 
respiratory failure 
- Acceptable reproducibility of parasternal electromyogram analysis between two 
UK based research centres 
- Simplification of parasternal electromyogram measurements are reliable 
improving accessibility and advocates future adoption into clinical practice 
- It is feasible for exploratory endpoints such as forced oscillometry and parasternal 
EMG to be incorporated into standard clinical care in chronic respiratory disease  
 
 
6.1: Adoption of new technologies in Glasgow Sleep and 
Breathing Support Service 
Inpatient sleep and breathing support referrals significantly rose following the merge of 
four hospitals in Glasgow to form the Queen Elizabeth University Hospital (QEUH) in 
2015. Failure of the legacy service model to meet the heightened service demands 
justified the exploration of new technologies to improve service efficiencies and patient 
outcomes. The Glasgow Sleep and breathing support research centre was established in 
early 2016 to address these increase needs through the adoption of new technologies 
and established a research base for future studies and service development. Utilisation of 
average volume assured pressure support with autoEPAP (AVAPS-AE) to benchmark 
inpatient domiciliary NIV titration demonstrated a reduction in occupied bed days in 
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comparison to legacy services. Incorporation of auto-titrating PAP and NIV devices 
enabled with two-way remote monitoring allowed the development of remote managed 
patient pathways with prompt identification of therapy issues, early remote optimisation 
of breathing support/ventilation and facilitated day case initiation of home NIV therapy in 
patients with stable hypercapnic respiratory failure providing noteworthy service 
efficiencies. The integration of clinical notes, investigations, and patient journeys into 
electronic health records (EHR) throughout Greater Glasgow and Clyde facilitated virtual 
vetting and timely investigations in those deemed high risk of sleep disordered breathing. 
Collation of data from EHRs and two-way remote monitoring of breathing support/home 
ventilation provides big data for further population studies to define high risk groups 
requiring enhanced personalised patient management pathways to ensure patient safety, 
improve clinical outcomes and measurable service efficiencies.  
 
6.2: Adaption of home non-invasive ventilation utilising two-
way remote NIV- realistic provision and clinical outcomes 
The data presented in this thesis demonstrates it is feasible to deliver effective home NIV 
using two-way remote monitoring in patients with persistent hypercapnic failure 
secondary to severe COPD and obesity related respiratory failure. Successful 
development of patient pathways for remote monitored home NIV allows prompt 
recognition of therapy issues and early remote optimisation of ventilation in the home 
setting. Whilst the reductions in carbon dioxide and bicarbonate in both cohorts confirms 
the safety of two-way remote monitored home NIV. 
Prolongation of time to re-admission or death in hypercapnic severe COPD patients who 
continued using remote monitored home NIV validates previous study findings and 
demonstrates the realistic application of home NIV out with the research setting. Similar 
results are seen with continued use of remote monitored home NIV in patients with ORRF 
and are consistent with previous research findings. Notably, continued use of two-way 
remote NIV in patients with hypercapnic severe COPD resulted in a median reduction of 
14 occupied bed days without shifting service demands to the community respiratory 
team, demonstrating tangible potential cost savings. Two-way remote monitored NIV 
facilitates day case initiation of home NIV in stable hypercapnic respiratory failure, 
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introducing significant potential cost savings and service efficiencies. Our data 
demonstrates the safety of day case initiation supporting previous study findings 
suggesting non-inferiority compared to inpatient multi-night multi-sensor titration and 
justifies future studies of cost-effectiveness of this service model.  
These data justify future studies in both severe COPD and ORRF cohorts to confirm 
patient safety, assess cost-effectiveness of two-way remote monitored service models 
and present clinical outcomes. Two-way remote NIV/PAP service pathways are 
incorporated into routine clinical practice in the West of Scotland with approximately 
1300 patients on remote monitored PAP therapy and 350 patients newly managed with 
remote monitored NIV since 2016. Further acquisition of remote NIV data will improve 
understanding, reveal novel physiological insights, and build a foundation of data for 
future population studies, for analysis and predictive modelling to facilitate personalised 
patient care in chronic respiratory disease. As a result, NHS GGC have been awarded over 
£1.7 million in funding (from Innovate UK, ResMed investigator-initiated research 
programme and the Scottish Government) for future studies in digital innovation 
incorporating physiology monitoring and remote monitored home ventilation in patients 
with COPD. The details of the RECEIVER study are discussed in section 6.5 of this chapter. 
Outcomes from this will include qualitative user experience and ongoing service 
development with interoperability evaluation as post-doctoral research in GSBSRC. 
 
6.3: Accessibility of parasternal electromyogram 
measurements  
The data presented in chapter 4: Simplifying the measurement of neural respiratory drive 
confirms it is feasible to use similar equipment utilised for longer term cardiac 
investigations for parasternal electromyography and maintain high quality signals. The 
utilisation of long-term cardiac electrodes in our exploratory endpoints study and inter-
observer variability analysis supports the simplification of parasternal EMG technique. 
Acceptable reproducibility of parasternal EMG analysis between two UK sites supports 
future multi-centre studies of neural respiratory drive as a research endpoint and 
advanced physiological biomarker in chronic respiratory disease. The estimation of 
respiratory rate derived from RMS of parasternal EMG signal introduces potential further 
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rationalisation of parasternal EMG measurements. The hypothetical omission of oro-nasal 
flow analysis and RIP band signals would improve accessibility of NRD measurements as a 
research endpoint, advanced physiological biomarker, enable future ambulatory and 
home monitoring in those debilitated by severe chronic respiratory disease. This data 
justifies future studies utilising this simplified methodology to consolidate our findings 
and allow wider application in the ambulatory setting.  
 
6.4: Advanced physiological markers in chronic respiratory 
disease 
The data presented as part of the Exploratory Endpoints study within this thesis supports 
the feasibility of incorporating serial advanced physiological measurements alongside 
standard clinical care for patients with a wide range of chronic respiratory conditions. It is 
feasible to monitor FOT and NRD in patients managed with two-way remote monitored 
breathing support and home ventilation. A significant reduction in small airways 
resistance, in-breath X5 (∆𝑋𝑅𝑆) and reactance was seen in patients with OSAS adherent to 
PAP therapy at 3months and baseline FOT measurements demonstrated tidal expiratory 
flow limitation in 50% of this cohort.  This novel insight into pulmonary mechanics suggest 
heterogeneity of large and small airway disease in OSAS, a disease previously 
characterised by recurrent upper airway obstruction in obesity.  
Airways resistance reduced following the initiation of PAP therapy or home NIV in all 
disease cohorts providing mechanistic insights into the effect of long-term breathing 
support in chronic respiratory disease. Likewise, NRD decreased following auto-titrating 
PAP initiation in OSAS patients which is consistent with previously demonstrated 
respiratory muscle “unloading” seen with PAP therapy.  
80% of patients with hypercapnic severe COPD demonstrated tidal EFL which is 
representative of the significant disease burden seen in a cohort susceptible to 
aggravated hyperinflation, unstable alveolar ventilation, V/Q mismatching predisposing to 
chronic respiratory failure requiring home NIV. This cohort demonstrated a strong 
correlation between the change in ∆𝑋𝑅𝑆 and change in symptoms measured by MRC 
dyspnoea scale 3 months following NIV initiation, suggesting small airways disease may 
be more influential on respiratory symptoms in COPD than previously assumed. However, 
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serial physiology measurements were more challenging in this COPD cohort compared to 
those with sleep disordered breathing, due to physical limitations and symptom burden 
of disease.  Future emphasis on ambulatory or home monitoring of advanced physiology 
is justified in this cohort to facilitate further disease phenotyping, target disease 
management, and provide mechanistic insights into chronic respiratory disease and 
respiratory failure.  
 
6.5: Future work 
6.5.1: RECEIVER: Digital Service Model for Chronic Obstructive Pulmonary Disease  
(Clinical trials.gov identifier: NCT04240353) 
The work in this thesis and the development of a clinical service model has facilitated a 
prospective observational study evaluating the implementation of digital innovations to 
enable routine care. Sponsored by NHS Greater Glasgow and Clyde in collaboration with 
the University of Glasgow and digital technology company, StormID™, GSBSRC is currently 
recruiting to an observational study of establishing a resource for high-risk COPD patients 
containing symptom diaries, continuous physiology monitoring via Fitbit™ and home NIV 
device, supporting self-management, record service requirements and enabling 
communications with the clinical teams via a cloud-based dashboard and mobile device. 
The incorporation of multi-media telemedicine with improved patient education will 
encourage patient engagement, endorse self-management, establish trusted 
communication, and develop a platform to collate wearable and device data with EHRs. 
Patient acceptability of new technologies in chronic disease management, service 
development and patient outcomes will be evaluated in post-doctoral research at 
GSBSRC. The acquisition of large data will facilitate future machine learned analysis for 






6.5.2: COVID-19 Advanced Respiratory Physiology (CARP) Study 
The work presented in this thesis demonstrating the feasibility of serial advanced 
physiology measurements alongside standard respiratory care has resulted in £123,000 
funding (Chief Science Office (RARC-19)) for a prospective observational study to 
determine the feasibility of in-hospital wearable respiratory sensors for serial advanced 
physiology monitoring in patients admitted to hospital with COVID-19 related respiratory 
failure. 51 patients have been recruited in the first 3 months to December 2020. The 
study will determine the feasibility of parasternal EMG, electrical impedance tomography 
and continuous wrist actigraphy on patients admitted with COVID-19 related respiratory 
failure. Further feasibility of extended wearable devices following hospital discharge after 
COVID-19 respiratory failure will be determined. Exploratory correlations of wearable and 
serial advanced physiology measurements with clinical events, changes in respiratory 
status, following interventions and post-discharge recovery to determine the disease 
behaviours and provide physiological insights to inform future work in disease monitoring 
and predictive modelling into severe COVID-19 respiratory failure.  
  
6.5.3: Advanced physiology in severe emphysematous COPD patients 
This thesis has demonstrated the feasibility of serial monitoring of advanced physiology in 
patients with chronic respiratory diseases justifying future studies focusing on specific 
patient cohorts such as severe emphysematous COPD patients who would be considered 
for lung volume reduction interventions. A large prospective observational study would 
be required in this cohort of patients where advance physiology measurements (FOT and 
NRD) at initial assessment for lung volume reduction and subsequent serial 
measurements following interventions, such as endobronchial valve insertion, would 
directly quantify expiratory flow limitation in conjunction with standard pulmonary 
function tests. This would provide mechanistic insights on the respiratory muscle load 
capacity relationship following surgical interventions. A prospective observational study 
of this kind would determine the feasibility of advanced physiology in this cohort of 
patients, establish their use as a biomarker and explore correlations with clinical 
outcomes. Utilising FOT as a non-invasive effort independent measurement of EFL to 
identify those eligible for lung volume reduction would be more acceptable in comparison 
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to strenuous pulmonary function testing in this cohort with increased symptom burden 
secondary to severe chronic respiratory disease.  
 
6.5.4: Advanced physiology in the optimisation of breathing support and ventilation 
The data presented in this thesis supports ongoing development of NRD as a research 
endpoint and clinical biomarker of chronic respiratory disease. Serial NRD analysis has 
demonstrated an “offloading” effect on the respiratory muscle capacity with a fall in NRD 
following the initiation of PAP therapy. Likewise, devices utilising FOT based auto titrating 
EPAP targeted to abolish expiratory flow limitation have demonstrated reduction in NRD 
in patients with hypercapnic severe COPD. In addition, continuous parasternal EMG 
measurements during NIV has been shown to identify patient ventilator asynchrony 
which correlates with ventilator intolerance and de-ventilation dyspnoea. This justifies 
future studies incorporating serial FOT and NRD analysis in patients with chronic 
respiratory failure to facilitate NIV titration and explore auto titrating NIV targets to 
optimise home ventilation. Furthermore, the potential continuous parasternal EMG 
monitoring in the ambulatory setting to allow remote assessment of work of breathing 
would facilitate early optimisation of home ventilation, could improve patient tolerance, 
and provide mechanistic insights into ventilatory control in chronic hypercapnic 
respiratory failure.  
 
6.5.5 Clinical respiratory failure team in NHS Greater Glasgow and Clyde 
This thesis builds a foundation for future development of a tertiary specialist respiratory 
failure team within NHS Greater Glasgow and Clyde. Current recruitment for the 
RECEIVER study has demonstrated a focus on facilitating remote early therapy 
optimisation with a multidisciplinary approach incorporating physicians, physiologists, 
respiratory specialist nurses, pharmacists, physiotherapists, and data sharing on EHRs for 
wider access for other practitioners. Multi-disciplinary face to face clinics with availability 
from the above specialists, clinical physiology, capillary blood analysis and medical physics 




The increasing inpatient burden of acute respiratory failure and its management during 
the COVID-19 pandemic has highlighted the importance of a multi-disciplinary approach 
in a specialist acute respiratory failure department to safely manage patients with 
unstable acute respiratory failure by physicians who have an established interest in non-
invasive and invasive ventilation. The establishment of a respiratory support unit would 
develop patient care pathways for the management of acute respiratory failure, improve 
patient outcomes, enable patient-physician education of evolving breathing support 
therapies and champion new technologies whilst facilitating ongoing research in 
advanced physiology and breathing support in acute and chronic respiratory failure.   
 
6.6 Conclusions 
In conclusion, the data presented in this thesis is considered exploratory but has enabled 
the establishment of a remote breathing support service within NHS Greater Glasgow and 
Clyde, which has been an invaluable tool for the management of home ventilation and 
breathing support during the global COVID-19 pandemic and the practical challenges it 
has created. This data has been the catalyst for ongoing digital innovation in clinical 
practice with the formation of a multidisciplinary multimedia interactive platform for 
prompt recognition of condition instability, early optimisation of patient care, encourage 
patient engagement and potential development of a proactive predictive model for the 
management of chronic respiratory failure. Our exploratory work has advocated ongoing 
studies incorporating advanced physiology in chronic respiratory failure and COVID-19 
related respiratory failure. This data demonstrates the tangible benefit of telemedicine at 
a time where unprecedented demands on our service have called for adoption of new 
technologies to facilitate standard respiratory care. I hope this data encourages the wider 
respiratory community to explore the incorporation of new technologies including 
wearable ambulatory monitoring, the utilisation of advanced physiology as disease 
biomarkers and provide physiological insights into both chronic respiratory disease and 
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Appendix 6: Parasternal electromyography method 
Neural Respiratory Drive is measured via parasternal EMG electrode signals sampled with band 
pass filters via the Dual Bio Amp (ADInstruments, Chalgrove, UK) Amplified signals are passed to a 
digital converter (Powerlab, ADInstruments, Chalgrove, UK). Filtering and analysis are done within 
Labchart software (ADInstruments, UK) on a personal computer. Airflow is measure via a 
spirometry model signals are amplified and passed to the digital converter before analysis in 
Labchart software. (figure 8.1)   
 
Method: 
1. Set up ADInstruments with a personalised computer (PC) with Labchart software 
for data collection and analysis 
2. Set up PowerLab input channels as detailed below: 
Channel Signal 
Channel 1 ECG 
Channel 2 Filtered EMG 
Channel 3  Thoracic RIP 
Channel 4  Spirometry module 
 
3. Turn on PC and ADInstruments, ensuring spirometry module is resting separate to 
the Bio Amp and Powerlab modules to avoid overheating. Allow at least 5 minutes 
for the spirometry module to warm up, when ready the light will turn green. 
4. Position patient at 45degrees and ensure they are comfortable in this position for 
prolonged period.  
5. Preparation of the skin prior to electrode application- palpate the 2nd intercostal 
space (ICS) and locate position approximately 3cms from central sternum. Shave 
area (if required) exfoliate with trace preparation tape (3M Red Dot Trace, 3M, 
Canada), clean with alcohol wipe and apply electrodes (Elite, Skintact, UK). Ensure 
the centre of the electrode is in the middle of intercostal space.  
6. Repeat skin preparation and electrode placement for lateral right clavicle position 
electrode.  
7. Attached electrode leads as detailed below and in Figure 8.2. 
Green (ground)- Right lateral clavicle 
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Black (positive)- Right 2nd ICS 
White (negative)- Left 2nd ICS 
8. Place Thoracic RIP band across the mid chest. Avoid direct contact with 
parasternal electrodes. (figure 8.2) 
9. Attached nasal flow cannula to spirometry module and position on the patient.  
10. Ask the patient to relax and record normal tidal breathing via Lab chart software.   
11. Once 5 minutes of tidal breathing is recorded inform the patient of transition to 
maximal manoeuvres recordings. Mark the end of 5 minutes of tidal breathing on 
Lab chart. 
12. Mark Labchart recording with “Measurement commencing” and ask the patient to 
close their mouth and continue breathing via the nasal passages. 
13. Prepare patient with count down of 3 breathes prior to a maximal sniff 
manoeuvre. Mark on Lab chart software at the time of “Sniff”. 
14. Repeat this process at least 10 times with a minimal of 30seconds of rest between 
each manoeuvre as per ERS guidelines.  
15. Once recording completed, stop Labchart. At this point if indicated patients can be 
moved to supine or upright positions and the above method repeated. 
16. Remove nasal cannula, RIP bands and electrodes.  













Figure 8.1: Parasternal electromyography set up: Parasternal electromyography measured with 
ADInstruments for EMG measurements. 








Figure 8.2: Patient position for parasternal electromyogram recording: Patient positioned at 45 degrees 
with parasternal electrodes placed in the 2nd intercostal space and right clavicle (black arrows). 








Appendix 7: Parasternal electromyography analysis 
1. Open file on Labchart software 
2. Right click on heading of columns in data pad sheet to set up: 
Column 1: Time at maximum (Statistics, Time of maximum value, Source: Channel 
EMG RMS) 
Column 2: Maximum value (Statistics, Max Value, Source EMG RMS) 
Column 3: Average Cyclic Rate (Cyclic measurements, Av. Cyclic rate, Source: Can 
be Channel Airflow or RIP bands) 
Column 4: Comments (Comments, Full comments, Source: Any channel) 
 
3. Review tidal breathing and select time where there is one minute of continuous 
resting breaths with minimal artifacts (usually the last minute of tidal breathing).  
4. Review the peaks in RMS EMG. Only select RMS EMG out with the ECG signal. See 
Figure 8.3  
5. Select peak RMS EMG of tidal breaths and save to data pad by selecting “cmd” + 
”D“keys ( “ctl” +”D”). Repeat for each breath in the one minute of tidal breathing.  
6. Repeat steps 4 and 5 for the 10 sniff measurements. (Ensure RMS EMG is out with 
the ECG signal)  
7. Save the Labchart file. Copy and paste the data pad to excel or mac equivalent.  
8. Calculate the mean EMGpara during tidal breathing.   
9. Select the maximum RMS EMG value during manoeuvres (Sniffs) which must be 
within 10% of other RMS EMG values for sniffs.  
10. Calculate EMGpara%max for each value selected during tidal breathing:  
EMGpara%max = (RMS EMGtidal / RMS EMGmaxsniff) x 100 
11. Calculate Neural Respiratory Drive Index (NRDI) for each value selected during 
tidal breathing: 
NRDI = EMGpara%max x Average cyclic rate 
12. Calculate mean EMGpara%max values and mean NRDI values. 
13. Record meanEMGpara, mean EMGpara%max and meanNRDI for each study candidate.  




15. Calculate absolute and percentage change in meanEMGpara, mean EMGpara%max and 












Figure 8.3: Parasternal electromyogram (EMG) data selection for analysis with the maximum peak of the 
root mean squared EMG signal (red arrow).  
Channel 1- Electrocardiogram signals, Channel 2- Filtered EMG signals, Channel 3- Root mean squared of 
EMG, Channel 4- Oro-nasal flow analysis, Channel 5- Respiratory rate derived from the root mean squared 




Appendix 8: Simplification of parasternal electromyography: 
deriving estimated respiratory rate from the root mean 
squared parasternal electromyogram signals.  
 
1. Parasternal EMG measurements should be collected as described in Appendix 6.  
2. To use RMS signal to estimate RR, select digital filter on a spare channel, the 
source should be RMS channel and filter set to “low pass” with a cut off 0.5Hz to 
filter ECG spikes. (fig 8.5) 
3. Name Channel RMS RR, respiratory rate derived from root mean squared EMG 
signal. (Fig 8.4) 
4. Right click on columns in data pad to set up: 
Column 1: Time at maximum (Statistics, Time of maximum value, Source: Channel 
EMG RMS) 
Column 2: Maximum value (Statistics, Max Value, Source EMG RMS) 
Column 3: Average Cyclic Rate (Cyclic measurements, Av. Cyclic rate, Source: Can 
be Channel Airflow or RIP bands) 
Column 4: Average Cyclic Rate (Cyclic measurements, Av. Cyclic rate, Source RMS 
EMGpara-RR) 
Column 5: Comments (Comments, Full comments, Source: Any channel) 
5. Proceed with analysis detailed in steps 3-15 in Appendix 7 







Figure 8.4: Digital filer selection in data pad for derived respiratory rate from root mean squared 
parasternal electromyogram signal. 
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Table 9.1 Parasternal electromyography measurements at baseline visit in patients with 
obstructive sleep apnoea syndrome initiated on remote monitored positive airway pressure 
therapy 
meanEMGpara- mean parasternal electromyography (microvolts), meanEMGpara%max- mean 
normalised parasternal Electromyography (microvolts), NRDI- Neural Respiratory Drive Index 
(arbitrary units) 
1 3.7818 12.279 148 
2 7.54545 47.1591 1019 
3 14.5636 51.1004 813 
4 4.94167 16.8658 213 
5 7.9 24.921 648 
6 3.36364 14.6884 294 
7 2.675 10.3682 197 
8 5.67273 17.9516 192 
9 4.52667 36.5054 807 
10 23.65 62.0091 608 
11 13.3933 56.512 1135 
12 7.79444 22.2063 227 
13 4.06 16.371 316 
14 3.42308 6.42233 73 
15 15.136 19.039 266 
16 4.333 17.4731 255 
17 1.34 2.9005 51 
18 3.33636 16.9358 238 
19 5.91667 12.9358 149 













Figure 9-1 Total airways resistance in patients with obstructive sleep apnoea syndrome 
Presentation of change in total airways resistence after 3 months of positive airway pressure therapy. Total 
airway resistane decreased in patient adherent to PAP therapy (blue)(>4hours use for >70% of nights) 




Figure 9-2 Parasternal electromyography in patient with obstructive sleep apnoea syndrome 
treated with positive airway pressure (PAP) therapy 
A- mean parasternal electromyography (meanEMGpara) in patients adherent to PAP therapy at 3 and 6 months. B- mean 
parasternal electromyography (meanEMGpara) in patients not adherent to PAP therapy at 3 and 6 months. C- Normalised 
parasternal electrmoygraphy (EMGpara%max) in patients adherent to PAP therapy at 3 and 6 months. D- Normalised 
parasternal electrmoygraphy (EMGpara%max) in patients not adherent to PAP therapy at 3 and 6 months. E- Neural 
respiratory drive index (NRDI) (measured in arbitary units (AU)) in patients adherent to PAP therapy at 3 and 6 months. F- 
Neural respiratory drive index (NRDI) (measured in arbitary units (AU)) in patients not adherent to PAP therapy at 3 and 6 





Figure 9-3 Change in symptom burden in patients with obstructive sleep apnoea syndrome treated 
with positive airway pressure (PAP) therapy 
A- modified chronic obstructive pulmonary disease assessment tool (mCAT) score, B- Medical research council 
dyspnoea scale (MRC), C- Performance status (PS) at baseline, 3months and 6months in adherence (blue) and 
non-adherence (red) to PAP therapy. (Adherence is considered >4hours use in >70% of nights used). Plotted as 











R5- Large airways resistence, R20- Large airways resistence, R5-R20- small airways resistence, ∆𝑋𝑅𝑆- in-breath 
change in reactance measured at 5Hz, Ax- reactance. Highlighted ∆XRS identifies tidal expiratory flow limitation. 
All oscillometry measured in cmsH2OsL-1 
 
 
  Mean EMGpara  Mean 
EMGpara%max  
NRDI  
1  3.7444  42.5585  438  
2  4.675  16.3373  321  
3  8.6  15.7509  334  
4  6.9882  15.7392  328  
Mean  







Table 9-3 Baseline parasternal electromyography measurements in patients with obesity related 
respiratory failure who were initiated on remote monitored non-invasive ventilation 
meanEMGpara- mean parasternal electromyography (microvolts), meanEMGpara%max- mean normalised 
parasternal electromyography (microvolts), NRDI-Neural Respiratory Drive Index (arbitrary units (AU))
  R5 R5-R20 R20 Ax ∆𝑿𝑹𝑺 Vt (L) 
1 11.85 3.96 7.89 150.81 11.69 0.7 
2 9.66 3.6 6.06 87.22 4.76 0.83 
3 6.12 2.58 3.54 78.76 8.81 0.77 















Table 9.2 Baseline oscillometry readings in patients with obesity related respiratory failure 




Figure 9-4 Control of hypoventilation in patients with obesity related respiratory failure treated 
with non-invasive ventilation 
Illustration of blood gas patients who were adherent (blue) and non-adherent (red) to home non-invasive . 
Serial carbon dioxide (CO2) (measured in kilo pascals (kPa)) and bicarbonate (measured in millimoles per litre 
(mmol/L) at baseline, 3months, 6months and 12 months after the initiation of non-invasive ventilation.  




Figure 9-5 Serial measurements of airways resistance and reactance in patient with obesity related 
respiratory failure treated with non-invasive ventilation 
Illustration of changes in oscillometry in patients with ORRF who were adherent (blue) and non-adherent (red) 
at baseline to 12 months following initiation. A- total airways resistence (R5), B- Large airways resistence (R20), 
C- small airways resisitence (R5-R20), D In-breath change in reactance at 5Hz (∆𝑋𝑅𝑆), E- reactacne (Ax). All 




Figure 9-6 Correlations between severity of sleep disordered breathing, body mass index (BMI 
(kg/m2)), forced expiratory volume in 1 second (FEV1) and baseline oscillometry in patients with 
obesity related respiratory failure requiring non-invasive ventilation 
AHI- apnoea hypopnoea index(events/hour), ODI- oxygen desaturation index (events/hour), R5- total airways resistence 
(cmsH2Os/L), R20- large airways resistence (cmsH2Os/L), R5-R20- small airways resistence (cmsH2Os/L), ∆𝑋𝑅𝑆- in-breath 




Figure 9-7 Correlations between forced expiratory volume in 1 second (FEV1 (percentage 
predicted)) and baseline oscillometry in patients with obesity related respiratory failure requiring 
non-invasive ventilation 
A- Correlation between FEV1 and large airways resistence (measured in cmsH2Os/L). B- Correlation between 





meanEMGpara meanEMGpara%max NRDI (AU) 
1 11.04 38.6014 560 
2 4.93 12.5445 285 
3 9.86471 23.7238 522 
4 13.3929 16.9642 288 
5 14.225 17.6708 382 
6 11.981 29.0808 521 
7 12.3333 22.8395 394 
8 6.35 10.1763 119 
9 17.3444 49.5554 973 










Table 9-4 Baseline measurements parasternal electromyography in patients with hypercapnic 
severe chronic obstructive pulmonary disease who require home non-invasive ventilation 
meanEMGpara- mean parasternal electromyography(microvolts) , meanEMGpara%max- mean normalised 
parasternal electromyography (microvolts), NRDI- Neural Respiratory Drive Index (Arbitrary units (AU))  
 
 
Figure 9-10 Serial blood gas analysis in patients with hypercapnic severe COPD following the 
initiation of home non-invasive ventilation at baseline, 3 months, and 6 months. 
A: Serial Carbon Dioxide (CO2) measured in kilo pascals (kPa). B- Serial serum bicarbonate levels (HCO3) 




Figure 9-11 : Serial measurements of airways resistance and reactance in patients with 
hypercapnic severe chronic obstructive pulmonary disease treated with non-invasive ventilation at 
baseline to 6 months 
A- total airways resistence (R5), B- Large airways resistence (R20), C- small airways resisitence (R5-R20), D In-




Figure 9-12 Serial measurements of parasternal electromyography (EMG) in patients with 
hypercapnic severe chronic obstructive pulmonary disease requiring home non-invasive 
ventilation 
A- Changes in mean parasternal electromyography (meanEMGpara) following the initiation of NIV at 3 & 6 
months. B- Changes in normalised parasternal electromyography (EMGpara%max) following the initiation of 
NIV at 3 & 6 months. C- Changes in neural respiratory drive index (NRDI) following the initiation of NIV at 3 & 6 




meanEMGpara meanEMGpara%max NRDI 
1 5.5357 17.8126 383 
2 14.2187 19.7905 413 
3 
   
4 12.4167 25.2371 457 
5 4.5375 12.9642 233 
6 3.65 15.6652 238 
7 4.63 33.7956 663 









Table 8-1 Baseline parasternal electromyography measurements in patients with chronic 
obstructive pulmonary disease- obstructive sleep apnoea overlap syndrome requiring remote 
monitored home non-invasive ventilation 
meanEMGpara- Mean parasternal electromyography (microvolts), MeanEMGpara%max- mean normalised 







Figure 9-13 Serial measurements of airways resistance and reactance in patient with chronic 
obstructive pulmonary disease- obstructive sleep apnoea overlap syndrome treated with non-
invasive ventilation at baseline to 6 months following initiation 
A- total airways resistence (R5), B- Large airways resistence (R20), C- small airways resisitence (R5-R20), D In-




Figure 9-14  Correlations between disease severity, positive airway pressure requirements in 
patients with chronic obstructive pulmonary disease- obstructive sleep apnoea overlap who 
were treated with home non-invasive ventilation 
A- Oxygen desaturation index (ODI) (events/hour) vs apnoea hypopnoea index (AHI) (events/hr), B- ODI (events/hr) vs 
95% inspiraotry positive airway pressure requirements (95%IPAP(cmsH20)), C- AHI (events/hour) vs 95%IPAP (cmsH20), 
D- ODI (events/hr) vs median inspiratory positive airway pressure requirements (mIPAP(cmsH20), E- AHI (events/hr) vs 
mIPAP (cmsH20), F- ODI (events/hr) vs 95% expiratory positive airway pressure requirements (95% EPAP (cmsH20)), G- 
AHI (events/hr) vs 95% EPAP (cmsH20), H- ODI (events/hour) vs median inspiratory positive 
 
